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ABSTRACT 
Phenylketonuria (PKU) is an inherited metabolic disease that affects about 
one in 10,000 of the population worldwide. In the classical form of the 
condition, the hepatic enzyme phenylalanine hydroxlase is absent or much 
reduced. If untreated, severe or profound mental handicap customarily results 
due to the accumulation of dietary phenylalanine (phe) which is neurotoxic. 
The mechanism by which phe impairs growth in the immature nervous system 
is little understood, but myelin metabolism appears to be disturbed. Treatment 
is by reduction of phe in daily food intake. Treatment should ideally begin in 
the neonatal period if intellectual loss is to be avoided. However, the safe 
range of phe concentrations during treatment and the age at which treatment 
can be discontinued without further damage being inflicted are uncertain. The 
studies reported in this volume investigated neuropsychological outcomes of 
treatment control and cessation factors. In addition, the question of whether 
executive functions are especially vulnerable to elevated phe concentrations 
during treatment was addressed. Patient samples conformed to the practice 
adopted in the West of Scotland regional centre for the management of PKU 
of maintaining dietary treatment until age 10 or beyond. Almost exclusively, 
negative findings emerged. These suggested that, if control of phe intake 
conforms to current UK recommendations for the preschool and primary years, 
neither global nor specific intellectual deficit result. Furthermore, the data 
supported the view that cessation of treatment at 10 years of age does not 
have harmful consequences. These findings have direct implications for the 
formulation of clinical policy on the treatment of PKU, but it must be 
recognized that the history of the successful treatment of PKU and mass 
screening for the disease spans a mere three decades. Thus, treatment 
outcome research to date is based only on children and young adults. In 
future investigations, a life-span approach will be required before the issues 
raised in this thesis can be finally settled. 
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FOREWARD 
The empirical core of this thesis is the six studies reported in Chapters Three, 
Five, Six, Seven, Eight and Nine. The chapters follow the chronology of the 
work. I was personally responsible for posing the questions addressed by the 
studies in Chapters Three, Five, Eight and Nine and for devising the 
methodologies. I formed part of a multi-disciplinary team consisting of 
paediatric, biochemistry and neurology colleagues that investigated the 
supplementation effects reported in Chapters Six and Seven. I was entirely 
responsible for the selection and, in some cases design, of all the 
psychological tests administered and for the analyses of the results derived 
therefrom. Blood samples were taken and biochemical assays were 
conducted by medical and biochemistry staff, mostly at Yorkhill and Stobhill 
Hospitals, Glasgow. The interpretations of the findings obtained by the 
research are my own. This thesis and the journal reports it embodies were 
written independently by myself though earlier drafts of papers and chapters 
have been commented on by academic and clinical colleagues. 
In the studies described in Chapters Three, Six, Seven and Eight some of the 
data collection was conducted under my supervision by undergraduate 
students pursuing their studies in the Department of Psychology, University of 
Stirling. I have acknowledged their help above. 
At the time of writing, three reports have been published (Chapters Three, 
Seven and Eight), one has been accepted (Chapter Six) and one submitted 
(Chapter Nine). 
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Chapter One 
INTRODUCTION 
Phenylketonuria: the disease and Its treatment 
Phenylketonuria (PKU) is a recessively inherited metabolic disease that falls 
into the category of aminoacidopathies. In PKU the conversion of the 
essential amino acid phenylalanine (phe) to tyrosine is impaired because of a 
deficiency of the hepatic enzyme phenylalanine hydroxylase (PAH). 
Consequently, abnormally high levels of phe accumulate in the blood and 
body tissues. Excess, un metabolized phe is toxic to the immature central 
nervous system (eNS). Left to run its natural course, PKU typically results in 
severe or profound mental handicap and associated motor dysfunction. 
However, if detected in the neonatal period, the disorder can be treated and 
intellectual deficiency prevented (Thompson & O'Quinn, 1979). 
In its untreated form, PKU is characterised by physical features such as fair 
skin and hair, blue eyes and a mouse-like body odour. The urine of the 
sufferer contains phenylketones (Cleland, 1978). These aromatic compounds 
give the urine a distinctive smell from which the name phenylketonuria 
originated, though terms like hyperphenylalaninaemia (abnormal level of phe 
in blood) or PAH deficiency more accurately describe the essential condition. 
Nowadays, in the Western world, children with untreated PKU are almost 
never seen, though adults can be found throughout institutional and 
community facilities for the learning disabled. 
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PKU is thus an enzyme deficency and belongs within the category of 'inborn 
errors of metabolism', an expression coined by Garrod (1909). It is the 
commonest disease entity within this nosological grouping, affecting on 
average about one in 8,000 live births in Western Europe (Smith & Brenton, 
1995). PKU was the first demonstration of a metabolic disease that could 
adversely affect intellectual ability. 
PKU is a 'silent' disease (Centerwall & Centerwall, 1961). The baby with PKU 
appears normal and asymptomatic. Before birth, excess phe crosses the 
placental membrane where it is metabolized by the normal matemal enzyme. 
Only later in post-natal life, when the unusual body odour, depigmentation of 
the skin and signs of deviant development become apparent, will clinical 
suspicion be raised. By this time effective treatment is impossible as the 
neuropathological process can only be arrested, not reversed. Biochemical 
analysis of a capillary blood sample, usually taken around the end of the first 
week of life, will indicate whether there are abormally high levels of phe 
circulating in the bloodstream. Persisting hyperphenylalanimaemia confirms 
the disease and treatment must be initiated immediately to prevent 
progressive brain damage. 
Treatment of PKU is by dietary prophylaxis and consists of severely restricting 
foodstuffs that contain phe. As yet, enzyme replacement and gene therapy 
are only theoretical possibilities. Phenylalanine is present in all protein; 
therefore meat, eggs, fish, poultry and dairy products are virtually excluded; as 
are vegetables and cereals that have a high protein content, such as pulses 
and wheat. To compensate for the protein deficiency that would result from 
such a narrow food intake, a dietary supplement containing essential amino 
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acids other than phe has to be administered. This formula is manufactured by 
firms specialising in dietary products, nowadays usually from synthesized 
chemicals. 
The protein restricted diet and supplement are normally managed on a day-to-
day basis by the PKU child's caretakers under the supervision of a 
professional dietician. The patients' and parents' organisation in the UK, the 
National Society for Phenylketonuria, publishes menus and recipe books to 
help carers provide variety at mealtimes. Blood phe levels are customarily 
monitored weekly to ensure maintenance within the therapeutic range and to 
ascertain the degree of compliance with the diet. The UK currently has 
around 38 laboratories providing population screening tests for newborns and 
biochemical assays for identified patients, this service having been 
established as a result of Government recommendations for nationwide 
coverage in 1979 (Wolff, 1981). In Scotland, a single centre at Stobhill 
Hospital, Glasgow, serves the entire region, screening roughly 60,000 infants 
a year. 
Psychological interest has centred principally on developmental and cognitive 
outcome variables in relation to treatment factors such as age of 
commencement and age of cessation of dietary therapy. Severity is also a 
factor. PKU is a genotypically heterogeneous condition and, in the 
phenotype, phenylalanine hydroxylase activity in the liver can vary from mild 
deficiency to nil. Neuropsychological research continues to focus on issues 
such as the effects on brain growth and cognitive function of dietary 
compliance and dietary continuation. A core issue that has direct implications 
for treatment policy is whether an age is ever reached at which normal eating 
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habits can be allowed without fear of damaging the CNS and impairing 
mental and behavioural functioning. 
PKU is a Mendelian recessive disorder. The carrier frequency in temperate-
zone populations is 2% and both parents have to be carriers for the genetic 
mutation to express itself. Even so, the probability is only one in four that a 
child born to two carriers will have the disease (Harris, 1970). Children born 
to individual mothers and fathers with PKU will not have the condition unless 
the partner is a carrier. Genetic counselling of parents identified as carriers 
following the birth of a PKU child and older PKU patients planning a family 
forms an integral part of contemporary treatment. The economics of mass 
genotyping precludes population screening for carriers at the present time. It 
is imperative that off-diet girls with PKU who are contemplating pregnancy are 
retreated with a supplemented, phe-restricted diet pre-conceptually and 
during gestation. Unless maternal blood phe levels are reduced, foetal eNS 
damage and malformation of other organs will almost inevitably result from the 
passage of phe-Iaden blood across the placenta, even though the unborn 
child does not itself have PKU (Smith et al., 1990b). 
In summary, PKU is a genetic disorder inherited by a child from two apparently 
healthy parents that prevents the normal utilization of protein food by the body. 
During digestion, protein is broken down into its constituent parts, one of 
which is phenylalanine. However, the liver in PKU is deficient in the enzyme 
that converts phe into tyrosine which is the next step along the metabolic 
pathway that would otherwise lead to the formation of, amongst other 
biochemically active substances, the catechol hormones adrenalin and 
noradrenaline. Unmetabolized phe is neurotoxic to the growing CNS. 
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Although the precise mechanism by which it affects neural structures is 
unknown, the overall process by which the genetic aberration becomes 
translated into brain damage in the immature organism is indirect, multi-stage 
and insidious. It can be conceptualised simply as follows. 
Genetic mutation.. Phenylalanine hydroxylase deficiency" Metabolic 
block" Biochemical imbalance .. Brain damage 
Early history 
The history of present-day knowledge of PKU is founded on the work of three 
men: Asbjorn Foiling, a Norwegian physician and biochemist; Horst Bickel, a 
German paediatrician; and Robert Guthrie, an American cancer specialist. 
Guthrie switched to research into the prevention of mental retardation 
resulting from inborn errors of metabolism following the birth of a mentally 
handicapped son. Respectively, they formulated solutions to the 
pathogenesis of PKU, its treatment, and its detection in the newborn 
population. 
PKU was discovered by Asbjorn Foiling, Professor of Nutritional Research at 
the Physiological Institute of the Veterinarian University of Oslo in 1934 
(Foiling, 1971}. In Norway it is still referred to as Foiling's disease, in 
recognition of Foiling's pioneering work, though he gave it the name 
'oligophrenia phenylpyruvica'. This Latinized term and its alternative 
'phenylpyruvic oligophrenia', with their allusions to feeblemindness, only 
enjoyed a brief period of currency as diagnostic labels. Shortly before World 
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War Two, Penrose and Quastel (1937) suggested the description 
'phenylketonuria' and this is the term in use today. 
The story of the discovery of PKU is a tale of scientific persistence and chance 
favouring the prepared mind. A mother brought her two developmentally 
retarded children, a boy of four and a girl of six, to Foiling's clinic for an 
opinion about their peculiar odour (Foiling, 1994). The children's father was 
asthmatic and so distressed by their smell that he was unable to tolerate their 
presence close by. A colleague of the father recommended consulting FOiling 
because of his earlier postgraduate work on acidosis. 
FOiling found no clinical signs in the children other than mental retardation 
and the distinctive, acetone-like aroma of their urine. Because of the strong 
suspicion of ketones being excreted, he tested their urine for diabetes by 
adding ferric chloride. Normally, ferric chloride turns urine purple in the 
presence of diacetic acid, but instead it turned green. This reaction had never 
been seen by Foiling and it was not described in the literature (Foiling, 1971). 
Foiling used classical organic chemistry and crystallography to determine the 
molecular composition of the unknown substance and established it as 
phenylpyruvic acid, a substance not normally present in urine. 
Foiling went on to survey 430 residents in hospitals for the mentally retarded 
and found the green reaction in the urine of eight. All these individuals were 
excessively fair in colouring and had eczema and spasticity. He correctly 
hypothesized that the syndrome was an inherited disorder of phenylalanine 
metabolism (Guttier, 1984). In exploring this idea, he was the first to use 
bacteria as a tool to measure the amount of phe in blood and urine and found 
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high levels of phe in the blood of patients diagnosed clinically and by the ferric 
chloride test. He suggested a block in the normal metabolism of phe which, 
on the basis of his observations of the disease in siblings and 
t 
consanguineous families, he considered was inherited as a rs'cessive trait 
(Bickel, 1980). 
Between 1945 and 1953, biochemical research on normal aromatic amino 
acid metabolism clarified that the main catabolic pathway of phenylalanine 
was its conversion to tyrosine in the presence of PAH. Jervis (1953) showed 
how biopsied liver samples from controls could catalyze this reaction in vitro 
but liver samples from individuals with PKU could not, suggesting the absence 
of hepatic PAH in PKU. 
Almost twenty years after Foiling's accidental discovery of a positive urine test 
for PKU, the first report of an experimental treatment was published as a case 
study (Bickel et al., 1953). In 1949, Horst Bickel moved from Zurich to the 
Birmingham Children's Hospital, as a research fellow, where routine ferric 
chloride tests were being applied to the urine of all mentally handicapped 
children attending outpatient clinics. In 1951, a colleague, John Gerrard, 
diagnosed PKU in a two-year-old, retarded Irish girl. Bickel confirmed the 
diagnosis by paper chromatography. In addition to the green phenylpyruvic 
acid reaction, the girl had fair hair, eczema and a mouse-like smell. Her 
mother pressed for treatment. Bickel wondered if excess phenylalanine itself 
had caused the child's brain damage and whether restricting its intake would 
improve the condition. 
Bickel and his colleagues treated the girl by reducing phe with a protein-
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restricted diet supplemented with a protein formula free of phe, casein 
hydrolysate, first mentioned to Bickel by Louis Woolf, a biochemist at Great 
Ormond Street Hospital, London. The therapeutic trial began in 1951, when 
the girl was 2 years 2 months old. Her behaviour improved in a few months. 
She sat upright, walked, interacted with people and showed interest in her 
surroundings; her hair darkened and her ketotic smell disappeared; she made 
up six months of development in a year as measured by the Terman-Merrill. 
Temporarily loading her diet with phe caused her to revert to her pre-treatment 
state. When discharged, sadly, her mother was unable to sustain the diet. 
The child was thus the first example of a treatment success and a compliance 
failure. Now in her mid-forties, she is severely mentally retarded and 
institutionalized (Bickel, 1996). Shortly after Bickel's publication, Woolf et al. 
(1955) observed that treatment with a low phenylalanine diet led to a 
reduction in neurological symptoms such as seizures and gait disorder but 
that IQ improvements were less dramatic. 
The findings of these early reports pointed to the conclusion that the best 
results could probably be achieved by early detection and implementation of 
the preventative diet. This implied screening every newborn for the metabolic 
error. Early attempts employed a development of Foiling's ferric chloride test: 
the Phenystix method. Phenystix kits contained strips impregnated with ferric 
chloride which, if soaked with urine from the infant's nappy, would show the 
green reaction if phenylpyruvic acid was present in large quantities (Heaton-
ward & Wiley, 1984). Kits were generally issued to district nurses and health 
visitors for use during post-natal follow-up. 
The measure yielded too many false negatives (Medical Research Council, 
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1981). As PKU babies were not always detected, and hence suffered the 
ravages of the disease, the shortcomings of the Phenistix method stimulated a 
search for a way of quantifying phe in the blood. A further impetus to finding a 
simple method for measuring blood phe was the increasing need to monitor 
blood levels of patients during dietary treatment to ascertain the degree of 
compliance. 
With a background of many years in cancer research, Robert Guthrie surmised 
that the technique of competitive inhibition, used for screening the blood of 
patients undergoing cancer treatment, might be modifiable for blood 
screening in PKU (Guthrie, 1996). The principle underlying the technique is 
that an inhibitor compound, which normally prevents growth of Bacillus 
Sub tilis , is neutralised by the presence of abnormal amounts of phe in culture, 
thereby allowing bacterial proliferation and showing a visible change in the 
appearance of the medium. Guthrie collected blood from a developmentally 
delayed niece of his who, at 15 months of age, was diagnosed late as having 
PKU. He pricked the heel, collecting the blood drops on filter paper for later 
assay in the laboratory. Apart from the procedure's practicality and simplicity, 
the appeal of collecting blood on absorbent paper lay in its being widely 
accepted by professionals and parents. Neonatal screening for PKU 
effectively began in 1961 when Guthrie started receiving filter paper 
specimens of blood from newborns in two Jamestown hospitals in New York 
(Guthrie & Susi, 1963). In the next few years, almost half a million babies in 
29 states were screened for PKU by means of the now-familiar 'Guthrie cards' 
- and 39 cases were found. Today, all 50 states require newborn screening for 
PKU by law and mass screening programmes are :n place throughout the 
North American continent, Europe, Australasia and the developed countries of 
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the world. 
In the UK, routine screening for PKU by means of the Phenystix method was 
introduced in the late 1950s and conducted mainly by health visitors. 
Between 25 and 50 per cent of PKUs were missed either because of false 
negatives or the test not being performed and, subsequently, the Phenystix 
approach to diagnosis was abandoned in favour of the microbiological 
inhibition assay (Guthrie testing). In Scotland, Phenystix were replaced by 
Guthrie tests as early as 1965. In the decade from 1968 to 1978, the detection 
rate for PKU improved radically with neonatal miss-rates falling to around one 
per cent for the UK as a whole (Wolff, 1981). 
Research into PKU treatment paralleled the inauguration of screening 
programmes and the need for a concerted approach to treatment issues was 
recognised early in Europe and the USA. In the UK, a National Register for 
PKU was set up in Liverpool by Freddie Hudson under the auspices of the 
Medical Research Council and the, then, Department of Health and Social 
Security. The date was 1964. Its purpose was 'to document the clinical and 
intellectual progress of patients treated by means of a low phenylalanine diet' 
(Smith & Wolff, 1978). After Hudson's death in 1976, the Register moved to 
London, Isabel Smith taking over the directorship. Biochemical and 
intelligence test results from centres throughout the British Isles, including 
Eire, were sent to London and entered into a national database. 
A similar project arose in the USA. The United States National Collaborative 
Study of Children Treated for Phenylketonuria was initiated in 1967, though at 
that time only 19 centres in 12 states actually submitted returns to the Los 
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Angeles headquarters (Koch et al., 1985). The purpose of the USA 
Collaborative Study was explicitly stated in terms of two questions: 1) lis 
dietary restriction of phenylalanine intake an effective treatment for 
phenylketonuria during the first six years of life?' and 2) lis dietary restriction of 
phenylalanine necessary in the treatment of phenylketonuria after six years of 
age?' (Wiliamson et al., 1985). The answer to the second question remains 
incomplete. Research in both the USA and UK was organised on a cohort 
basis with all children detected and treated during the first five years of each 
project being followed up for the first six years of life before subsequent 
analysis of IQ outcome data was undertaken. 
Following his demonstration of the treatability of PKU, Bickel returned to 
Germany from Birmingham. In 1978 he inaugurated the German 
Collaborative Study of PKU, a multicentre project based in Heidelberg 
collating data from paediatric departments in Berlin, Dusseldorf, Gottingen, 
Hamburg, Heidelberg, Munich, Munster and Ulm. Almost forty years after 
Foiling's discovery, Bickel published results of intelligence testing from the first 
longitudinal study of PKU in Western Europe based on mass screening 
(Bickel et al., 1973), although small sample research findings of IQ outcome 
had been reported earlier (e.g. Berman et al., 1966; Kang et al., 1970). 
Incidence of phenylketonuria 
Epidemiological findings emerged from work on population screening well in 
advance of treatment results as data suitable for determining incidence could 
be collected immediately following successful establishment of national 
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programmes. It soon became apparent that the geographical distribution of 
PKU was variable both within and between countries. 
Between 1969 and 1970, 63 per cent of newborns in the UK were being 
screened by Guthrie testing. By 1974, this figure had risen to 99 per cent of 
live births. Thus, incidence figures virtually equate with prevalence. The 
following table is adapted from frequency data derived from the MRC/OHSS 
Phenylketonuria Register during the period 1974 to 1976 inclusively for 
England, Scotland, Wales and Northern Ireland and provides a comparison 
with 1975 data, in brackets, for Eire (Smith & Wolff, 1978). 
Number 
screened 
England and Wales 1,809,720 
Scotland 201,119 
Northern Ireland 79,065 
(Eire 67,269 
PKU cases 
identified 
174 
18 
22 
35 
Incidence 
per 100,000 
9.61 
8.95 
27.83 
26.90) 
Table 1. Annual Incidence of PKU in the British Isles from 1974 to 1976. 
The above incidence figures relate to all cases of infants with persistently 
elevated phe levels. This early survey confirmed the now accepted average 
prevalence estimate of about 1 per 10,000 for the UK, but revealed an 
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imbalance between mainland Britain and Ireland - both the North and the 
Republic - with the Irish figures being around three times greater than those 
found on the mainland. A breakdown of the figure for England and Wales 
showed substantial regional differences, with a low rate in East Anglia {5.12 
per 100,OOO} and high rates in North West and South West England {14.62 
and 12.15 respectively}. Modern population genetic studies suggest that 
mutations of the gene coding for PAH fall into two broad locational categories 
in the UK: an eastern, probabably reflecting the migration and settlement 
patterns of the Scandinavian races; and a western, probably reflecting those 
of the Celtic peoples {Scriver et al., 1996}. The mixed ancestry of inhabitants 
of the British Isles rather than intragenic crossover more likely accounts for the 
heterogeneity of genotypes in the UK and Ireland {Tyfield et al., 1991}. 
By 1971, mass screening of over five million neonates in eight European 
countries had been achieved, 668 cases being identified as having classical 
PKU (persisting blood phe levels over 1200Jlmol/l). The incidence rate was 
found to vary considerably in different countries from 1 per 3000 in Ireland to 1 
per 28,000 in Belgium (Guttier, 1984). World-wide, Northern Ireland has the 
highest rate, Japan the lowest. The ratio for Scotland is 1 per 8200 (Guthrie, 
1980), the preponderance of cases being in the West. Figures as high as 1 
per 40 have been found in populations where there is a high degree of 
consanguinity such as Gypsies {Nyhan, 1981}. About 70 children with PKU 
are born in the UK each year (Clark et al., 1995). 
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Biochemistry 
Phenylalanine is an essential amino acid: that is to say, it cannot be 
synthesized by the body but has to be obtained from food intake. All natural 
protein contains phe which is found linked to other amino acids like glycine, 
valine, leucine and cystine in polypeptide chains. These giant, linear 
polymers consist of concatenations of up to 300 amino acid molecules. 
During digestion, peptidases in the small intestine attack peptide links, 
breaking down proteins into 20 single amino acids. These are then 
transported to conversion sites such as the liver by the bloodstream (Brody, 
1994). 
The molecular structure of phenyalanine is a phenyl radical with alanine 
(methyl, carboxyl and amino groups attached to a CH hub): 
CH=CH 
I \ 
CH C - CH2CHCOOH 
\\ 1/ I 
CH -CH 
When hydroxylated by PAH, tyrosine is formed: 
/ 
HO-C 
\\ 
CH=CH 
CH -CH 
\ 
C - CH2CHCOOH 
1/ I 
Figure 1. Molecular structures of phenylalanine and tyrosine. 
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In normal phenylalanine metabolism, phenylalanine is hydoxylated to tyrosine 
(tyr) and transaminated to phenylpyruvic acid (phenyl pyruvate) and its 
metabolites, phenyllactic acid (phenyllactate) and phenylacetic acid 
(phenylacetate). The complete phe hydroxylating system only occurs in the 
liver in humans and comprises the three enzymes phenylalanine hydroxylase, 
dihydropteridin reductase and dihydrofolate reductase; and the cofactor 
tetrahydrobiopterin (Scriver & Clow, 1980). The metabolites of phenylpyruvic 
acid are excreted in the urine, but not phenylpyruvic acid itself. The next stage 
along the metabolic pathway is the conversion of tyr to the three hormones 
thyroxin, noradrenaline and adrenaline (Morgan, 1965). Thyroxin is a 
compound of tyr and iodine. Formed in the thyroid gland, it governs energy 
metabolism. The catecholamines, noradrenaline and adrenaline, stimulate 
the sympathetic branch of the autonomic nervous system. Acting as 
neurotransmitters, they are released by catecholaminergic neurones. 
Dihydroxyphenylalanine (dopa) and dopamine are precursors of 
noradrenaline and adrenaline, dopamine being an important neurotransmitter 
and implicated in psychosis. At the dopaminergic synapse dopamine is either 
released or destroyed by monoamine oxidase (Bender, 1993). 
Phenylalanine is thus necessary for the formation of key hormones and 
neurotransmitters, but a nutritionally varied diet ensures sufficient intake. A 
simplified scheme of phenylalanine metabolism is as follows. 
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(+ Phenylalanine aminotransferase .. Phenylpyruvic acid 
Phenylalanine ( 
( + Phenylalanine hydroxylase 
... 
Tyrosine .. Thyroxin 
... 
Dopa 
... 
Dopamine 
... 
Noradrenaline 
... 
Adrenaline 
Figure 2. Normal metabolism of phenylalanine. 
Phenylketonuria is the commonest disorder among the group of metabolic 
diseases collectively known as the hyperphenylalaninaemias, accounting for 
about 95% of cases. The two main variants, dihydropteridin reductase and 
tetrahydrobiopterin deficiency, are caused by impaired coenzyme synthesis. 
Dihydropteridin reductase deficiency cannot be treated whereas 
tetrahydrobiopterin deficiency responds to daily doses of biopterin (Smith & 
Brenton, 1995). 
Phenylketonuria can best be regarded as phenylalanine hydroxylase 
deficiency, the metabolic block occurring at the point in the pathway where 
phe is converted to tyr (see Figure 2). The severity of the disease depends on 
the degree of PAH activity. In 'classical' PKU, there is little or no PAH activity 
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and phe accumulates rapidly in the bloodstream and tissues. Classical PKU 
is operationally defined as phe levels in blood consistently in excess of 1200 
Jlmol/l (Bickel et al., 1973). In the West, neonates with blood levels of this 
magnitude or greater are always treated. 
Mild hyperphenylalaninaemia (hyperphe) is indicative of a reduction of PAH 
activity rather than its absence or near-absence. Children with very mild 
hyperphe whose levels do not consistently exceed 400 Ilmol/l are not usually 
treated (Medical Research Council, 1993a). The condition is regarded as 
benign, and intellectual and neurological impairment have not been 
demonstrated in later life (Weglage et al., 1996). 
If classical PKU is untreated, high concentrations of circulating phe result. In 
the absence of PAH, phe is metabolized to phenylpyruvic acid, phenyllactate 
and phenylacetylglutamine which are excreted in urine in approximately 
equal amounts. Phe is a} decarboxylated to phenylethylamine, 90 per cent of 
which is oxidized to phenylacetic acid and 10 per cent to mandelic acid; and 
b) transaminated to phenylpyruvic acid, about half of which is converted into 
phenyllactate and hydroxyphenylacetic acid (Fulton et al., 1980). 
Phenylpyruvic acid permits the green ferric chloride diagnostic test. 
Phenylpyruvic acid and phenylacetic acid are ketones and are probably 
sweated as well as excreted, giving rise to the typical aroma. 
Because of the metabolic block, blood tyrosine levels remain very low. 
Normally, some tyrosine is catabolized to the brown pigment, melanin, by the 
enzyme tyrosinase. Melanin is found in skin, hair and eyes; sunlight 
increases production, resulting in tanning. However, in addition to failures of 
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hormone production, tyrosine deficiency affects melanin synthesis in 
untreated PKU. Furthermore, the increased phe pool inhibits tyrosinase. 
Depigmentation or partial albinism are characteristic, producing the fair-haired 
and blue-eyed appearance found when the disease has been left to run its 
natural course (Salway, 1994). 
Genetics 
Phenylketonuria is an autosomal recessive disorder whose transmission 
follows Mendelian principles {Jervis, 1939}. Almost all {99%} of 
hyperphenylalaninaemia mutations map on to the phenylalanine hydroxylase 
gene on chromosome 12. Lidsky et al. (1985) first localized the mutations for 
PKU on the long arm of chromosome 12. Woo and his team in Texas found 
the gene that coded for PAH and identified 12q24.1 as the locus for the great 
majority of mutations (Eisensmith & Woo, 1991). Analysis of 3986 mutant 
chromosomes by 81 investigators in 26 countries has, to date, identified 243 
different mutations in 788 different associations {Scriver et al., 1996}. By the 
end of the 1980s, some 18 mutations only had been defined (Cotton, 1990). 
Despite the enormous genetic heterogeneity of the condition, a few PKU 
alleles occur at high relative frequencies and often on only one haplotype. 
About two-thirds of PKU genes in Europeans carry just four PAH mutations. 
Thus, within a population there are a few prevalent mutations and a number of 
rare ones. These concentrations suggest positive selection and recurrent 
mutation in the past. Around 75 per cent of European PKU genotypes are 
compounds which may first have arisen 10,000 to 20,000 years ago when 
major dem!c immigration from the Middle East into Northern Europe is thought 
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to have occurred. The high frequency of PKU - in terms of abnormal genetic 
traits - is probably not due to a high mutation rate of the human PAH gene but 
rather the expansion of a handful of mutant alleles in the population (Woo, 
1989). 
The PAH enzyme is a protein consisting of 452 amino acids arranged in a 
genetically-determined order. Each PAH gene has 13 coding sequences 
(exons). Mutations occur when the units in the coding sequence become 
exchanged. This results in a wrong amino acid in the enzyme string. Different 
mutations exert different influences on PAH activity. Variation in the severity of 
PKU - classical, moderate or mild - is dicatated by the combination of mutant 
genes contributed by each parent carrier. Thus, PKU is a spectrum of PAH 
deficiency disorders. Guttier (1996) has proposed that genotyping of 
newborns will, in the near future, provide a method for precise diagnosis of the 
severity of PKU, as there is a high correlation between mutation genotype and 
blood phe level. 
Neuropathology 
The neuropathogenic mechanism by which the growing CNS is damaged in 
untreated PKU has yet to be described. A mouse model of PKU has been 
created by McDonald (1994) who produced PAH deficiency in the normal 
mouse by administration of the germline mutagen ethylnitrosourea. 
Laboratory animals so treated possess the characteristics of human PKU such 
as inter-individual variation in hepatic PAH activity and hypopigmentation that 
abates when treated by a low-phe diet. Animal research has the potential to 
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circumvent some of the practical and ethical difficulties surrounding controlled 
experimentation with human subjects, not the least of which is the rarity of the 
condition. But the promise of further understanding of the pathophysiology of 
PKU by means of animal studies has yet to be fulfilled. 
Controversy even exists about whether phe itself is the neurotoxic agent. 
Following the proposal by Kaufmann (1977) that phe is the culprit, most 
authorities subscribe to this view, a conclusion consistent with animal studies 
in which high doses of phe injected in infancy have been shown to result in 
brain damage in the mature organism (Hommes et al., 1982). However, 
Fulton and his co-workers theorised that phenylacetic acid is the neurotoxic 
agent, its action interfering with synaptic development and ultimately 
producing mental handicap. These authors were able to demonstrate that the 
other metabolites of phe (phenylpyruvic acid, phenyllactate and mandelic 
acid) are harmless, but were initially unable to separate the effects of 
phenylacetic acid from those of phe in an empirical study (Fulton et al., 1980). 
In a later study, the same group injected experimental animals with 
phenylacetic acid and found selective impairment of cholinergic and 
GABAergic synaptic terminals but not of noradrenergic, sertoninergic and 
glutamatergic terminals (Loo et al., 1984). Perturbation in the untreated CNS 
appears much more widespread than the narrow range of synaptic effects 
associated with excess phenylacetic acid reported by Fulton and his 
colleagues, and the phenylacetic acid theory has not received subsequent 
support. 
The candidate most favoured by present-day theorists as the target for phe is 
the neurone, the formation of myelin sheath having received particular 
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attention (Gordon, 1976). Early brain biopsy studies of patients with untreated 
PKU consistently revealed disturbances in myelin development. Alvord et al. 
(1950) were among the first to show neuropathological alterations indicating 
arrested myelin growth. Corsellis (1953) and others confirmed the presence 
of disrupted myelination. In autopsies of eight severely mentally retarded 
patients who died between the ages of 9 and 40 years of age, Malamud 
(1966) found no evidence for neuronal degeneration, but extensive white 
matter changes. Frank demyelination was only sporadically observed in 
severely handicapped adult cases, but sponginess and arrested myelination 
were ubiquitous in the brains of both adults and children. He concluded that a 
dysmyelination pattern was characteristic in younger patients whereas active 
demyelination seemed confined to older age groups. 
Shah et al. (1972) found myelin deposition in untreated PKU reduced to 62 
per cent of normal, but concluded that the general pattern was more 
suggestive of dysmyelination rather than demyelination as pathological 
changes were indicative of an increase in the rate of myelin turnover rather 
than decomposition. 
On the basis of microscopic histological analyses of the brains of three adults 
with untreated PKU, Bauman & Kemper (1982) concurred with Shah et al.'s 
interpretation, finding no evidence for demyelination or decomposition. 
Instead they found widespread abnormalities in myelin deposition. In 
addition, they found poor dendritic arborization. What was most notable in 
Bauman and Kemper's data was the selective sparing of structures like the 
oculomotor nucleus, which matures pre-natally, compared with disruption of 
cells in areas like association cortex which have a long post-natal cycle of 
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myelination. This apparently time-structured pattern led them to propose that 
the metabolic abnormalty in PKU interferes with or disrupts normal growth 
processes rather than damaging existing structures. 
Hommes (1991) argued that elevated concentrations of phe produce adverse 
neuronal effects at all stages of development by means of a dysmyelination 
mechanism. It was clear from animal models of PKU that phe increases 
myelin turnover in the immature brain (Vorhees et al., 1981). In an earlier 
animal study, Hommes subjected 25 day-old rats to a high phe supplement. 
At this age the rat brain is considered mature, yet he found phe-related 
disturbance of myelin biosynthesis (Hommes et al., 1992). In human 
subjects, the small amount of evidence available is consistent with the view 
that the deleterious effects of phe depend on the maturational stage of the 
nervous system. For instance, Sick et al. (1991) compared magnetic 
resonance imaging (MRI) scans of children who were early and late treated. 
MRI is highly sensitive to myelin change. These authors found the severest 
white matter abnormalities in those who were either treated very late, very 
poorly or both. Only in this group of patients were there signs of subcortical 
involvement. In early treated patients, these areas were unaffected, the only 
minor anomalies being found in the posterior periventricular areas. Similar 
findings were reported by Thompson et al. (1990) whose MRI scans of the 
brains of early-treated, off-diet patients in adulthood showed highly localized 
rather than diffuse white matter anomalies, periventricular locations again 
being those most commonly found. 
Sick and his colleagues suggested that white matter disturbance in PKU 
needs to be understood within the context of the normal sequence of 
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myelination. From an autopsy survey of 162 infantile deaths, Kinney et al. 
(1988) formulated the following rules about early myelination. 
1) Proximal pathways precede distal. 
2) Sensory pathways precede motor. 
3) Projection areas precede association. 
4) Central sites precede cortical. 
5) Occipital poles precede frontal. 
It follows from this scheme that sites that myelinate slowly during infancy may 
be particularly vulnerable to prolonged phe exposure. From these premises, 
Bick et al. (1991) speculated that in untreated PKU, the brain stem area may 
be spared as it myelinates before birth, but diffuse cortical and pyramidal 
damage may occur. In early-treated PKU, dysmyelination should be minimal. 
Nevertheless, myelination procedes hierarchically from areas subserving the 
lowest (vegetative) functions to the highest (symbolic) functions (Yakovlev and 
Lecours, 1967) and loss of phe control, even after early initiation of the 
restricted diet, could carry the risk of subtle disorders of frontal or prefrontal 
function. This model remains to be validated empirically, but a fair 
generalization is that infancy is a critical time for myelin formation over wide 
areas of the CNS and that the system is especially vulnerable to phe during 
this period. 
Even though myelination in humans continues till 20 years of age, major 
deposition is complete by two (Davison, 1973). Results from post-mortem 
histological analyses of brain tissue in untreated PKU led Davison to conclude 
that, in PKU, infancy was the stage of maximal vulnerability and in non-PKU, 
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the pre-natal stage. Thus, nutritional hyperphenylalaninaemia should affect 
eNS growth most adversely in early life, producing lesser disruption as 
maturation proceeds and perhaps reaching a point where none occurs that is 
of any functional significance. In defence of this sensitive period hypothesis, 
Davidson drew attention to the devastating effects on the foetal CNS of 
sustained high concentrations of phe in the PKU mother even though the 
foetal liver is not deficient in PAH. Vorhees et al. (1981) wamed that the 
myelin malformation theory in human PKU is based on correlative, rather than 
dynamic, evidence and this remains the position today. 
A major unanswered question is, once the eNS in PKU has successfully 
myelinated as a result of phe restriction during the vunerable early period and 
beyond, can the mature system withstand subsequent phe exposure without 
suffering structural damage or loss of function; and, if so, at what age does this 
protection emerge? 
Myelin defects impair intra-neuronal impulse conduction. However, an allied 
neurochemical question centres on inter-neuronal communication and the 
functioning of the synapse. Doubt has been raised about the integrity of the 
synapse in PKU because of the neurotransmitter shortage that results from the 
metabolic block. Moreover, poor dendritic arborization, as seen in untreated 
PKU, may stem from synaptic dysfunction (Davison, 1973). Specifically, the 
issue is whether dietary discontinuation in the mature human organism and its 
attendant risk of neurotransmitter deficiency manifestly affects mental and 
motor functioning. Knowledge of neurotransmitter biosynthesis suggests it 
WOUld, but experimental evidence on the matter is only now beginning to 
emerge as subjects become available who have been screened, treated from 
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an early age, stopped diet and been exposed to high phe levels. 
Guttier and Lou (1986) articulated the theoretical basis for concern about 
neurotransmission problems in post-treatment PKU. They contrasted what 
they termed the juvenile form of PKU with the adolescent form. In the 
untreated, juvenile form of the disease, severe mental handicap results. This, 
they proposed, is probably due principally to myelin malformation. In the 
treated form of PKU, stopping the low-phe diet in adolescence produces 
hyperphenylalaniaemia, but in a more mature organism. Thus, the juvenile 
and adolescent form of PKU are both chemical insults to the brain but at 
different stages of maturity. What is unknown is whether the biochemical 
imbalance associated with untreated PKU is harmful later in life. Put 
otherwise, the question is whether the mature brain can function normally 
despite an abnormal biochemical environment. Guttier and Lou suggested 
that maturity brings protection against the devastating effects of phe, but that 
subtle dysfunction might arise due to impaired biosynthesis of 
neurotransmitters such as dopamine and noradrenaline. 
If myelination and associated neurohistological growth processes such as 
synaptic and dendritic formation are the key to understanding the mechanism 
of progressive brain deterioration in untreated PKU, questions arise about 
how best to control hyperphenylalaninaemia. For instance, is a maturational 
point ever reached when elevated phe levels cease to have a deleterious 
effect on the structural integrity or functional capacity of the eNS? Issues 
about the effect of phe on neurological growth and psychological 
development are at the core of treatment practice and policy in PKU and are 
outlined in the next chapter. 
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Chapter Two 
TREATMENT ISSUES 
There are three core issues relating to outcome in dietary treatment of PKU. 
The purpose of treatment outcome research is to further theoretical 
knowledge of the neurochemistry and neuropsychology of the disease and 
ultimately guide treatment policy towards the formulation of an optimum 
regimen. In the form of questions, the issues are: 
1) at what age should dietary treatment be started in order to avoid early 
damage to the eNS? 
2) within what range is circulating phe innocuous during treatment? 
3) at what age, if any, is it safe to discontinue treatment? 
These matters have been approached almost exclusively from the standpoint 
of research into psychological outcome, although some additional evidence 
has been derived from autopsies and, within the past decade or so, brain 
scans of living patients. 
Psychological outcome research 
Sample definition 
In the reviews that follow and in the empirical studies described in later 
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chapters, it should be noted that data are derived from subjects representing 
the classical PKU population unless otherwise stated. 'Classical PKU' refers 
to extreme enzyme deficiency in which there is little or no PAH activity. The 
classical subgroup is by far the largest among the hyperphenylalaninaemias, 
constituting over 90 per cent of the population. Even so, classical PKU is not 
caused by the entire PAH gene being deleted (Woo, 1989). It is operationally 
defined as blood phe levels persistently in excess of 1200 Jlmol/l and is 
usually contrasted with the 'variant' subgroup, whose levels range from 600 to 
1200, and the 'benign' subgroup whose levels fall below 600 (Koch & Wenz, 
1987). These divisions are arbitrary. In reality, the degree of 
hyperphenylalaninaemia in PKU is a continuum, reflecting the broad 
heterogeneity of the underlying genotype. But, for convenience sake, the 
tripartite scheme of classical, variant and benign remains in operation. The 
figure of 1200 JlmoVI employed to define the threshold for classical PKU is ten 
times the level of blood phe found in the normal population (Walter, 1995). 
Age of treatment commencement 
The question about what age treatment should be initiated in classical PKU 
was one of the first to be addressed following Bickel's demonstration of 
successful dietary prophylaxis. There is now no doubt that the earlier 
treatment is begun the better the prognosis for sparing of intellect. One of the 
first studies of the relationship between treatment age and IQ concluded that 
treatment should be immediate (Berman et al., 1968). This principle has 
nowadays become almost axiomatic, though in practice treatment is not 
effected until some days after birth as elevated phe levels, as measured by 
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Guthrie tests, take time to stabilize. 
In a meta-analysis of patients treated at progressively later ages, Berman and 
her colleagues found an inverse relationship between age and 10 outcome. 
The figure below is adapted from their data and shows the dramatic and 
sytematic decline in 10 to a severely mentally handicapped level following a 
treatment delay of one to two years. Datum points are mean las from samples 
of about 10 classical PKU subjects at each age. 
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Figure 3. Decline in 10 as a function of treatment delay. 
In some cases, outcome 10 was measured over four years after initiation of 
treatment and no attempt was made to control for dietary compliance. Thus, 
starting age and compliance were probably confounded factors. 
Nevertheless, assuming compliance was random, this series of patients 
provided strong evidence for an inverse relationship between the age 
treatment commenced and later 10. 
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As a historical aside, some of the early-treated patients entered into Berman's 
analysis were among the first to be picked up by newly-established screening 
programs. Others, mainly those who were late-treated, were siblings of this 
group who were born before screening was in place. 
In the late 1960s, Kaplan (1969) reviewed the available evidence for the effect 
of treatment onset age on 10 and concluded that if treatment was delayed until 
6 to 18 months, figures in the mildly handicapped range (10 50 to 70) were to 
be expected; whereas a delay of beyond 24 months almost invariably led to 
severe mental handicap {IO < 50}. 
Hanley et al. (1971), in a study of Canadian children, corroborated this view, 
demonstrating a steady decline in later 10 as a function of treatment delay. 
These authors reported 10 averages of 94, 72, and 55 for delays of 2, 6 and 
12 months respectively. 
In a well-constructed, early study of 58 children all selected for classical PKU, 
Kang et al. (1970) demontrated the slippage in 10 that occurred when diet was 
implemented later than 8 months of age compared with implementation 
before 6 weeks. The percentage frequency distributions below are adapted 
from their data and show the abnormal intellectual levels associated with late 
commencement. 
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IQ of Early- and Late-Treated Patients 
Proportional Comparison (after Kang 
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Figure 4. IQ distributions of early- and late-treated patients. 
Bearing in mind that the population norm for the IQ distribution is 100 and the 
standard deviation 15, the slight positive skew in the above data for the early-
treated group suggests that even 6 weeks might be sub-optimal for treatment 
commencement. Analyzing IQs from children in this group in terms of the 27 
who began prior to 3 weeks and the 12 who began between 3 and 6 weeks, 
Kang et al. found a mean difference of 10 points, the average la for the pre-3 
week group being 99 and that for the 3-to-6 week group being 89. Compared 
with their siblings, the pre-3 week group's las were non-significant, but the 3-
to-6 week group's were significantly lower (P < 0.001). 
Apart from confirming the suspected dynamic relationship between age of 
treatment commencement and subsequent IQ, Kang and her colleagues' 
findings pointed to the need for starting treatment as early as possible to avoid 
loss of intellect. 
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Over the past quarter-century the picture has remained fundamentally 
unchanged. The direct link between early exposure to phe and later 10 was 
weakly confirmed by some of the first analyses to emerge from the UK 
Collaborative Study (Smith et al., 1973), these researchers finding a 
nonsignificant trend towards a negative correlation between the age treatment 
began and 10 outcome. As Smith et al.'s patients were tested between the 
ages of 6 and 16 years, compliance and age of treatment cessation were 
additional treatment variables, but their possible effects were not analysed by 
the authors. However, Barclay and Walton (1988) provided controls for these 
factors by testing a well-controlled, on-diet group and found a significant 
inverse relationship between age of treatment onset and 10. 
Bickel's own results were reviewed by Schmid-Ruter and Grubel-Kaiser in 
1977 (see Bickel, 1980). This survey was limited to patients whose treatment 
was started in the first year of life. Normal intellectual development was 
achieved only in those who began treatment in the first two months, 10 
deClining progressively thereafter. 
Data from the larger sample of 134 patients available to the US Collaborative 
Study showed a dramatic fall-off in 10 following early treatment delay. The 
mean for patients who started in the first month of life was 95 whereas that for 
patients who started in the second was only 85 (Koch & Wenz, 1987). 
Stepwise regression analysis of a subset of the US Collaborative Study 
sample established that age of treatment onset was a significant predictor of 
later 10, though age of treatment cessation and parental IQ were stronger 
(Legido et al., 1993). 
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There is no evidence that the damaging effects of early exposure to phe can 
be reversed by later treatment. Neither late-treated children nor adults show 
any signs of intellectual normalization. It should be remembered that Bickel's 
first therapeutic trial was on a two-year-old who would nowadays be regarded 
as late-treated. While her demeanour, attention and social behaviour 
improved, her intellectual status remained severely mentally retarded. He 
wrote that older children and adults would probably not benefit from treatment 
because of pre-established brain damage and presumed that 'the best results 
of dietetic treatment of phenylketonuria will be obtained if treatment is started 
in infancy and particularly in the neonatal period' {Bickel et al., 1954}. While 
this view has been vindicated by subsequent research, today there is 
mounting interest in the use of the low-phe diet in previously untreated 
patients, not because of any prospect of fundamentally changing intellect, but 
because mood and behaviour may be improved. Studies of this issue 
published so far have been equivocal. The majority are frankly contradictory 
(see Harvey & Kirk, 1995) and interpretations of apparent improvements have 
tended to ignore non-phe factors such as Hawthome effects. 
Treatment policy as proposed by Bickel in the fifties has never been 
fundamentally challenged, subsequent treatment onset findings serving 
largely to substantiate his original presumption. Research in this area has 
been formally translated into treatment policy in the UK and Continental 
Europe, though curiously no treatment guidelines have been published for the 
USA (Schuett, 1996). The UK recommendations are for commencement of 
treatment before 20 days if phe levels are persistently above 600 Jlmol/l 
(Medical Research Council, 1993a). In Europe, treatment is recommended 
before the third week of life when phe levels are in excess of 400 Jlmol/l 
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(Schuett, 1996). In practice, Guthrie tests are usually taken close to the sixth 
day of life and treatment often begun the week after (Smith & Brenton, 1995). 
Dietary control and optimal therapeutic range 
The setting of a lower limit to the therapeutic range for phe in PKU is dictated 
primarily by dietary needs and thus recommendations have been largely 
based on theoretical considerations. By contrast, recommendations for the 
value of an upper limit are, at present, entirely empirically based and have 
shown some fluidity over the period since the inception of screening and 
treatment programmes. 
The objective in setting lower and upper limits for phe during treatment is to 
minimize adverse long-term neuropsychological effects without compromising 
nutrition. In the early days of treatment, some children were severely deprived 
of phe in infancy. Their intake was only around 25 mg per kg of bodyweight 
daily for many months and they stopped growing, became dystrophic and 
anorexic, and developed bone lesions (Feinberg & Fisch, 1962). This was 
before it was realised that young infants with PKU require around 50 mg of 
phe per kg daily to prevent protein catabolism and aminoaciduria due to 
essential amino acid deficiency. Warnings about overtreatment were issued 
(e.g. Woolf, 1967) and consensus was reached by clinical practitioners on 
120 Jlmol/l as a minimum level for blood phe control during treatment. This is 
the figure formally recommended in current UK and continental European 
guidelines as the lower target limit for treatment irrespective of age (Medical 
Research Council, 1993a; Schuett, 1996). However, Bickel (1980) took the 
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view that 60 Jlmolll was tolerable and treated his patients in Heidelberg 
accordingly without apparent harm. 
In dietary practice, the small amount of phe necessary for growth and normal 
protein metabolism is obtained from natural food. A daily dose of phe is 
calculated and carefully measured amounts of protein having known phe 
concentrations are permitted. These are usually low-protein foods such as 
cereals, potatoes or milk - including breast milk and baby milk in infancy. The 
dose prescribed rises slightly with age and is expressed in units of 
equivalence known as 'exchanges'. Each exchange contains 15 mg of phe. 
Thus, one exchange is equal to 15 g of rice cereal, 60 g of boiled potatoes, or 
100 g of a proprietory apple yoghurt dessert (National Society for 
Phenylketonuria, 1996). 
The exact upper limit of phe to be aimed at during treatment remains 
controversial and varies between clinics and countries (Editorial, 1991). The 
decision about what constitutes an optimum level has been informed by 
research studies, usually entailing outcome comparisons between naturally 
arising groups of well- and poorly-controlled patients or correlations between 
dietary control and intellectual outcome. In relation to the magnitude of the 
issue, such studies are surprisingly few in number. 
Reporting findings from the USA Collaborative Study, Dobson et al., (19n) 
were among the first to demonstrate the influence of dietary control during 
treatment on subsequent IQ. These authors divided a sample of 111 four-
year-olds with classical PKU into nearly equal groups, one representing good 
control over the period and the other poor. Degree of control was indexed by 
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calculating individual children's median phe levels for the entire period and 
group allocation determined by whether this figure fell into the upper or lower 
half of the distribution. Children with indices above 600 Jlmolll were excluded 
from the analysis. The cut-off point (median of medians) that emerged was 
350 Jlmoi/l. The mean Stanford-Binet la for the well-controlled group 
(medians <350 Jlmol/l) was 97, that for the poorly-controlled group (medians 
350-600 Jlmol/l) was 89 (P<0.01). Treatment cessation was not a factor as all 
subjects were on-diet but age of treatment onset was not partialled out. 
Assuming this was random, the la difference suggested that quality of dietary 
control in the first four years of life was a factor determining intellectual 
outcome and that average phe levels in the range 350 to 600 Jlmol/l might be 
harmful. 
In a multiple regression analysis of an enlarged sample (n = 132) from the 
USA Collaborative Study, Williamson et al., (1981) ascertained the relative 
weightings of maternal la, age of treatment onset and dietary control in the 
determination of IQ at age 6. They found, not surprisingly, that maternalla 
contributed the highest, accounting for 25% of the variance; whereas age of 
treatment onset accounted for 7% and dietary control only 4%. These authors 
nonetheless concluded that blood phe levels during the early treatment 
period affected outcome and should be maintained between 120 and 600 
JlmoVI, despite the earlier finding by others within the same research team that 
the latter figure may be too high. 
Berry et al. (1979) provided indirect evidence for the hypothesis that 
intellectual deficit is related - at least in part - to degree of dietary control, 
obtaining a correlation of -0.68 (P < 0.01) between concurrent phe level and 
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10 (Binet) at age 4. No analysis based on historical phe data was performed, 
the assumption here being that concurrent phe reflects (i.e. correlates with) 
earlier phe levels. 
In a study of groups from the Heidelberg clinic classified as having low or high 
phe levels during the first 10 years of treatment, Schmidt et al. (1987) found a 
mean difference of 18 10 points in favour of the low-phe group, the average 
phe-Ievels being 276 and 546 Jlmolll for the low and high groups respectively. 
Schmidt and her colleagues interpreted the finding as supporting the phe-
control hypothesis, but failed to test the data statistically. T~e indication is that 
when control is governed by an upper limit of, say, 300 Jlmol/l, a higher level 
of intellectual functioning results. However, the possibility must be 
acknowledged that dietary control and parental 10 may be confounded. If 
parents with lower 10 were those whose treatment control was worse, the 
lower 10 of the children in the poorly controlled group could simply have been 
a reflection of that of their parents. It could be that parental 10 and dietary 
compliance are associated. 
PKU research is riddled with methodological and interpretive difficulties, many 
arising out of lack of statistical analysis or experimental control. For instance, 
in reviewing the data sent to the UK PKU Register in the seventies and 
eighties, Smith & Beasley (1989) found 10 at age 4 to be fairly stable 
irrespective of phe level up to 650 Jlmol/l but to decline when this level was 
exceeded. The graph below depicts mean las for groups with increasing 
mean phe levels for the four year period. 
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Figure 5. IQ and historical phe level. 
This finding contradicts that of Dobson et al. (1977) in that no deterioration 
was evident between mean phe levels of 300 to 600 Jlmol/l, suggesting that 
an upper limit of 600 may be acceptable as a dietary control target in the pre-
school years. However, as with Schmidt et al.'s (1987) data, Smith and 
Beasley provided no statistical test of the mean differences, thereby 
undermining confidence in the IQ pattern being reliable. 
Because of the paucity of information about what might constitute an optimal 
therapeutic range - especially in the seventies after the introduction of mass 
screening - national policies have varied. Some countries have exercised 
more clinical caution than others. In the USA, the range widely adopted was 
180 to 600 Jlmol/l throughout the entire treatment period (Schuett & Brown, 
1984), whereas in Germany control within the range 60 to 360 was sought 
from birth to 10 years of age, and 120 to 720 for 10 to 15-year-olds (Burgard, 
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1991). In Denmark, upper limits of 420 were thought desirable from birth to 7, 
600 from 7 to 10 and 720 from 10 to 12 (Andresen, 1991). 
A consensus remains to be reached. In the UK, the range in common use 
was 180 to 600 for pre-school children. This was superseded by a clear 
recommendation in the early nineties that clinicians aim to keep phe levels 
below 360 Jlmol/l in the pre-school period, below 480 in the primary school 
period and below 700 in adolescence (Medical Research Council, 1993a). 
Germany retains the tradition, established by Bickel, of endeavouring to 
achieve even lower levels: less than 360 Jlmol/l before age 10 and less than 
600 between 10 and 15 years (Burgard, 1994). 
Some of these goals may be more idealistic than realistic. Even in the best 
controlled children, levels inexorably rise with age. For entire populations, 
even when vigorously treated, loss of control occurs progressively. For 
instance, despite the recommendations of the German Paediatric Society, 
Weglage et al. (1993) reported mean phe levels rising from 461 to 648 Jlmol/l 
between the ages of 5 and 10 and progressing to 812 by age 15 in their 
sample of 34 Munster patients. 
Age of treatment cessation 
No single issue in PKU research has generated more controversy than the 
age at which dietary treatment should be stopped. As with dietary control 
criteria, national differences have emerged. For example, in France cessation 
of treatment as early as age 5 was commonplace in the seventies and early 
. 
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eighties (Saudubray et al., 1987). Over this period in the USA, many children 
discontinued at age 6 (Schuett et al., 1980). In the UK, at least 50 per cent of 
subjects on the Register were on relaxed diets (500 to 1000 mg of phe per 
day) by age 8, (Smith et al., 1990a) though the West of Scotland Centre 
treated strictly till age 10. In Germany, strict control was attempted at least for 
the first 7 years of life (Burgard, 1994). 
Eight years after Bickel's first report, concern was expressed about the lack of 
knowledge surrounding relaxation of dietary restriction (Moncrieff & Wilkinson, 
1961). Bickel's own approach to the question of dietary cessation was 
theoretical. Jervis and others had shown that untreated patients did not 
deteriorate in adolescence; Gruter had suggested this might be due to brain 
myelination being complete by puberty; and Crome had demonstrated that 
phe could interfere with myelination: from this information, Bickel concluded 
that dietary termination in adolescence might be safe (BiCkel, 1980). 
Empirical data at that time were only available from a handful of case studies. 
For example, Murphy (1963) described outcomes in two children who were 
treated before 2 months, discontinued at 4 years of age and followed up at 7. 
In the first, the on-diet IQ was 85 and the off-diet 88; in the second, the on-diet 
IQ was 90 and the off-diet 85. Such equivocal findings clearly emphasized 
the need for larger-scale research, but it was not until the late seventies when 
information from the various collaborative studies began to emerge. 
The very earliest studies revealed more about the need for careful 
methodology than about the influence of treatment termination age on 
subsequent intellect. For instance, Brown and Warner (1976) reported an on-
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diet group's 10 being eight points higher than an off-diet group's but, as the 
groups were unmatched for age of commencement and control, and even age 
of cessation was not given, no clear conclusion could be drawn about the 
relationship between the two variables. 
It was Cabalska et al. (1977) who perhaps did most to raise concern about 
diet discontinuation in the pre-school period. Comparing IQ during dietary 
restriction with 10 after four years of free diet in two samples of classical PKU 
children drawn from the Polish Collaborative Study who, respectively, 
stopped at 2 years 6 months and 4 years 8 months, these authors found both 
overall between-group differences and within-group decline in scores at 
fOllow-up. The table below shows the pattern of mean lOs. 
Mean IQ 
On-diet Four years later 
Group One (n=22, cessation: 4 yrs. 8 mths) 101 
Group Two (n=10, cessation: 2 yrs. 6 mths) 91 
90 
77 
Table 2. 10 following dietary cessation (after Cabalska et al., 1977) 
Superficially, the data strongly suggested that 4 or 5 is too young an age to 
terminate diet without risk of compromising intellectual development and this 
was the authors' conclusion. Unfortunately, the study contained several 
methodological flaws which weakened the argument. First, Group Two, as 
well as stopping early, were also late-treated: at 40 days as opposed to 25 in 
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Group One. Second, Group One contained three children whose dietary 
control was poor. And third, no statistical analysis of the main factors and, 
even more importantly, the interaction term was undertaken. Thus, besides 
sampling and between-group comparability problems, the reliability of the 
data obtained was not tested. 
Smith et al. (1978) published the first group study on data from the UK 
Register pertaining to the treatment cessation issue. Only a subgroup of 21 in 
their overall sample was homogeneous for age of commencement and 
cessation, nonetheless these 21 uniformly started under 6 weeks and stopped 
at 8 years. On-diet, their average IQ was 96, but this fell on follow-up after two 
years of free diet to 91 (P < 0.05), suggesting that exposure to excess phe 
during the later primary school years might still carry a risk, and that even 8 
might be too young an age to discontinue. 
These findings were undermined by a report from Boston by Koff et al. (1979). 
This well-controlled, longitudinal study revealed no significance difference in 
pre-termination and off-diet 10 in a group of 30 classical PKUs who had 
stopped between 4 and 6.5 years of age and who were followed up, on 
average, 3.5 years later. These authors saw the result as a vindication of the, 
then, usual US practice of discontinuing diet between 4 and 6. However, this 
may be too simplistic an interpretation as no attempt was made to relate 10 to 
the period of post-dietary exposure to phe. The case would have been 
weakened, had a significant negative correlation emerged from such an 
analysis. 
By the early eighties it was becoming clear that the criteria for evaluating 
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methods used in treatment discontinuation research were good control of 
non-treatment factors such as severity of the disease and of treatment factors 
such as age of commencement and compliance with therapeutic limits. Also, 
post-cessation management can be a factor if children are placed on relaxed 
rather than free diets as is customary in Germany. Furthermore, length of 
follow-up period is an important factor as the extent of brain damage caused 
by a given level of phe over a given time seems to diminish with age and 
short-term follow-ups may yield false negatives. 
Apart from this last criterion, the others were met by the initial study on diet 
discontinuation from the US Collaborative Study (Koch et al., 1982). These 
authors adopted a quasi-experimental approach to the question, randomly 
allocating 115 early-treated children at their sixth birthday to continuing and 
discontinuing groups - matched for size, age, sex and severity - and retesting 
10 at age 8. They found no reliable change in IQ for either group despite the 
disontinuers' phe level having doubled, leading them to conclude that if diet is 
stopped at 6 no major intellectual deterioration occurs in the short-term. 
Nevertheless, the authors added the caveat that the high phe group may fare 
worse in the long term. In a follow-up study of the groups conducted after a 
further two years of high phe exposure for the discontinuers, Fishier et al. 
(1987) then found a significant 10 difference in favour of the continuing group. 
While the discontinuers' las remained near-constant, the continuers' rose. 
Combining mean data from the two studies gave the following table. Figures 
at 6 years are baselines when both groups were on diet. The interaction 
between group and age was significant (P < 0.05). 
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Discontinuers 
Continuers 
6 yrs. 
97 
101 
8 yrs. 
97 
102 
10 yrs. 
96 
105 
Table 3. Treatment discontinuation and serial 10 {after Fishier et al., 1987}. 
Thus, the suspicion was raised that six years of age may be too young to 
discontinue treatment. Though there appeared to be no dramatic decline in 
10 in the slightly longer term following treatment termination at this age, 
compared with the continuing group those who stopped seemed to fare worse 
in the late primary school period. 
In a report published almost simultaneously with that of Fishier et al. (1987), 
considerable weight to the argument that treatment cessation at 6 is 
premature was added by an analysis of another subset of the US 
Collaborative Study's cohort (Koch et al., 1987). In this work, las were 
obtained at the later age of 12 for two groups, one of which stopped diet at 6 
and one that stopped at 8. The outcome here was strikingly different to that 
found by Fishier et al. in that the mean 10 for the earlier-stopping group was 
well below that of the later-stopping group: 87 compared to 101. The 
significance of this apparently large difference is unknown as no statistical test 
of the distributions was provided. 
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Earlier findings reported by Seashore et al. (1985) from a small-sample study 
(n=14) closely mirrored the above 14-point discrepancy and cast more doubt 
on the wisdom of terminating treatment as early as 6 years old. These authors 
found mean las fell from 104 at age 6 when the subjects came off diet to 90 at 
age 13, this being a significant difference (P < 0.05). 
By the mid-1980s, the tentative conclusion from the US Collaborative Study 
was that treatment should continue at least until age 8 and possibly beyond 
(Holtzman et al., 1986). As children detected in the early days of mass 
newborn screening grew older and increased in number, empirical research 
improved due to greater sample selectivity and investigation of longer dietary 
- and, indeed, phe exposure periods - becoming possible. Hence, by the 
1990s workers from the US Collaborative Study were able to compile a 
sample of 95 treated subjects with classical PKU, all of whom commenced 
early (average = 17 days), were reasonably well-controlled and lost dietary 
control at different ages but with some continuing beyond 10. Because of 
these characteristics, Azen et al. (1991) were able to compare 10 results from 
three modestly sized subgroups that varied on the termination parameter, one 
stopping before 6 years of age (n=23), one before 10 (n=47) and one carrying 
on beyond 10 (n=25). She and her colleagues found a progressive and 
significant deterioration in mean WISC-R lOs at age 12 as a function of age of 
dietary cessation, the mean for the early group being 87, that for the middle 
group 96 and that for the late group 101 (P < 0.01). These researchers 
concluded that the PKU diet should be maintained until at least 12 years of 
age, however they failed to take into account the fact that quality of control and 
age of cessation were confounded. Thus, even before age 4 when all the 
subjects were nominally on diet, the early cessation group had the worst 
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control and the late cessation group the best, mean phe levels for the period 
from diagnosis being respectively 576 and 354 JlmoVI. The middle group had 
an intermediate level of 462. 
Because of the often retrospective nature of treatment cessation research, 
other treatment factors cannot be controlled experimentally. An alternative 
approach to comparing IQ outcome in on- and off-diet groups, is multiple 
regression analysis. The theoretical basis for this methodology is the now 
accepted view that outcome in treated PKU does not depend exclusively on 
the single treatment factor of age of cessation but on an amalgam of 
constitutional and treatment variables related to phe. The causal model can 
be expressed as an equation as follows. 
Severity + age begun + quality of control + age stopped = mental 
level 
The constitutional variable of severity refers to genotypic expression and the 
level of phenotypic PAH activity associated with different genetic mutations. 
The other three variables concern how treatment is managed clinically and 
domestically. While this simple predictive model is generally accepted by 
practitioners and scientists, what genetic and biochemical research has 
endeavoured to elucidate is the weightings of each variable and how they 
interact. This quest is ongoing and the multiple regression technique lends 
itself to the holistic approach required once a model such as the above, with 
its multiplicity of interactive parameters, is acknowledged. However, few 
studies to date have attempted to incorporate data into a multivariate scheme. 
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One example is a follow-up study by Chang et al. (1983) of 49 patients, 33 of 
whom were off diet when tested. The aim of their study was to identify and 
weight factors affecting 10 outcome by means of multiple linear regression. 
Data on both phe and non-phe factors were fed into the analysis. They found 
that parental education, commencement of treatment, on-diet phe level and 
length of treatment all predicted 10. Leaving aside parental education, which 
is a non-PKU-specific predictor, higher 10 was most associated with early 
treatment and, to a lesser extent, low on-diet phe levels and prolonged 
treatment. However, the design and sample characteristics of the study 
precluded these authors from making a statement about the best age for 
treatment cessation. 
In another study based on a multiple regression analysis, Michals et al. (1988) 
corroborated Chang and his colleagues' findings, obtaining 10 results from a 
sample stratified by age of cessation. These workers found that parental 10 
and age of treatment commencement were, respectively, directly and 
inversely proportional to later 10 and, furthermore, that blood phe level after 
treatment discontinuation was a predictor. Curiously, they recommended that 
diet be continued beyond 10 years. However, this conclusion was not 
necessarily warranted by their findings. None in their sample was older than 
10, thus no off-diet data after this age were available. 
Treatment control and discontinuation policy 
Research has largely settled the issue of treatment commencement, 
overwhelming evidence supporting an early intervention policy, ideally with 
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treatment beginning as soon as is practicable. In age terms this is the second 
week of life as diagnosis before then is unreliable due to transient 
hyperphenylalanaemia. During treatment, a phe-Ievel ceiling as high as 600 
Jlmol/l, such as used to be commonplace in the US, may be too high and 
nowadays in the UK and Germany a formal policy has been adopted of 
restricting phe, at least in the pre-school years to within a 360 Jlmol/l limit. 
Treatment discontinution policy remains to be better informed by research. 
Some practitioners have taken the extreme view that treatment should be 
lifelong (e.g. Naughten et al., 1987) and this position has been more widely 
advocated in recent years. However a 'diet-for-life' treatment regimen may be 
personally and socially disruptive for the patient and some concern has been 
already raised that the policy may be precipitate, overstated and unjustified by 
empirical findings (Walter, 1995). The logic of extrapolating from research that 
suggests that diet should be maintained until, say, age 10 to a lifelong 
treatment regime does not stand scrutiny, yet this line of reasoning has been 
followed by several authors in the nineties. 
For instance, Smith et al. (1990a) analyzed longitudinal 10 data from two large 
cohorts within the UK PKU Register - the first, children born between 1964 
and 1971 (n=224) and the second, children born between 1972 and 1978 
(n=375). To control for possible shifts in 10 population norms, she and her co-
workers converted obtained lOs into Z-scores based on the estimated true 
mean for the population at the individual child's fourth birthday (when the first 
10 measure was taken) and the standard deviation of the test. These 
transformed lOs were then regressed against historical phe concentrations. A 
significant negative correlation was found between 10 at age 8 and phe levels 
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in the previous 4 years. 10 at age 10, however, showed only a weak inverse 
association with control in the preceding two years in one cohort and none in 
the other, and IQ at ages 12 and 14 in relation to phe levels after age 10 was 
random. 
Smith et al. concluded that by middle childhood 'maturation of the nervous 
system has advanced to a stage where the parameters of intelligence have 
stabilised and are therefore less vulnerable to the biochemical effects of 
phenylketonuria'. Nothwithstanding this clear statement about the eNS 
eventually reaching a stage when it achieves protection against the malign 
influence of phe, and despite the lack of empirical evidence for a harmful 
effect of phe on 10 after age 10, Smith et al. went on to recommend that 
patients with PKU will 'have to be advised to continue a low phenyialanine 
diet indefinitely'. Their reasons for this apparent non sequitur stemmed from 
sporadic case reports of adults who were treated early showing abnormal MRI 
scans (e.g. Villasana et al., 1989; Thompson et al., 1990) but without knowing 
whether such findings relate to post-treatment phe exposure in the second 
decade. 
Similarly, at the end of a review of 12 treatment discontinuation studies, 
Potocnik and Widhalm (1994) concluded that the evidence pointed to 
treatment continuing until 10 years but then, paradoxically, went on to 
recommend a diet for life. This has already become the stated policy of clinics 
throughout Eire (Naughten et al., 1987) and to a lesser extent in Holland 
(Slijper et al., 1988). 
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Aim of present research 
Treatment research and policy are inseparable in PKU. A more sober 
assessment might suggest that generalizations about discontinuation policy 
be withheld until further knowledge is obtained about long-term psychological 
functioning in adolescence and adulthood following treatment. PKU research 
continues to evolve and studies of older patients who were well treated in 
childhood is the next natural stage in the process. Hitherto, such 
investigations were not possible. Because national mass screening 
programmes only began in the late sixties and early treatment criteria were 
undecided, until now there were insufficient older individuals available for 
constructing samples in which severity and treatment variables were 
satisfactorily controlled. 
Compilation of such samples is now a reality and the first aim of the research 
described in this volume is to shed light on the issue of whether 
neuropsychological functioning is impaired by excess circulating phe 
occasioned by dietary cessation following strict phe control up to the tenth 
year of life. This was treatment policy in Glasgow from the inception of mass 
screening and one that enabled a group to be collated that had good 
homogeneity for treatment variables. Evidence of post-diet dysfunction in 
such a group would imply ongoing eNS susceptibility to the neurotoxic effects 
of phe and would indeed provide support for treatment continuation at least 
into adolescence - though not necessarily for life. The phe-restricted diet is a 
harsh regime whose psychosocial cost both for child and caretaker is 
considerable. Research must demonstrate that the benefits of remaining, 
perhaps indefinitely, on a phe-restricted food intake outweigh the demands 
Chapter 2: Page 61 
and privations of the treatment. 
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Chapter Three 
INFLUENCE OF POST-TREATMENT 
HYPERPHENYLALANINAEMIA ON NEUROPSYCHOLOGICAL 
FUNCTIONING 
Background 
The study reported in this chapter arose out of an opportunity to examine 
neuropsychological functioning in a group of adolescents and young adults 
with PKU, all of whom had been diagnosed and treated early, had remained 
on a well-controlled diet until age 10, had ceased treatment abruptly at this 
age and had subsequently been hyperphenylalaninaemic for three years or 
more. These sample characteristics were determined by the policy in the 
West of Scotland of keeping patients, diagnosed at neonatal screening as 
having classical PKU, on a strict diet throughout childhood, then discontinuing 
treatment on their 10th birthday. Compared with, say, the early French and 
American approaches of terminating treatment at 6 or even earlier (Schuett & 
Brown, 1984; Saudubray et al., 1987), the policy in Scotland was a 
conservative one founded on a combination of theory and caution. 
In the 1970s, insufficient empirical data were available to guide clinical 
practice. Theoretical considerations of when might be safe to stop treatment 
centred on the knowledge that myelination of the human CNS is largely 
complete by 10 years of age. It was therefore assumed that, thereafter, the 
CNS would be sufficiently protected to withstand the high levels of circulating 
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phe that would result from dietary liberalization. The prediction stemming from 
this theoretical position was that post-treatment neuropsychological 
functioning would be unaffected by long-term exposure to phe after the age of 
10. This was the hypothesis tested in the study. 
A cross-sectional design was necessary to investigate outcome in patients 
falling into this category. A longitudinal study would have been preferable, as 
each subject could have acted as their own control, but this was precluded by 
an absence of on-diet test results. A control group procedure was chosen 
instead, with results from a carefully selected group of ten older off-diet PKUs 
being compared with those from a group of matched non-PKU controls. 
Further control for phe-effects was achieved by incorporating into the design a 
group of younger on-diet PKUs matched with a second non-PKU group. All 
four groups were tested using the same neuropsychological battery, the 
subtests of which were selected so as to suitable for a wide age range. 
The model for the null hypothesis was as follows. 
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• PKU Gl r2) Control u 75 c: 
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Figure 6. Null hypothesis model. 
The figures on the ordinate for test performance are notional. The age factor 
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was expected to show a difference in favour of better performance by both 
older groups - PKU and control - on developmental grounds. The PKU factor 
was expected to show either no difference or perhaps a slight loss of 
performance for both PKU groups, the latter being a common finding even in 
well-treated PKU (Beasley et al., 1994). The interaction was the critical term in 
the analysis. If post-dietary phe had had no specific effect, then the interaction 
between treatment status and age would be non-significant. If, however, phe 
had had a significant deleterious effect after an exposure period of three or 
more years, then the interaction term would reveal this, the score pattern for 
the alternative hypothesis being as follows. 
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Figure 7. Alternative hypothesis model. 
A battery of eight paired neuropsychological tests was devised. The four pairs 
represented motor, attentional, generative and memory functions. Each pair 
contained one verbal and one spatial test. No between-test differences were 
hypothesized ad hoc, the principal aim of the study being to explore whether a 
specific phe effect would emerge that could be attributable to treatment 
cessation. 
Chapter 3: Page 65 
Introduction 
Global mental handicap in classical phenylketonuria (PKU) can be prevented 
by early implementation of a phenylalanine-restricted diet. However, research 
over the past decade or so has suggested that subtle psychological 
deficiencies might arise in patients with phenylketonuria after discontinuation 
of prophylactic treatment, despite early commencement. Problems reported 
include mild diminution of IQ (Koch et al., 1982), scholastic underachievement 
(Seashore et aI, 1985), spatial dyspraxia (Pennington et al., 1985), visuo-
motor incoordination (Faust et al., 1986) and atypical sensory evoked 
potentials (Pueschel et al., 1983). In all these studies, however, patients' 
dietary control was lost at around 5 to 6 years of age, which may be too early 
to ensure protection of the CNS against the harmful effects of phenylalanine. 
Holtzman et al. (1986) concluded that treatment should continue until at least 
age 8 and Azen et al. (1991), on the basis of evidence from the USA 
Collaborative Study, recommended continuing dietary restriction until age 10 
if loss of IQ is to be reliably avoided. 
The optimum age for dietary termination in PKU remains controversial. No 
world-wide age standard has been established for stopping treatment, past 
figures varying from 4 to 14 years (Smith et al., 1978; Schuett et al., 1980). 
Since the introduction of national screening in the 1960s, the age adopted in 
the West of Scotland for treatment discontinuation in PKU has been 10 years. 
During the first 5 year period of treatment the objective has been to maintain 
phenylalanine levels below 400 Jlmolll and during the second 5 years below 
600 Jlmoi/i. Because of this policy, the rare opportunity arose of investigating 
the psychological status of a selected sample of PKU patients who were well 
Chapter 3: Page 66 
treated until age 10 but who then discontinued diet and subsequently 
experienced several years of high phenylalanine intake as adolescents or 
adults. The present study explored the question of whether 10 years of 
treatment during the most vulnerable neuromaturational period is sufficient to 
provide long-term immunity against the mentally disabling effects of 
phenylalanine. What distinguishes it from previous research is not only the 
prolonged duration of treatment, but also the subjects' length of exposure to 
high levels of phenylalanine thereafter: three years in all cases and as much 
as 11 in some, these latter being among the first babies detected following the 
introduction of neonatal screening in the UK (Wolff, 1981). 
Psychological investigation focussed on motor, perceptual and cognitive 
functions. Measures derived from neuropsychology were used (Griffiths, 
1989), the rationale being that information-~rocessing, multi-trial learning, 
sustained attention and decision-making tasks consistently show greater 
sensitivity to non-focal organic impairment than 10 tests with their high 
proportion of long-term memory items (Barbizet, 1970; Miller, 1977). 
Test performance of off-diet PKU subjects was compared with that of 
unrelated, developmentally normal adolescents and adults. As a control for 
dietary effects, a group of younger, on-diet PKU subjects was also tested and 
their results compared with normals. We hypothesized that, if exposure to 
phenylalanine is psychologically harmful ev~n after 10 years of treatment, the 
older, off-diet group would show adverse effects (i.e. diminished performance) 
on neuropsychological tests; by contrast, the younger, on-diet group who had 
not been exposed to chronically high levels of blood phenylalanine would not 
show the same effects. On the basis of the well-established finding that minor 
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cognitive deficiencies are present even in treated PKU patients who remain 
on diet (Berry et al., 1979; Brunner et al., 1983; Beasley et al., 1994), we 
expected some diminution in performance relative to normal by the PKU 
sample overall, but that the decrement would be greater in the off-diet group if 
post-treatment hyperphenylalaninaemia were a deleterious factor. 
Methods 
Subjects 
Forty subjects in total were tested, 20 PKUs and 20 controls. The PKU sample 
consisted of 10 younger children (seven boys, three girls) who were still on 
diet and 10 older adolescents and adults (same sex ratio) who had stopped. 
All 20 had been diagnosed as having classical PKU at birth, the mean 
neonatal blood phenylalanine level before treatment for the younger group 
being 1977 Jlmolll (s.d. 500) and for the older group 1912 Jlmol/l (s.d. 1077). 
The groups did not differ statistically in severity (t= 0.17, P= N.S.). All were 
diagnosed and treated within three months of birth, the median age at which 
treatment commenced for the younger group being 15 days (range 12-20) and 
for the older group 31 days (range 8-75). Again, this difference was not 
significant (U = 25, P = N.S.). On average, both PKU groups maintained their 
blood phenylalanine levels below 600 J.1molll throughout treatment and at 
least for the first six years of life stayed within what is nowadays 
recommended as the therapeutic range of 120 to 360 J.1mol/l (Medical 
Research Council, 1993a). The older group's level rose steeply on 
discontinuation of the restricted diet at age 1 U. Figure 8 shows changes over 
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time for the two groups' indices of dietary control. 
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Figure 8 Index of dietary control: average phenylalanine blood levels for 
both PKU groups during each year of life. Means are derived from annual 
median values for each subject. The restricted diet was formally discontinued 
in the older group at age 10. The figure shows a sharp rise in the average 
level for the subsequent year. 
At testing, the median age of the younger PKU group was 7.53 years (range 
5.58-9.75), that of the older group 20.59 years (range 13.58-28.42). The 
median age for dietary discontinuation in the older patients was 10.17 years 
(range 9.50-11.42) and all had been exposed to high levels of phenylalanine 
for at least three years, the median period being 10.50 years (range 3.58-
17.00). The mean phenylalanine level of the younger group when tested was 
348 Ilmol/l (s.d. 167), that of the older group 1014 Ilmol/l (s .d. 216). This 
difference was highly significant (t= 7.72, P < 0.001). Overall, the PKU 
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sample had a working-class bias. 
Each PKU subject was matched with a non-clinical control on the basis of 
age, sex and approximate socio-economic status. The average ages of the 
younger and older control groups did not differ significantly from those of the 
PKU samples (younger controls: median 7.59 years, range 5.66-9.75, U = 
49.00, P= N.S.; older controls: median 20.54 years, range 13.58-27.92, U= 
47.50, P= N.S.). All control subjects were free from major developmental 
disorders as far as could be ascertained by parental- and self-report. 
Tests and administration 
Eight tests were selected on the basis of Pennington's (1991) developmental 
neuropsychological model, each providing respectively a measure of motor 
speed, sensory-motor coordination, visual perception, visual attention, verbal 
fluency, visual fluency, list learning and position learning. In addition to their 
sensitivity to organicity, a major factor in the choice was their applicability to a 
wide age range. 
Test details are as follows. 1) Simple Reaction Time Button-pressing in 
response to single light stimulus. Preferred hand. Ten trials summated. 2) 
Peg Transfer Purdue Pegboard (Lafayette Instruments) without collars and 
washers. Total time for transferring 25 pegs from left to right column of holes 
and back again. Preferred hand. 3) Matching Figures Visual matching-to-
sample of complex drawings. First ten items from MFFT20 (Cairns and 
Cammock, 1978). One-minute time-limit per figure. 4) Letter Cancellation 
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Visual letter-search (Neisser, 1967). Twenty target stimUli, 1180 distractors. 
Four minute time limit. 5) Verbal Fluency Thurstone's cued lexical retrieval 
task. Number of words beginning with letters IF', lA' and IS' generated in one 
minute respectively (Spreen & Benton, 1969). 6) Design Fluency Spatial 
counterpart of Verbal Fluency. Number of non-repeated designs made from 
two straight and two curved pieces of flat plastic in three minutes (Griffiths, 
1991). 7) Rey Verbal Learning Recall of orally-presented 15-word list, 
repeated five times (Rey, 1941). 8) Rey-Davis Manual Labyrinth Spatial 
counterpart of Verbal Learning. Systematic search and recall, repeated five 
times, of single peg positions in each of four stacked wooden boards, each 
board containing a further eight distractor pegs (Zangwill, 1946). 
General procedure and design 
Subjects were tested individually and given standardised instructions. To 
minimise order effects, the eight tests were randomised and the first-ta-last 
sequence counterbalanced. Each measure yielded a single, objective 
performance score. The study conformed to a cross-sectional mixed design 
with matched pairs, independent samples and non-repeated measures. 
Results 
For each subject, scores across items or trials on each neuropsychological 
test were summated. Table 4 shows the mean scores and standard deviations 
on the eight tests obtained by the four groups. Figure 9 depicts mean data 
only. Reaction Time and Peg Transfer values are times in seconds: the lower 
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the value the better was the performance. The remaining values are number-
correct scores. No basal or ceiling problems were encountered on any test. 
young Old 
PKU (ondiet) Control PKU (off-diet) Control 
Tests Mean SO Mean SO Mean Sp Mean Sp 
Reaction Time (sees) 3.31 0.89 2.95 0.52 2.37 0.77 2.20 0.47 
Peg Transfer (sees) 88.50 19.56 72.70 12.80 51.50 5.42 46.90 4.75 
Matching Figures 4.90 1.52 4.80 1.55 7.20 1.40 8.80 1.23 
Letter Cancellation 3.33 0.77 3.51 1.46 7.36 3.52 9.76 5.06 
Verbal Fluency 1B.BO B.95 19.00 9.63 33.80 9.43 3B.90 8.63 
Design Fluency 11.90 2.56 12.20 2.35 18.20 3.43 24.50 3.41 
Rey Verbal Learning 42.40 10.09 43.00 7.65 46.70 8.0B 55.10 7.40 
Rey Labyrinth 10.50 4.74 13.10 4JlB 14.50 3.95 17.60 LOB 
Table 4. Means and standard deviations for neuropsychological tests. Data 
are performance scores expressed as total correct items except for Reaction 
Time and Peg Transfer tasks which are scored in seconds. See also Figure 9. 
Data from the test battery were analysed by ANOVA. The focal point was the 
interaction term as it provided an indication of differential performance 
between the on- and off-diet groups and therefore whether post-treatment 
hyperphenylalaninaemia impaired psychological function. 
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Figure 9. Group mean scores on neuropsychological tests. Bars: (grey) 
younger, on-diet PKUs; (black) older, off-diet PKUs; (hatched) controls. All 
interactions were non-significant except for Design Fluency (P < 0.01) and 
Matching Figures (n.s. trend, P = 0.07). 
Separate ANOVAs were conducted on each set of test results. F-ratios and 
Significance levels are displayed in Table 5. A highly significant age effect on 
each measure was found. Given the 13-year average difference between the 
younger and older PKU and control groups, the influence of a developmental 
factor favouring the older subjects is scarcely surprising. Findings for the 
diagnosis factor were patchier with the PKU subjects showing significantly 
poorer ability than the controls on the Peg Transfer and Rey Labyrinth tests 
irrespective of age or treatment status. Design Fluency also showed a PKU-
effect. Furthermore, Design Fluency was the only test to reveal a significant 
interaction between diagnostic and treatment status, the older, off-diet PKU 
group doing differentially much worse than the younger on-diet group 
(Scheffe, P < 0.001). Apart from Design Fluency, none of the other interaction 
terms was significant at the 5 per cent level, although that for Matching Figures 
showed a trend towards significance at the 7 per cent level, again with the off-
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diet group specifically performing worse than the controls. There was no 
significant PKU-effect on this variable. 
Eaclo[ 
Ageldiel Diagno~is Inle[a~tiQn 
Tests F p F P F P 
Reaction Time 15.20 0.001 1.50 N.S. 0.19 N.S. 
Peg Transfer 63.35 0.001 7.22 0.05 2.28 N.S. 
Matching Figures 48.47 0.001 2.75 N.S. 3.53 N.S.T. 
Letter Cancellation 26.50 0.001 1.79 N.S. 1.05 N.S. 
Verbal Fluency 36.23 0.001 0.84 N.S. 0.71 N.S. 
Design Fluency 97.73 0.001 12.31 0.01 10.17 0.01 
Rey Verbal Learning 9.59 0.01 2.89 N.S. 2.17 N.S. 
Rey Labyrinth 11.28 0.01 5.07 0.05 0.04 N.S. 
Table 5. F-ratios from two-factor ANOVA and significance levels at P=/<0.05. 
'Age/Diet' factor refers to younger, on-diet PKU children and controls versus 
older, off-diet PKU adolescents/adults and controls. 'Diagnosis' factor refers 
to all PKU subjects, i.e both on- and off-diet, versus all controls. Degrees of 
freedom 1/36 throughout. Only Design Fluency interaction term achieved 
significance. 
Matching Figures interaction showed a non-significant trend at P=0.07. Peg 
Transfer, Design Fluency and Rey Labyrinth showed an overall PKU effect 
(see also Figure 9). 
Correlating raw test scores derived from the older PKU group (n = 10) with the 
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lengths of time these subjects had been off diet yielded no significant 
statistics. Six of the eight coefficients were negative, but the strengths of the 
associations were insufficient to indicate any relationship between time off diet 
and poor test performance. 
As a final analysis, test scores for the off-diet group were standardised by 
converting each into a Z-score based on the mean and standard deviation 
derived from the older control group's distributions on each of the tests. With 
signs reversed for Reaction Time and Peg Transfer, individual PKU subjects' 
Z-scores were summated across the eight tests to provide a composite score 
for the battery as a whole. Composite scores were then correlated with time 
off diet (i.e period of hyperphenylalaninaemia), but the coefficient was not 
reliable (r= -0.52, d.f. 8, P= N.S.). While the negative sign implies that overall 
test performance declined with time off diet, the association was weak and 
failed to represent even a non-significant trend at P < 0.10. No correlation 
was found between composite scores and post-treatment phenylalanine level 
(r= -0.04, d.f. 8, P = N.S.), nor with age of treatment cessation (r=0.03, d.f. 8, 
P = N.S.), although the range of the latter variable was very narrow. None of 
the treatment-related variables correlated reliably with any of the tests singly. 
Discussion 
Overall, the results from the present study failed to provide convincing 
evidence that prolonged exposure to unrestricted phenylalanine during 
adolescence and early adulthood is harmful to cognitive and motor 
functioning in well-treated PKU when dietary termination is delayed until at 
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least 10 years of age. Methodological factors such as diagnostic and 
treatment variables were tightly controlled to produce homogeneous 
experimental samples. Nevertheless, as group sizes were small and 
functions tested limited, inferences about the wider PKU population should be 
made with caution. The findings from the present study, however, appear to 
vindicate the West of Scotland practice of continuing dietary treatment until 
age 10, but do not necessarily support a diet-for-life policy as advocated by 
some authors (e.g. Beasley et al., 1994). Further research, ideally multi-
centre, with larger numbers and more varied tasks is required to settle this 
issue. 
The finding that both the on- and off-diet PKU groups under-performed the 
controls on the Peg Transfer, Design Fluency and Rey Labyrinth tasks was 
broadly in keeping with previous work. Although marginally lowered IQ in 
early-treated PKU, despite good dietary compliance, has been reported by 
several authors (e.g. Berry et al., 1979; Brunner et al., 1983; Smith & Beasley, 
1989), it may be that the discrete functions tapped by these 
neuropsychological measures (rapid eye-hand coordination, visual creativity 
and learning of spatial sequences) are especially vulnerable to prolonged 
exposure to the mildly elevated phenylalanine blood levels found even in 
well-treated patients. 
Welsh et al. (1990) found specific impairments on neuropsychological tests 
tapping executive motor and cognitive functions in pre- and early-school 
treated PKU children. She and her colleagues hypothesized that even well-
treated PKU chidren are susceptible to mild!y elevated levels of phenylalanine 
early on in life and, in particular, suffer from selective deficits in executive 
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functions such as attentional control, maintenance of mental set and motor 
planning. These authors proposed a prefrontal dopamine depletion 
mechanism to explain the specificity of the functional data. Diamond et al. 
(unpublished) have pursued this line of enquiry, arguing that the conventional 
therapeutic range of 100 to 600 Ilmol/l is too liberal, given that the upper 
phenylalanine limit is five times the norm. On the basis of comparative and 
neuropsychological evidence, she and her colleagues have concluded that 
elevated circulating phenylalanine as customarily found in well-treated PKU 
has a specific negative effect on cognitive-executive functions mediated by the 
prefrontal cortex of the brain even as early as infancy. In view of this, it is 
noteworthy that the three tests performed badly by both the on- and off-diet 
PKU groups fall broadly into the category of prefrontally-mediated executive 
functions, being characterised respectively by behavioural regulation, 
ideational productivity and spatial planning. While these findings may lend 
support to the idea of a specific executive-function defect in treated PKU which 
is identifiable early in childhood and persists into adulthood, the results 
nevertheless contained exceptions to this scheme. Scores on Verbal Fluency 
and Letter Cancellation were inconsistent, for example, even though these 
tasks are generally considered to represent executive activities dependent on 
prefrontal integrity (Beaumont, 1983). 
What is perhaps of greater concern is that deficits of any kind were found in 
the PKU patients overall. Both the on- and off-diet groups' average indices of 
dietary control in the early treatment period were within or close to the lower, 
revised therapeutic range as currently recommended of 120 to 360 Ilmol/l 
(see Figure 8) and not the more liberal rang~ of 180 to 600 Ilmol/l that was 
actually in operation at the time (Medical Research Council, 1993a). Despite 
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families' above-standard compliance with treatment early in the life of the 
children, three of the eight neuropsychological tests showed significant 
abnormalities of function later, two of these being unrelated to subsequent 
exposure to unrestricted phenylalanine. 
The Design Fluency task showed not just a general PKU effect but an off-diet 
effect as well. Impaired design fluency has been found in patients with focal 
frontal lesions (Jones-Gotman & Milner, 1977), adding weight to Welsh et al.'s 
view that the prefrontal cerebral cortex and its functions may be particularly 
vulnerable to the harmful effects of phenylalanine. Furthermore, this finding 
extends the prefrontal theory by implicating the adolescent and early adult 
period - when most patients have either terminated or relaxed the diet - as a 
time of possible additional risk. Whether deficient skill in the invention of 
visual designs after treatment for PKU is a temporary toxicological 
phenomenon and therefore perhaps reversible by dietary reinstatement 
remains to be investigated. 
It should be emphasized that the Design Fluency result was an isolated one, 
necessitating replication, and may represent at best a chance phenomenon or 
at worst a minor dysfunction. Further research is required before any firm 
conclusions can be drawn about prolongation of dietary treatment into 
adolescence and beyond. 
commentary 
Neuropsychological measures were chosen for testing phe effects on the 
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grounds that these are more likely to be sensitive to subtle cognitive 
dysfunction in PKU than IQ tests (Burgard, 1996). Nonetheless, the failure to 
incorporate IQ measures in the study could be regarded as a shortcoming as 
the presence of such data, in addition to shedding light on the concurrent 
validity of the experimental measures, would have made the results more 
readily comparable with those in the bulk of the literature. 
The non-significant interactions found on the Rey Verbal and Rey Labyrinth 
tests suggested no derangement of verbal or spatial memory as a 
consequence of post-treatment exposure to phe. However, this result conflicts 
with one recently obtained by Demellweek (1996) who found a significant 
discrepancy (P < 0.05) between the mean Full-Scale IQ on the WAIS-R (101) 
and the mean General Memory Index on the WMS-R (82) in six adolescents 
and adults with treated PKU. Though fewer, the individuals in his sample 
were all early-treated, but had been off diet for slightly longer: 5 to 13 years. 
The degree of comparability between the two samples as regards severity and 
phe-control is unclear as concurrent and historical phe levels were not 
reported. Oemellweek's finding is striking but, to date, an isolated one that 
remains to be substantiated. 
Non-homogeneity of the treatment commencement variable was a minor 
methodological flaw. Statistically, the older off-diet did not differ from the 
younger on-diet group, but the age range at which treatment began in the 
former patients was greater - as much as 75 days in one case. This slight 
confound did not cause interpretive difficulties as the analyses, except one, 
were uniformly negative. Nevertheless, it highlights the need for strict 
inclusion-exclusion criteria in sample construction. Many earlier studies of 
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treatment outcome have been lax in their sample specifications (see Chapter 
Two). Now that screening and treatment services are better integrated, a 
reasonable aim for future research might be to avoid including patients treated 
later than, say, 28 days after birth. 
With a specific phe effect only being shown on Design Fluency and non-
specific phe-effects being revealed by Peg Transfer and the Rey Labyrinth, the 
weight of evidence was in favour of accepting the null hypothesis. However, 
the risk of making a type 2 (Beta) error must be acknowledged because of the 
small sample sizes involved. Clearly, collaborative multi-centre research with 
larger, assiduously compiled samples is desirable. To date, few well-
controlled studies addressing the question of treatment cessation in the older 
patient have emerged from the national PKU databases. 
The significant interaction and PKU effect on Design Fluency are consistent 
. 
with the hypothesis that executive functions are specifically impaired in treated 
PKU. However, these findings were not corroborated by Verbal Fluency or 
Letter Cancellation, tests which are regarded by some as executive measures 
(Kelly et al., 1996). Further studies on this question are reported below in 
Chapters Eight and Nine. 
The index of dietary control (IDC) chosen was the median capillary blood phe 
reading per annum. This method of quantifying dietary control is in agreement 
with Rupp and Burgard (1995), though some authors have used the median 
for six months only. Throughout the studies reported here, the IDC has been 
standardized on the annual median as shorter time-spans in some subjects 
would have reduced the number of phe-samples to single figures. Diurnal 
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and day-to-day phe-Ievels vary considerably (Rylance et al., 1996). The more 
readings included in a unit measure, the more the standard error diminishes. 
The following is an illustration of the raw data from which yearly IDCs were 
calculated in a single patient, the abscissa representing the date of the assay 
and the ordinate the blood phe level in Jlmoi/i. Readings are from the first year 
of life, the first being taken on day 6. In the case of this child (M.McD.) the 
median annual level for year 1 was 360 Jlmoi/i. The graph below clearly 
shows neonatal levels well above the 1200 Jlmol/l threshold for the diagnosis 
of classical PKU. 
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Figure 10. Case illustration of neonatal phe control. 
The IDC curves in Figure 8 are characteristic of well-controlled PKU. The first-
year IDC is often high as good dietary control takes a while to be 
accomplished. The pre-school period is usually a time of very strict control, 
but after school-age levels start to creep up as children become more self-
determining in their eating habits, fall victim to peer pressure or actively defy 
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the rule of parents and dieticians {Weglage et al., 1993}. 
At the time of writing, the possibility of replicating this study or expanding the 
sample no longer exists. Shortly after it was conducted, the long-standing 
policy in Glasgow of dietary discontinuation on the 10th birthday was reversed 
in favour of a permanent treatment regime. The reasons for this decision were 
principally that MRI abnormalities were beginning to be reported in scans of 
PKU patients despite early and continuous treatment (Villasana et al., 1989). 
It was thought that dietary prolongation might furnish some protection against 
white matter disturbance and so it was considered prudent to advise patients 
to keep phe levels down indefinitely. This issue remains controversial 
(Brenton, 1996) - especially as white matter abnormalities do not appear to 
coincide with intellectual impairment (Thompson et al., 1993). 
As samples of patients who were homogeneous for age of cessation were no 
longer available, the research henceforth had to rely on subjects who had 
spontaneously discontinued at different ages. In the next chapter, the 
treatment discontinuation question is explored from the different 
methodological angle of experimental manipulation of phe. In the pilot study 
reported in Chapter Five, the matched groups design was replaced by a 
simple repeated measures design, and cognition and motor function studied 
in treated adults who returned to diet after several years of ad libitum phe 
intake. 
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Chapter Four 
EXPERIMENTAL MANIPULATION OF PHENYLALANINE: 
THEORETICAL AND METHODOLOGICAL BACKGROUND 
In the 1980s, due to the widespread policy, especially in the USA, of stopping 
treatment at or around the end of the pre-school period (Schuett et al., 1980), 
research into treatment factors mainly concentrated on intellectual outcome 
after dietary cessation (e.g. Koch et al., 1982; Seashore et al., 1985). The 
commonest methodology was the retrospective follow-up. Nevertheless, 
having a large sector of the PKU population off diet permitted a more 
experimental approach, namely, of deliberately manipulating the independent 
variable by reinstating treatment in previously treated but currently off-diet 
subjects. Exploration of possible phe-related changes in cognitive and 
behavioural functioning by this method could shed light on whether the 
neurotoxicological potency of phe extended into later childhood, adolescence 
or even adulthood. Moreover, the experimental approach could provide 
insights into the reversibility of phe-effects, if found. 
In addition to these important clinical issues, controlled experimention held 
the promise of expanding theoretical knowledge about the role of CNS 
maturation as a protective mechanism against the damaging effects of phe 
and the related question of how to conceptualise damage in the more mature 
organism. This latter issue concerns whether high levels of phe have 
predominantly structural or synaptic effects on neural tissue and whether the 
magnitude of these effects alters dynamically as a function of CNS maturation. 
Chapter 4: Page 84 
As discussed in Chapter One, neuropathological theories implicate the 
neurone as the prime target for phe. In particular, myelination was singled out 
as a likely candidate for disruption, though synapse formation and dendritic 
arborization occur simultaneously and are impaired by phe. Mental capacity 
is related to all three. 
Naturalistic versus experimental methodologies In the study of 
phenylalanine effects 
Throughout the history of phenylketonuria research, the influence of excess, 
circulating phenylalanine on neural structure and psychological functioning 
has been investigated both by naturalistic and experimental methodologies. 
For reasons of treatment ethics, naturalistic studies constitute the majority of 
studies. These may be small-scale, as in single-centre projects where sample 
sizes are customarily restricted by the availability of patients; or large-scale, as 
in the National Collaborative Studies of the UK (Smith & Beasley, 1989) and 
the USA (Koch et al., 1987). Irrespective of scale, naturalistic studies tend to 
be characterised by retrospective designs, a frequently adopted paradigm 
being to relate anatomical or functional data to dietary history (e.g. Behbehani 
et al., 1986). Such designs necessitate careful subject selection to avoid 
ambiguous effects from confounding or extraneous variables, and sufficient 
and consistent sampling of phe levels to enable comparability between 
subjects. Where samples are heterogeneous or where control has been 
weak, problems of causal attribution can arise. 
Control problems are inherent in the naturalistic approach. The independent 
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factor (phe level) typically varies according to forces over which the 
researcher may have little or no direct control, such as age of treatment onset 
or dietary compliance. In the experimental approach, on the other hand, the 
independent variable is deliberately manipulated by the researcher. 
Dependent variables studied are usually common to both approaches and 
may be neurological - for example, clinical or brain scan parameters; or 
psychological - for example, measures of skill, learning or adjustment. 
Experimentally raising phe during dietary restriction or lowering phe following 
dietary discontinuation are alternative means by which treatment issues have 
been addressed. If, as might be inferred from Davison's position (Davison, 
1973), there is an age in PKU beyond which the eNS is unaffected by 
hyperphenylalaninaemia, then raising phe from low levels or lowering phe 
from high levels, either artificially or naturally, should fail to potentiate changes 
in structure or function in individuals who fall into that age category. This logic 
has been the driving force behind the experimental approach in PKU, the 
origins of which date back to the 1970s. 
Experimental phenylalanine manipulation by challenge 
By nature, the experimental approach is prospective and fosters planned 
comparisons. Six years or so after mass neonatal screening for PKU was 
introduced in Europe and the USA, the first study emerged in which 
phenylalanine was experimentally manipulated in an endeavour to explore 
functional outcome (Frankenberg et al., 1973). In this prototype study, the 
authors selected six non-retarded children with treated classical PKU aged 
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four to five years and subjected them to a 20-day period of raised phe by 
means of a high phe supplement that simulated the average daily phe intake 
of a normal four-year-old. The group's mean blood phe-Ievel rose seven-fold 
from 342 to 2400 J,lmolli. A double-blind, repeated measures protocol was 
adopted. Each day, mothers rated dimensions such as withdrawal, 
hyperactivity and emotionality on an ad hoc instrument but the results 
revealed no measurable behavioural consequences of the manipulation, at 
least in the brief term of the experiment. Thus, the study failed to support the 
view that temporary hyperphenylalaninaemia produces psychiatric 
symptomatology in treated PKU. However, caution about generalizing the 
finding is required, given the small sample and short exposure period. 
Frankenburg et al.'s study illustrates the use of a challenge paradigm in 
experimental PKU research. In this approach, subjects who are being treated 
and therefore maintaining a low phe diet are temporarily exposed to high phe 
and concomitant measures of neurological or psychological variables taken. 
The integrity of the CNS is thus challenged by transitory 
hyperphenylalaninaemia and possible neurotoxic effects explored by tests of 
structural or functional change. This approach has also been used as an 
investigative tool with non-PKU subjects. For example in a study of the food 
additive aspartame which contains phe in large proportion, Zametkin et al. 
(1987) found that hyperactive children did not show behavioural toxicity 
effects after two weeks during which they were given phe at a level equivalent 
to the 99th percentile for adult consumption. 
Three other studies that fall into the challenge category are those by Krause 
et al. (1985), Hogan et al. (1986) and Clarke et al. (1987), the last two 
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stemming from the same Canadian laboratory. 
Krause et al. improved upon Frankenburg et a/.'s methodology by adopting a 
triple-blind, double-crossover design. These authors adjusted phe level in a 
similar fashion by adding phe to the dietary supplement. However, their 
sample was very heterogeneous for age (6 to 24 years), experimental 
treatment periods (low vs high phe) were only a week long and reporting of 
data was highly selective. Of eight neuropsychological tests administered 
(rapid automatised naming, trail-making A and B, grooved pegboard, choice 
reaction time, digit span, Benton visual retention and digit symbol), Krause 
and her colleagues only documented results derived from choice reaction 
time. They reported having found an inverse relationship between transitory 
phe level and psychological performance, but choice RT was the sole basis 
for the putative effect and the claim was not substantiated by statistical 
analysis. 
Hogan et al. (1986) studied seven subjects aged 13 to 17, six of whom had 
terminated treatment and been hyperphenylalaninaemic for four to 14 years. 
The age at which diet was stopped in this group was very young: between two 
and eight years. All had low las and some were mildly mentally handicapped, 
the overall 10 range being 60 to 90 with an average of 79. The combination of 
early dietary cessation and low 10 strongly suggested phe-related 
neuropathology. These authors first retumed the children to a restricted diet 
with a standard phe-depleted formula (Lofenalac or Phenyl-Free), then 
imposed a challenge by means of a high-phe supplement and finally 
reinstituted the low-phe supplement. During challenge, phe rose to an 
average of 1327 ~molll from an average of 713 Jlmolll during normal 
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treatment. The two intervals during which phe was experimentally altered 
were each five weeks long. Serial neuropsychological testing was conducted, 
the examiners being blind to condition. The measures included simple and 
choice reaction times, pegboard and trail-making tests, and others not 
specified in the report. The results showed no systematic effect of phe level 
on neuropsychological functioning, thus weakening the case for an element of 
phe neurotoxicity extending beyond childhood into adolescence. The 
negative findings did not provide evidence justifying the prolongation of the 
phe-restricted diet into late adolescence, but the borderline retarded sample 
studied was atypical and not representative of the well-treated PKU 
population. 
The same Canadian group published findings a year later (Clarke et al., 1987) 
that partly contradicted Hogan et al.'s (1986). Again based on a very small 
sample (n=9), it is not clear whether the subjects were largely those who 
participated in Hogan et al.'s study, but tested more extensively. This is the 
suspicion, however, as many of the features of the two samples were identical. 
Clarke et al. manipulated circulating phe by administering oral capsules 
containing high or low phe instead of a modified supplement. They employed 
a triple-blind, single cross-over design and collected data from the WISC, the 
WRAT and an eight-subtest neuropsychological battery, including choice 
reaction time, from a group of adolescents with classical PKU. Apart from the 
small sample size, subjects were non-homogeneous for treatment variables, 
some having terminated diet in infancy and showing las in the mildly retarded 
range. Clarke et al. found no reliable hyperphenylalaninaemia effects on any 
test from the WISC, WRAT or neuropsychological battery except for choice RT. 
thus providing some support for Krause et al.'s contention that choice RT 
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might be a phe-sensitive measure. 
The strength of the challenge model lies in the tight control the experimenter 
can exert over the independent variable. Equivalent control over treatment 
variables to avoid heterogeneous samples is just as desirable but, as none of 
the studies so far reported was conducted on patients whose treatment 
conformed to modem criteria, generalization to the PKU population as treated 
by present-day standards is difficult. The available literature from challenge 
studies can inform about the effects of transitory changes in phe on conduct 
and psychological test performance - albeit in patients many of whom 
discontinued diet earlier than would now be considered safe and whose 
exposure periods were very varied. The results to date, however, are 
equivocal and suggest that neither widespread nor severe intellectual 
deterioration attend experimentally induced hyperphenyalaninaemia 
irrespective of age of treatment discontinuation. If indeed any cognitive 
dysfunction does occur as a response to temporarily elevated phe, it may be 
in the area of rapid decision-making, but research data derived from 
representative samples and subjected to appropriate statistical analysis is 
currently lacking. 
Experimental phenylalanine manipulation by resumption of diet 
In experimental studies of the possible dynamic relationship between phe and 
CNS function in PKU, the dietary resumption paradigm has been more 
commonly employed than the challenge model. In the dietary resumption 
procedure, the independent variable, circulating phe, is manipulated by 
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returning treated patients to the restricted diet who have terminated treatment 
and therefore experienced a period of hyperphenylalaninaemia, perhaps 
several years long. 80th the resumption and challenge paradigms are 
reversal techniques but resumption is the mirror image of challenge. Viewing 
each longitudinally, the challenge method follows a low-high-Iow sequence, 
while the resumption method follows a high-low-high sequence. In terms of 
time-series treatment designs where A represents baseline and 8 treatment 
(Vasta, 1979), challenge can be represented as BAB and resumption as ABA 
(bearing in mind that the pre-treatment baseline in PKU is characterised by 
hyperphenylalaninaemia). Ethical principles dictate that, in challenge studies, 
the period during which the CNS is exposed to high phe is strictly limited, 
subjects always being returned to diet thereafter. However, in resumption 
studies, some subjects choose to remain on diet indefinitely. 
Apart from the difference in the sequence of conditions between the challenge 
and resumption approaches, the resumption method relies on manipulating 
phe by food and supplement variation rather than by supplement alone. In 
challenge studies, dietary restriction remains constant across all phases, only 
the supplement being altered so as to be phe-Ioaded or phe-limited. This 
readily enables blinding of subjects, parents and researchers to the condition 
imposed and enables tight control of the phe variable so long as subjects' 
dieting behaviour remains consistent. As a research procedure, the 
resumption method is the more erratic and difficult to control because it 
depends on behavioural change, and therefore motivation, on the part of 
subjects. Thus, unlike the challenge method, where phe intake can be altered 
imperceptibly, the resumption method cannot avoid awareness by participants 
of the transition between the high and low phases. 
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Achieving patient compliance with low-phe dietary treatment is perhaps the 
hardest task for the clinician. For the researcher, the goal may be doubly 
difficult to attain a) because resumption occurs after a period of unrestricted 
eating, and b) because it is usually imposed in adolescence or adulthood 
when parental mediation of dietary intake has been replaced by self-
determination. Furthermore, representative samples of patients may not be 
achievable. Because of the self-discipline and motivation required to return to 
diet, those prepared to do so will inevitably constitute a self-selected subset of 
the treated PKU population. 
Despite the intrinsic methodological shortcomings of the resumption 
procedure for experimentally manipulating phe levels, it has enjoyed a certain 
popularity in recent years amongst researchers investigating possible 
transitory neurotoxic effects of phe in treated PKU. Returning patients to diet 
in later life can provide information about adverse phe effects and their 
possible reversibility. Thus, if function is found to improve following dietary 
resumption in the older patient, this might be interpreted as evidence for 
reversal of phe-related toxicity occasioned by a free diet. 
Although the bulk of such work has concentrated on patient groups in their 
teens and twenties, Michals et al. {1985} explored dietary resumption in a 
group of 12 primary school children with PKU from the USA Collaborative 
Study. These authors followed up a cohort of 28 well-treated children with 
classical PKU who started treatment early and discontinued around their sixth 
birthday, as was the norm in the US throughout the seventies. Of this number, 
11 showed falls in IQ greater than seven points when tested after three years 
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on a normal diet and 24 had scholastic learning problems as evidenced by 
the need for repeating classes or for special tutoring. These findings 
principally called into question the wisdom of terminating treatment as early as 
six, but gave rise to the ancilliary question of whether loss of intellectual 
function could be regained by resumption of treatment. Michals and her 
colleagues addressed the reversibility issue by identifying twelve patients with 
an average age of 11 years who, as a group, had shown a mean fall in 10 of 
eight points: from 96 when treatment was stopped to 88 some three years 
later. For a further three years, they returned this group to a phe-restricted 
diet, retesting them at the end of the period. The researchers were unable to 
report that retreatment had been effective. They observed no change in 10 
and scholastic attainments showed a downward trend, suggesting that 
reintroducing diet later in the developmental period, even for several years, 
cannot rectify intellectual decline. 
This finding carries important implications for the theory of brain damage in 
PKU. While it fails to illuminate the precise neuropathological mechanism, it 
points to the six to nine year period as one during which the CNS remains 
vulnerable. As the adverse effects of phe appeared to be irreversible, it is a 
reasonable conclusion that the nature of neural disruption consequent on 
high phe in middle childhood is likely to be structural rather than biochemical -
neuronal and histological rather than synaptic and neurohumoural. 
In a companion study to Michals et al. (1985), Schuett et al. (1985) surveyed a 
larger and more heterogeneous group from within the USA Collaborative 
Study who had resumed dietary treatment after a period off diet. Seventy-two 
patients with PKU were identified who had restarted because of clinical 
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problems such as hyperactivity, moodiness and skin disease; and scholastic 
problems such as poor classroom performance. As the average age for 
treatment cessation in this group was six, there were probably many who 
stopped even earlier. Several subjects had IQs in the mentally handicapped 
range, suggesting CNS damage due to poor phe control. Thus, they could not 
be regarded as having been well-treated by contemporary criteria. The age 
for resuming diet varied between six and 19 years, about 30 per cent relapsed 
and few were able to maintain blood phe below 600 J.1mol/l. Off· versus on· 
diet changes were measured by a questionnaire completed by parents, 
teachers and clinic staff. After dietary resumption, improvements were 
recorded in scholastic learning, mood, activity level and maturity in 42 
patients. Eleven worsened on these dimensions and the remainder stayed 
unchanged. No comparison was made between improvement and age of 
dietary cessation, however a subgroup analysis by IQ band revealed that the 
greatest changes for the better were reported in the mildly and severely 
mentally retarded patients. These were mainly in mood and maturity. 
Though alterations in behaviour coincided with a return to diet, the case for 
attributing behavioural change to phe reduction was weakened by a lack of a 
significant correlation between off- versus on-diet blood phe differences and 
the questionnaire variables. No attempt to control extraneous factors was 
made and the authors did not acknowledge expectancy effects or the 
possibility of a Hawthome effect accounting for improved maturity. Nor did 
they consider that the intrinsically healthier PKU diet· with its high vegetarian 
content and low proportion of refined or manufactured foods· might have 
accounted for a lessening of hyperactivity (Egger et al., 1985). 
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The equivocal results of Schuett et al. (1985) illustrate the weaknesses of the 
resumption method. Apart from motivational factors and the difficulty of 
diminishing phe consistently across subjects, naivety on the part of subjects, 
caretakers and researchers as to dietary condition is impossible to achieve. 
This control limitation may result in positive changes in outcome variables 
being falsely attributed to phe reduction when effects are really due a third 
factor such as increased social attention or a generally better dietary regimen. 
Pietz et al. (1993) in Germany chose performance measures rather than rating 
scales in a study of phe effects on attention in a group of classical PKU adults 
with a history of good phe control. Though only five in number, compared with 
Schuett et al.'s (1985) sample the group was homogeneous for treatment, all 
subjects having been treated early and continuously until 12 years of age. 
Furthermore, dietary compliance was good, the average index of dietary 
control being 418 JlmoVI during childhood. IQ scores in the 105 to 126 range 
at age 20 provided evidence that early damage from elevated phe during the 
vulnerable infancy and early childhood period had been avoided. Phe was 
manipulated by dietary restriction and relaxation, the study conforming to a 
counterbalanced rather than a reversal design. This meant, however, that 
subjects and investigators were aware of the conditions imposed and that 
subgroups were only two or three strong. A dot-pattern task was used to 
measure sustained attention, subjects being required to press a key with the 
left finger in response to a three or five dot stimulus and with the right to a four 
dot stimulus. The authors claimed that sustained attention worsened under 
the high- compared with low-phe condition though numbers were too small to 
permit inferential statistical testing. 
Chapter 4: Page 95 
Though minimal, Pietz et al.'s (1993) evidence hinted that functioning in 
treated PKU might be compromised following dietary relaxation even after 
prolonged and well-controlled dieting. As a sequel to this study, members 
from same Heidelberg group (German Collaborative Study of PKU) conducted 
a more thorough investigation with a larger sample (n=14) and employed a 
reversal design incorporating a return to baseline, though phe was again 
manipulated by natural diet intake rather than by supplement (Schmidt et al., 
1994). All subjects were measured on de Sonneville's dot-pattern task while 
off diet, on diet, then off again at intervals of five weeks. Average phe-Ievels 
during the three phases were 1320, 630 and 1410 Ilmoi/l. Data for accuracy 
of detection (hits) were not reported. Analyses of errors and response 
latencies revealed covariance between phe and performance with the middle 
phase (low phe) the best. The authors interpreted these findings as indicative 
of a temporary adverse phe effect on attention. Such a conclusion may not be 
so straightforward, however, as phe and practice were confounded in the first 
and second phases. A significant improvement in attentional performance 
between the second and third phases would have vindicated the conclusion, 
but this was not found on post hoc testing. Thus, the main effect was a decline 
in errors and an increase in speed on the dot-pattern task between the first off-
diet phase (baseline) and the middle on-diet phase (treatment), but this effect 
was not reliable for the return-to-baseline transition, leaving open the 
possibility that practice or familiarity with a novel task could have been the 
active factor. 
The combination of a possible confound and selective data reporting with hit-
rates not presented, calls into doubt the credibility of the conclusion drawn by 
the authors that, in adulthood following good and prolonged treatment, 
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transient phe produces a toxic but reversible state in PKU. Further anecdotal 
evidence undermining the plausibility of the phe-toxicity theory comes from 
the authors themselves who found that subjects did not complain of relative 
cognitive impairment or improvement when questioned about everyday 
functioning during the high-low-high phe conditions. Some were university 
students, but individuals in this subgroup did not describe cognitive changes 
in relation to studying, inte"ectual activity and academic performance. 
MRI data and dietary resumption 
No MRI studies published to date have followed the challenge model. 
However, MRI scanning in the context of dietary resumption was undertaken 
by McCombe et al. {1992} in a case study of a 19 year-old male with classical 
PKU. Their patient had been treated from 16 days post partum until 12 years 
when diet was relaxed. Control during childhood was described as fair rather 
than good, perhaps accounting for an IQ at 16 years of 88. Diet was 
abandoned completely at 18 and phe levels rose to around 1900 Ilmoi/i. 
Eight months later the patient developed hypertonicity in all four limbs. MRI 
revealed abnormalities in deep cerebral white matter. Although the authors 
do not say so explicitly, the suspicion must be of pyramidal system 
involvement. The patient was returned to diet, reducing phe levels to around 
900 J..lmol/l, and the motor signs gradually improved. A repeat MRI, however, 
was unchanged. 
The amelioration of the patient's motor disorder following dietary resumption 
implies reversibility of the factors underlying the condition. McCombe et al. 
Chapter 4: Page 97 
considered post-diet elevated phe concentrations to be the active agent and 
sporadic reports of motor dysfunction, such spasticity and ataxia, associated 
with hyperphenylalaninaemia following treatment do exist in the literature 
(e.g. Rylance, 1989; Smith, 1985; Thompson et al., 1990). However, the 
apparently reversible toxicological effect may be related to vitamin 812 rather 
than phe. Vitamin 812 is strongly suspected of being implicated in the 
aetiology of slowly progressive spastic paraparesis in PKU (Hanley et al., 
1993). Vitamin 812 forms part of the amino acid supplement used in treating 
phe and some patients discontinuing diet may run the risk of vitamin 812 
deficiency if they fail to change their eating habits to include natural foodstuffs 
containing this vitamin (Walter, 1995). 
Treatment policy and experimental research 
The worth of experimental approaches to treatment questions in PKU lies in 
their potential to relate phe and function directly, minimize extraneous effects 
and thereby inform policy-making. Of the two methods of varying phe intake -
supplement manipulation and dietary resumption· the former is the more 
scientific, the latter more ethically acceptable. While foreknowledge of the 
hypothesis cannot be withheld in either procedure, supplement manipulation 
can be conducted blindly and phe more rigidly controlled as subjects are 
essentially passive during the periods when it is altered. A disadvantage of 
this method is that there are ethical constraints on the length of time dieting 
patients can reasonably be exposed to high levels of phe. Dietary resumption 
entails practical and methodological difficulties. As volunteers are required 
who are prepared to recommence diet, a self-selected sample will result that, 
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as a subgroup, may not be representative of the treated PKU population. 
More problematic is the degree of phe reduction and control that might be 
achieveable in a group that previously had eaten normally. Whereas the 
supplement manipulation method requires no motivation to change eating 
behaviour, dietary resumption necessitates a fundamental realignment of 
motivation and eating habits, both on the part of patients and caretakers, that 
may be difficult to achieve. 
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Chapter Five 
EXPERIMENTAL MANIPULATION OF PHENYLANINE: PILOT 
STUDY OF DIETARY RESUMPTION IN TREATED OFF-DIET 
ADULTS 
With the considerations outlined in Chapter Four in mind, we faced the 
decision of which approach to adopt in investigating the effects of varying phe 
after treatment until at least 10 years of age. As screening in the West of 
Scotland began in the late 1960s and policy at that time was to discontinue 
treatment on the tenth birthday, a small group of young adults with classical 
PKU was available for research who had terminated treatment at age 10 and 
who had been on normal diet for over a decade thereafter. Individuals were 
approached and asked if they would be prepared to return to diet for a period 
of six months. Four agreed to be retreated and thus a small-scale pilot study 
was possible using a resumption approach. However, obtaining a potentially 
larger, though younger, group for a supplement approach was also a 
possibility as treatment policy in the early 1990s had switched from 
termination at 10 to indefinite continuation. These patients, who were mainly 
in their teens, offered the possibility of a challenge paradigm as all were on 
diet. The quandary was whether they could be persuaded to be temporarily 
exposed to high levels of phe and if so for how long. 
We decided to proceed with an exploratory study of the adult group as a first 
step. In addition to measuring psychological concomitants of dietary 
resumption, we were able to investigate neurological correlates by means of 
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MRI scanning, clinical neurological examination and transcranial magnetic 
stimulation (TMS) - a technique for quantifying nerve conduction in the brain 
and spinal cord (Devinsky, 1993; Belmaker and Fleischmann, 1995). Funding 
was obtained from the Scottish Society for PKU to cover the costs of dietary 
preparations and scans. Sufficient funds were available to follow up the 
dietary resumption study with a challenge study if recruitment of subjects was 
successful. 
Methodological and theoretical aims of the resumption study 
The methodological aims of the dietary resumption study were two-fold: 1) to 
appraise the soundness of the procedure, in particular the practicalities of 
returning adults to diet after many years off, and 2) to try to identify specific 
neuropsychological tests that would be maximally sensitive to functional 
change. The theoretical aim was principally to determine whether, in the 
mature CNS, any empirical evidence could be found either for improvement in 
psychological function or normalization of neurological structure (or both) that 
could be attributed to medium-term reduction of circulating phe. 
A multiple case-study AB design was adopted. Baseline measures were 
taken when subjects were off-diet and compared with repeated measures 
taken six months after they had returned to a phe-restricted diet. 
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Hypothesis 
It was hypothesised that, if long-term exposure of the CNS to phe in adults 
with treated PKU has a functional neurotoxic effect, reducing the level of phe 
circulating in the bloodstream for a six-month period would lead to improved 
performance on psychological and neurological measures, and possibly result 
in reversal or partial reversal of white matter abnormalities. 
Method 
Subjects 
Of the four young adults who agreed to resume diet, two were males and two 
females. All were aged between 20 and 25 years on entry to the study and 
had classical PKU. Subjects 1,3 and 4 were detected and treated early. As 
infants, they were among the first to be identified by the mass newborn-
screening programme introduced in the West of Scotland in 1967. Only 
patchy information on Subject 2 was available from hospital records. This girl 
was diagnosed and treated elsewhere, her family moving to Glasgow when 
she was in her teens, at which time she was inducted into the maternal PKU 
programme at RHSC. In each case, including Subject 2, treatment was 
discontinued on or around the 10th birthday. Thereafter, eating habits were 
unrestricted. Table 6 shows demographic data, neonatal phe levels, age 
treatment begun, chronological age on entry to the pilot study and IQ for the 
four subjects. 
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No. Sex DoB Neonatal phe Age treated CA IQ 
(S) (M/F) (Jlmolll) (days) (yrs) (FS) 
1 M 02/03/67 >1250 32 25.17 101 
2 F 10/03172 >1200 ? 20.17 92 
3 M 26/11/68 >1250 22 23.58 122 
4 F 01/02/67 >1250 12 25.33 111 
Table 6. Patient characteristics. 
The late 1960s predated modern biochemical assay techniques such as 
fluorimetry and high pressure liquid chromatography and measures above 
1250 Jlmol/l were not reported precisely. However, all subjects' neonatal phe 
levels exceeded the 1200 Jlmol/l threshold for classical PKU. 
Figure 11 shows historical phe data as indices of dietary control (median phe 
level per annum) for each of the first 10 years of life for subjects 1, 3 and 4. 
Lifetime phe indices for subject 2 could not be calculated as biochemical 
records were very incomplete. Despite this, sufficient data exist to ascertain 
that by the 10th month of life her levels were below 120 Ilmol/l, though by year 
seven one at least had risen to around 720. 
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Figure 11. lOGs for first decade of life. 
At the time, the local therapeutic target range for blood phe levels was 120 to 
480 J.lmoll for the first 10 years of life. Throughout this period Subjects 1 and 3 
maintained yearly averages within this band. Subject 4's control was similar 
until the ninth and tenth years when the upper limit was exceeded. 
At the time of psychological testing, the occupations of Subjects 1 to 4 were 
respectively: joiner, VDU operator, university student and nurse. 
Psychological tests: measures, rationale and conceptual scheme 
Possible phe-related changes in psychological functioning were explored by a 
battery of eight neuropsychological tests. These were: Matching Familiar 
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Figures, Leter Cancellation, Verbal Fluency, Design Fluency, Digits Forwards, 
Rey Verbal Learning, Purdue Pegboard and Stylus Tremor. 
The choice of tests making up the neuropsychological battery was dictated by 
their ability to cover a reasonably broad range of mental and motor functions 
and by the hypothesis that certain skills might be differentially phe-sensitive 
and deficient in treated PKU. Knowledge about whether particular cognitive 
areas are affected more than others remains poorly developed and insufficient 
to enable the identification of ideal experimental and control measures. 
However, sporadic reports in recent years have emerged suggesting that 
executive functions - attention, concentration, response inhibition and set 
maintenance - may be especially vulnerable (Welsh et al., 1990; Diamond, 
1994). For this reason, the MFFT and Letter Cancellation tests were 
incorporated as indices of selective and sustained attention; and Verbal and 
Design Fluency as indices of verbal and spatial inhibition and set 
maintenance. Memory impairment has been reported in older early-treated 
but off-diet patients with PKU (Demellweek, 1996), and so Digit Recall and the 
RVL T were brought in as tests for possible short-term retentive and learning 
deficits respectively. Case reports of motor dysfunctions such as mild 
spasticity and Parkinsonian tremor in suboptimally treated patients (Rylance, 
1989; Villasana et al., 1989; Shaw et al., 1990; McCombe et al., 1992) led to 
the inclusion of the Purdue Pegboard and Stylus Tremor tests. In addition to 
documented findings, a further consideration underlying the choice of tests 
was that, in the PKU and maternal PKU Clinics at RHSC, off-diet patients had 
reported symptoms of poor concentration, memory and shakiness. 
The tests divided into four pairs, each providing two measures of visual 
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attention/perception, ideational productivity (executive function), memory and 
motor coordination. Individual tests conform to the scheme in Table 7. 
Domain Construct Test 
1) Attention (Exec) Selective attention Matching figures 
Sustained attention Letter cancellation 
2) Set maintenance (Exec) Verbal production Verbal fluency 
Spatial production Design fluency 
3) Memory Short-term Digits forward 
Long-term Verbal learning 
4) Motor Finger dexterity Pegboard 
Motor steadiness Stylus tremor 
Table 7. Test battery scheme. 
Details of the neuropsychological battery 
Matching Familiar Figures. Odd-numbered items from the MFFT20 (Cairns & 
Cam mock, 1978). Ten in all. Visual matching to sample. One-minute time-
limit per item. Total correct score. Letter Cancellation. Marking the letter IZ' 
with a pencil in 50 rows of 24 random letter stimuli arranged in four columns of 
six. Twenty targets randomly located but never more than one in a block of six 
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or in adjacent rows. 1180 distractors. Upper case letters, 12-point size. Two-
minute time limit. Total correct score. (Neisser, 1967). Verbal Fluency. 
Number of non-repeated words beginning with the letters 'F', 'A' and'S' 
generated in one minute to each stimulus (Spreen & Benton, 1969). Design 
Fluency. Number of non-repeated designs created from two straight and two 
curved pieces of flat plastic in three minutes. (Griffiths, 1991). Digit Recall. 
Random digits forwards. Eight pairs. Two-long to nine-long strings. Total 
correct score. (Wechsler, 1992) Verbal Learning. Word list of 15 concrete 
nouns. Orally presented. Five repetitions. Recall after each presentation. 
Total correct score. (Rey, 1941). Pegboard. Modification of Purdue Pegboard. 
Matrix of 25 holes. Pegs inserted then collars and washers placed over pegs. 
Preferred hand. Time to completion. (Lafayette Instrument Company. 
Available from Campden Instruments Ltd., King Street, Sileby, Loughborough, 
LE127LZ, UK.) Stylus Tremor. Modification of Hole-Type Steadiness Tester. 
Insertion and withdrawal of stylus into seven holes of progressively smaller 
diameter without touching sides. Impulse counter measures contacts. 
Preferred hand. Untimed. Total contact score. (Lafayette Instrument 
Company. From Campden Instruments Ltd., address as above.) 
Procedure and design 
Baseline psychological data were collected from the four subjects while they 
remained off-diet. The order in which the tests were given was: MFFT, Verbal 
Fluency, Digit Recall, Pegboard, Letter Cancellation, Design Fluency, RVLT 
and Stylus Tremor, i.e. the first attention, set maintenance, memory and motor 
task in the scheme shown in Table 7 followed by the second. A neurological 
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examination and MRI scan were also conducted. Dr R. McWilliam, Fraser of 
Allander Unit, RHSC, performed the neurological examination which 
consisted of ratings of briskness of tendon reflexes and severity of crossed 
adductor reflexes, maximum tandem (heel-to-toe) stance and transcranial 
magnetic stimulation (TMS). MRI scans were arranged by Dr D. Hadley, 
Institute of Neurological Sciences, Southern General Hospital, Glasgow. The 
reason for combining TMS with MRI was that the MR scanner available would 
image brain but not spinal cord. However, TMS can provide an index of spinal 
cord function. By measuring the evoked response in peripheral muscle 
following magnetic stimulation of the motor cortex, conduction time in central 
motor pathways can be assessed. The psychological testing and neurological 
examination were performed during the same out-patient appointment. MRI 
scanning took place within a week. 
A repeated measures design was adopted with each subject acting as their 
own control, data first being gathered during the off-diet phase then at the end 
of the on-diet phase six or more months later. The independent variable, phe 
level, was measured concurrently along with other biochemical parameters 
such as tyrosine. The psychological tests were given in the same order on 
retest as baseline. 
Informed consent and ethics approval were obtained and the subjects agreed 
to follow a six-month phe-restricted diet. Dietary control was supervised by 
Mrs B. Clark, Dietetics Department, Royal Hospital for Sick Children, Glasgow, 
who prepared menu lists and supplied the vitamin-enriched amino acid 
supplement, XP Maxamum (SHS International, 100 Wavertree Boulevard, 
Liverpool, L7 9PT, UK). The 'XP' prefix in the product description denotes 
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'without phenylalanine'. 
Results 
Phenylalanine levels 
Table 8 shows median off-diet (baseline) and on-diet (treatment) phe levels in 
)lmol/l for the four subjects with ranges in brackets. Phe readings were taken 
approximately fortnightly during the six-month period preceding the onset of 
dietary restriction and similarly during the six- or more month period of dietary 
restriction. With the alpha level set at 0.05, the results demonstrate that 
Subjects 2, 3 and 4 achieved statistically significant reductions in whole blood 
phe levels during the on-diet phase compared with off-diet (Mann-Whitney). 
Subject 1, however, did not lower his levels significantly, thus calling into 
doubt his compliance with the phe-restricted diet. The independent variable 
(phe) was therefore successfully manipulated in the desired direction in 
Subjects 2, 3 and 4, but not in Subject 1. 
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No. Phe off-diet 
1 900 (600-1038) 
2 1200 (600-1363) 
3 1200 (720-1200) 
4 1200 (1200-1212) 
Phe on-diet 
870 (617-1099) 
376 (170-1000) 
664 (255-1086) 
253 (181-484) 
u 
103 
6 
17 
o 
P 
N.S. 
<0.001 
<0.001 
<0.01 
Table 8. Phe changes off and on diet. Median phe concentrations (Jlmol/l) 
and ranges for the four subjects. Mann-Whitney comparisons and P-values. 
Table shows no significant reduction of phe in Subject 1. 
Neuropsychological test battery 
The next table contains the raw scores from the neuropsychological test 
battery for each of the four subjects when off and on diet. Abbreviations are as 
follows. MFFT:Matching Familiar Figures. Cancel: Letter Cancellation. 
VIFlu: Verbal Fluency. DIFlu: Design Fluency. Digits: Recall of forwards digits. 
RVL T: Rey Verbal Learning Test. Pegs: Purdue Pegboard. Tremor: Stylus 
Tremor Test. Data are all number-correct scores except those for the Purdue 
Pegboard, which are time-to-completion in seconds, and those for the Stylus 
Tremor Test, which are the number of contacts between the stylus and the 
holes. Thus, high scores on these last two tests indicate poor performance 
whereas high scores on the remainder denote good performance. The inter-
test interval (ITI) in months is shown against the Subject number. 
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No. ITI MFFT Cancel V/Flu D/Flu Digits RVLT Pegs Tremor 
Off On Off On Off On Off On Off On Off On Off On Off On 
1 (6.87) 8 10 10 13 27 40 14 15 10 10 47 55 141 141 24 23 
2 (6.63) 3 3 11 9 32 26 8 9 8 8 25 48 159 159 27 30 
3 (7.57) 8 8 15 14 37 39 15 16 11 12 45 62 139 134 11 12 
4 (9.30) 8 8 9 13 46 48 13 23 12 10 53 59 152 129 15 9 
Table 9. Test battery scores. 
The following table shows test score differences (d) between the dietary 
conditions for each subject. The polarity of the score difference indicates the 
direction of change in performance from the off-diet to the on-diet condition: 
improvement (+) or deterioration (-). The percentage (%) column shows the 
size of the change as a proportion of baseline level, multiplied by 100 with the 
sign retained. 
No. MFFT Cancel V/Flu D/Flu Digits RVL T Pegs Tremor 
d % d % 
1 
2 
3 
4 
d%d%d%d%d%d% 
+2 (+25) +3 (+30) +13 (+48) +1 (+7) 
o (0) -2 (-18) -6 (-19) +1 (+13) 
o (0) -1 (-7) +2 (+5) +1 (+7) 
o (0) +4 (+44) +2 (+4) +10 (+77) 
o (0) +8 (+17) 0 (0) +1 (+4) 
o (0)+23(+92) 0 (0) -3 (-11) 
+1 (+9) +17 (+38) +5 (+4) -1 (-9) 
-2 (-17) +6 (+11) +23 (+15) +3 (+40) 
Table 10. Change and percentage change scores. 
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When interpreting the results in the above table, it is important to bear in mind 
that Subject 1 failed to return to diet and thus any changes in his results 
cannot be attributed to diminution of phe. The other factor that could account 
for changes in test performance between conditions is practice as the 
repeated measures design meant that the subjects retook the same test at 
follow-up six to nine months later. 
The results failed to reveal consistent gains in perceptual, cognitive and motor 
functioning between the off- and on-diet conditions. Subject 2 only improved 
on two of the eight measures; Subject 3 improved on five and Subject 4 on six, 
however. Subject 1 also improved on six of the measures but these 
increments in performance are paradoxical considering he did not show a 
reduction in phe level across the test-retest period and suggest another active 
factor. No change was recorded for Subject 1 on two measures, for Subject 2 
on three, for Subject 3 on one and for Subject 4 also on one. Minor 
decrements in performance were recorded for Subject 2 on three measures, 
for Subject 3 on two and for Subject 4 on 1. Thus, the three subjects who 
achieved a significant reduction in phe produced six poorer scores between 
them on retest compared with none in Subject 1 who did not reduce his phe 
level. 
Thus, in the three subjects who succeeded in reducing phe levels, none of the 
neuropsychological measures yielded systematic results indicative of 
improvement between the conditions with the exception of Design Fluency 
and the Rey Verbal Learning Test. On the Design Fluency Test, improvements 
were minimal for Subjects 2 and 3 and equal to the change found in Subject 1 
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whose phe level was unchanged. On the Rey Test, Subjects 2 and 3 made 
considerable gains on retest, though Subject 4 did not and did less well than 
Subject 1. 
Neurological examination 
The data in the table below were collected and reported by Dr McWilliam. 
Columns refer to tendon reflexes (TR), crossed adductor reflexes (CAR), 
maximum tandem stance (MTS) and transcranial magnetic stimulation (TMS). 
The tendon reflexes variable is a four-point rating scale (0 = absent, 1 = 
reduced, 2 = normal and 3 = increased). The crossed adductor variable is also 
a rating scale (0 = absent, 1 = present and 2 = pathologica~. Ratings were 
made by the examiner. The maximum tandem stance score is the maximum 
time in seconds the heel-to-toe position could be held by the subject up to 25 
seconds. The trancranial magnetic stimulation variable is average time in 
milliseconds for a single pulse over the skull above the left motor cortex to be 
conducted to the calf muscle of the right leg, the interval measured being that 
between the onset of the pulse and the onset of the EMG response. 
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TR (0-3) CAR (0-2) MTS (sec) TMS (msec) 
Diet Off On Off On Off On Off On 
No. 
1 3 3 1 1 25 25 284 346 
2 2 2 0 0 25 25 N/A N/A 
3 2 2 0 0 25 25 N/A N/A 
4 3 3 2 2 25 25 364 384 
Table 11. Neurological examination data. Subjective ratings of tendon 
reflexes (TR) and crossed adductor reflexes (CAR): higher scores indicate 
possible pathology. Maximum tandem stance (MTS): time in seconds position 
held up to 25 sec. Transcranial magnetic stimulation (TMS): conduction time 
in msec. NIA (not available) indicates refusal to be tested by subjects 2 and 3. 
All the indices chosen for inclusion in the examination were of motor 
functioning. Abnormal tendon and crossed adductor reflexes were found in 
Subjects 1 and 4. Otherwise the examination revealed no deviant 
neuromuscular responses. The ceiling scores on the maximum tandem 
stance test were contra-indicative of pathology. Administration of the 
transcranial magnetic stimulation test was incomplete, Subjects 2 and 3 
withdrawing because of intolerance of rising energy levels in the magnetic 
field as the power was increased. 
None of the indices showed any change between the off-diet and on-diet 
conditions in the subjects who demonstrably lessened their phe intake (2, 3 
and 4) with the sole exception of a change in TMS for Subject 4. It is unlikely 
that this minor difference could have occurred as a function of the reduction in 
circulating phe as Subject 1 manifested an even greater shift in his TMS score 
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in the same direction as Subject 4 but in the absence of a concomitant phe-
level change. 
Magnetic resonance imaging 
The information about the results of the MRI investigations was provided by Dr 
Hadley who assessed the MRI scans qualitatively. His appraisal of the images 
from the four subjects when off diet is summarized below. 
No. Comments 
1 Foci of increased T2 signal 
2 Periventricular white matter increase in T2 signal and foci of isolated 
increased T2 signal 
3 Posterior periventricular white matter increase in T2 signal 
4 Posterior periventricular white matter increase in T2 signal 
Table 12. Summary of MRI findings. 
When re-scanned at the end of the six- to nine-month period on diet, Dr 
Hadley reported no detectable differences in the scans of the four subjects. 
The minor perventricular white matter abnormalities persisted in the three 
subjects who had successfully restricted their phe intake, but the pattern had 
not changed following medium-term phe reduction. 
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Discussion 
Because of the AB design chosen for this pilot study, phe and practice were 
confounded factors. An ABA reversal design would have been preferable to 
separate out the effects of phe and familiarity with test demands and content. 
Taking return-to-baseline measures during a third experimental phase would 
have meant the subjects coming off diet again • a possibly unacceptable 
course for them· however, such a design was successfully implemented by 
Schmidt et al. (1994). 
Having Subject 1 fail to return to diet as intended was a fortuitous 
circumstance. As Subject 1 's test data were unrelated to any observed 
change in phe, they therefore provided a control for non-phe effects and could 
be compared with the other subjects' data. Apart from the Digits and 
Pegboard tests, all Subject 1 's scores rose in varying amounts on retest. 
These gains in test performance strongly suggested a practice effect despite 
an inter-test interval of 6.87 months. 
It is noteworthy that the instrument most likely to be influenced by long-term 
memory, the Rey Verbal Leaming Test, was one of the two that showed 
consistent improvement across all four subjects. This may have been a 
savings effect with some of the items retained or at least recognised on retest. 
The other measure on which all subjects did better on retest was Design 
Fluency. This may have been a familiarity effect as the demand characteristics 
of the test (constructing stick patterns) are unusual. 
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When possible practice and familiarity effects are considered in the 
interpretation of the findings, there is little consistent evidence to suggest that 
a reduction in phe in the three adults who complied with the dietary 
manipulation led to improved perceptual, cognitive and motor functioning. 
Irrespective of the magnitude of change, 11 test scores were unchanged or 
worse compared with only 13 that were better and non-phe factors could have 
been responsible for the improvement. This unclear pattern emerged despite 
the three compliant subjects descreasing their average circulating phe levels 
to between a half and a fifth of their off-diet norm. 
The principal value of this small-sample pilot study lay in its ability to highlight 
methodological weaknesses in the dietary resumption approach. The central 
problem in this method is adherence to the phe-restricted diet. The four 
subjects, as adults, had experienced a normal range of foodstuffs for over a 
decade. Dietary resumption necessitated voluntarily self-denial and a high 
degree of motivation to persist. Despite support from the Hospital service, one 
of the four subjects was unable to exercise the discipline needed to obtain a 
substantial reduction in blood phe. 
Being unable to blind subjects and researchers to the conditions in a 
resumption study is another major drawback of the method. Collecting self-
report data or subjective ratings has little worth because of contamination by 
expectancy effects. Because of this, no formal assessment of subjective state 
was made in the present study but, in principle, such a measure could be 
important. For instance, it might cut down the risk of false negatives if tests 
selected failed to detect real behavioural changes either through insensivity or 
inappropriateness. 
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A further inherent difficulty with the resumption method is that, unless Guthrie 
cards are submitted very frequently, say daily, subjects can eat liberally but 
deliberately diet immediately prior to a blood test and so falsify the reading. 
Though it was impossible to control for wilfully fraudulent behaviour in the 
current study, there were no grounds for suspecting that subjects were being 
deliberately deceptive about their phe levels. 
The independent variable in AB designs is open to confounding with practice 
when the treatment measure is a straightforward repeat of the baseline 
measure. Even an inter-test interval of over six months, as in the present 
study, may produce insufficient decay of memory traces or interference to 
prevent learning. Delaying repetition may enhance performance through 
consolidation, savings or a fresh problem-solving strategy. 
Incorporating a control group in the design is one feasible solution to the 
problem of confounding phe and practice variables but, in small sample 
research, careful subject matching is required to avoid introducing a between-
subjects confound. Building in a return-to-baseline phase and hypothesising 
that the negative effects of phe during this phase would disrupt the learning 
curve is second solution, but one that presents interpretative difficulties if test 
performance during the final off-diet phase is not worse than during the on-diet 
condition. A third solution is the use of parallel test forms; however, amongst 
the battery used here, only five out of the eight (Matching Familiar Figures, 
Letter Cancellation, Verbal Fluency, Digit Recall and Verbal Learning) lend 
themselves to this approach and, even for these, test-retest reliability 
coefficients are unknown. 
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Conclusion 
Clear evidence did not emerge from this small-sample pilot study of patients 
with treated PKU that reducing blood phe-Ievel for six months or more after 
over a decade of a liberalized diet leads to improved psychological 
functioning, neurological functioning or normalization of minor 
neuroanatomical anomalies. 
Methodological weaknesses undermined the interpretation of the findings. 
The treatment of three patients had adhered closely to the standards 
prevailing in the West of Scot/and in the 1970s of dietary commencement in 
the first month of life, termination at 10 years of age and average phe levels 
being maintained within the 120 to 600 Ilmolll range. However, one subject's 
historical phe data were lost to investigation. The psychological measures 
were almost certainly contaminated with practice effects, a further subject's 
phe levels on retest showed a lack of compliance with dietary manipulation 
and the study was characterised by non-naivety about its aim on the part of all 
the subjects and the researchers. 
Although the confounding variables in the psychological data could not be 
controlled statistically, scores from the single subject who did not diet 
provided points of comparison. This subject's performance either remained 
unchanged or improved on retest, sometimes with even greater magnitude 
than that of the three subjects who dieted successfully - a pattern suggestive of 
factors other than phe contributing to better test results. 
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An absence of change in the findings from the clinical neurological 
examination and MRI scans weakened support for the hypothesis that the 
eNS is sensitive to phe after at least 10 years of treatment. Medium-term 
attentuation of circulating phe after prolonged post-treatment exposure did not 
appear to provoke any detectable change in motor function or brain 
neu roanatomy. 
In view of the methodological shortcomings of the resumption method for 
investigating phe effects in older PKU patients - non-naivety of subjects, 
difficulty of controlling the experimental variable and confounding factors· we 
sought an alternative investigative model. The pilot study described here 
amply demonstrated the severe methodological and interpretive problems 
intrinsic to the simple AB experimental design and we decided to abandon this 
model in favour of an ABA challenge paradigm with manipulation of the phe 
variable under the control of the experimenter. Though more exacting and 
ethically less defensible, we opted for a triple-blind crossover design to control 
for confounds and a study in which phe loading was varied by means of the 
amino acid supplement instead of by diet. 
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Chapter 6 
MANIPULATION OF PHENYLALANINE BY AMINO ACID 
SUPPLEMENT: COGNITIVE AND MOTOR OUTCOME 
Background to study 
Aside from the author, the personnel in the research team at RHSC, Glasgow, 
who ran this study were Professor Cockbum (Director) and Dr Harvie of the 
Department of Child Health, Dr McWilliam of the Fraser of Allander Unit, Dr 
Logan and Mrs Cain of the Department of Biochemistry and Mrs Clark of the 
Department of Dietetics. Also involved were Dr Hadley from the Institute of 
Neurological Sciences at the Southem General Hospital, Glasgow; and Mr 
Nicholas Ward and Miss Caroline Smith from the Department of Psychology 
at the University of Stirling, both of whom were undergraduate students who 
assisted in the collection of some of the psychological data. 
Blood phenylalanine levels in the subjects who volunteered were 
manipulated by means of special protein supplements prepared by Miss 
Katrina Roberts of the Research and Development Department of Scientific 
Hospital Supplies (SHS) International, Liverpool. Low and high phe 
supplements were coded by the suppliers who labelled each according to 
their order of administration for individual subjects. Each child was randomly 
assigned either to a low/high or highllow supplement condition and 
information about his or her specific protocol was kept secure by the project 
Director, Professor Cockbum. The Director made the group allocations and 
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thus knew the condition to which each child belonged, but was not involved in 
gathering data. The other members of the team, all of whom were involved in 
either biochemical, neurological or psychological testing, were blinded to the 
condition imposed, as were the children who participated and their parents. 
The study followed a clinical drug-trial model (Stuart-Hamilton, 1995). In the 
psychological sector of the study, phe level was the independent variable and 
performance on various measures within a neuropsychological test battery 
the dependent variables. High phe could be thought of as the treatment or 
active drug', low phe as the placebo. Contrary to the usual prediction in drug 
trials, elevated phe level in this case was expected to be associated with 
deterioration of psychological performance rather than improvement. A 
randomised, single crossover design with repeated measures was adopted in 
order to separate phe effects from possible confounds such as practice 
(Yaremko et al., 1982). The crossover design obviated the need for a control 
group as each subject acted as their own control (Vasta, 1979). 
Subjects were selected from the West of Scotland PKU Register according to 
well-defined criteria in order to recruit a sample that was characterised by 
early and fairly strict treatment, and continuation of treatment until at least the 
end of the first decade of life. Following approval of the study by the Hospital 
and University ethics committees, an explanatory meeting was held for 
families identified as having suitable children at which the purpose and the 
method of the study were detailed. Parents and children had the opportunity 
to question and discuss what was intended with representatives of all the 
clinical disciplines on the team and were given several weeks during which to 
contact the staff for further information and come to a decision. From a total of 
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19, consent was given by 16. Reasons for refusal were not formally sought 
from the three families who declined to participate. 
A three month period of phe-induced neurotoxicity was chosen as the effects 
of such lengthy exposure had not been explored before by studies employing 
a phe-supplement experimental paradigm. Krause et al. (1985) achieved 
only one week of hyperphenylalaninaemia in their subjects, Frankenburg et 
al. (1973) about three weeks, and Hogan et al. (1986) and Clarke et al. (1987) 
about five weeks. We assumed that more than doubling the phe-exposure 
period compared with Clarke et al.'s procedure would lead to increased 
confidence in the robustness of the neuropsychological outcome findings. 
On the basis of Guttier and Lou's (1986) theory, we hypothesized that three 
months of elevated circulating phe levels would be sufficient to bring about 
changes in neurotransmitter biosynthesis in the CNS and that effects would 
be visible in lowered performance on neuropsychological tests. On the 
grounds that excessive phe decreases both tryptophan and tyrosine levels in 
the CNS and hence serotonin, dopamine, epinephrine and norepinephrine 
concentrations, Guttier and Lou argued that biochemical synaptic changes 
similar to those commonly found in untreated PKU (Behbehani & 
Langenbeck, 1982) also occur in the mature organism after treatment 
cessation. They concluded that, in treated older children and adolescents 
who discontinue diet, hyperphenylalanaemia gives rise to subtle neurological 
and neuropsychological deficiencies via the intervening mechanism of 
deficient neurotransmitter production. 
The aim of the study was to test the hypothesis that transient elevation of phe 
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level by artificial means would result in neuropsychological dysfunction, the 
prediction being that phe intoxication would cause test performance to decline 
as a consequence of disrupted neurotransmission. If such a relationship were 
demonstrated, then it would have important implications for treatment policy. 
As all the subjects selected were over 10 years old, the age considered safe 
for treatment relaxation in Germany (Stellungnahme der APS, 1990), the 
finding of phe-related information processing deficits after this age would 
strengthen the case for continuation of dietary treatment or at least provoke 
debate as to whether the intellectual benefits of maintaining the diet outweigh 
the burdensome and socially handicapping nature of the treatment (Burgard 
et al., 1997). 
Introduction 
Little at present is known about life-span intellectual functioning in treated 
phenylketonuria (PKU, McKusick 26160). However, as individuals age who 
were detected by mass screening in the late 1960s and after (Medical 
Research Council, 1981), research opportunities become increasingly 
available for charting the long-term course of mental development in the 
treated disease and relating outcome to treatment history. It is now firmly 
established that implementation of the low phenylalanine diet is necessary as 
early as possible in the neonatal period to prevent subsequent mental 
handicap (Medical Research Council, 1993a). However, consensus on policy 
about optimal blood phenylalanine (phe) levels during treatment has yet to be 
achieved (Lancet, 1991) and the age at which prophylactic treatment may 
safely be discontinued remains controversial. 
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The principal method for illuminating the dietary termination issue has been 
the retrospective follow-up study in which 10 or neuropsychological test 
performance is compared either with phe levels during treatment or age of 
treatment cessation (Azen et al., 1991; Smith and Beasley, 1989). Studies of 
early-treated subjects with good dietary control in childhood suggest that the 
risk of intellectual deterioration declines dramatically after the first decade 
(Behbehani et al., 1986), the inference being that from 10 years of age 
onwards the nervous system may be sufficiently mature to withstand the 
neurotoxic influence of persistent hyperphenylalaninaemia. For example, 
widespread adverse effects on neuropsychological functioning were not 
found in a recent study of adolescents and young adults with classical PKU 
who were treated early «20 days post-natally) and fairly strictly (average phe-
level < 300 IlmoVI from birth to five years and <600 IlmoVI from five to 10), who 
discontinued the low phenylalanine diet abruptly at age 10 and who were 
hyperphenylalaninaemic (average> 1000 Ilmol/l) for three or more years 
thereafter (Griffiths et al., 1995). These findings corroborate 10 data from the 
United Kingdom National PKU Register (Smith et al., 1990; Beasley et al., 
1994) and the German Collaborative Study on PKU (Schmidt et al., 1996) 
which failed to demonstrate negative trends in 10 as a function of elevated 
phe levels after 10 years of age. 
An alternative method to post-treatment follow-up in researching the dietary 
cessation question is experimental manipulation of phe by dietary 
supplement. This is a prospective approach that allows better control of the 
independent variable (phe level) than does retrospective food intake. The 
effects on neuropsychological performance of altering phe in a controlled 
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manner have been explored (Clarke et al., 1987; Frankenburg et al., 1973; 
Krause et al., 1985), but in all these studies treatment factors were 
heterogeneous and none was based on samples characterized by early and 
continuous phe restriction. 
To examine whether medium-term elevation of phe level has a deleterious 
outcome in treated PKU, we adopted a triple-blind, single-crossover design 
similar to that used by Krause et al., (1985) in which we raised blood phe for 
three months in an on-diet sample of older children and adolescents by 
means of a phe complement. However, our subjects differed from those 
previously documented in that we included only those who had been 
continuously treated from early infancy until at least age 10. 
We hypothesized that, if reducing phe by dietary treatment during the first 
decade of life confers protection on the immature nervous system, subsequent 
medium-term hyperphenylalaninaemia would not result in temporary 
neuropsychological impairment. 
Method 
Subjects 
The inclusion criteria for entry into the study were classical PKU (neonatal phe 
above 1200 Jlmol/l), initiation of treatment within three weeks of birth, phe-
control below 480 JlmoVI between birth and 5 years of age and below 900 
JlmoVI between 5 and 10, continuation of dietary treatment and absence of 
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other diseases. Sixteen patients (10 boys, 6 girls) satisfied these criteria and, 
along with their parents, consented to participate following an explanation of 
the procedure. Fu" approval for the study was granted by the Ethics 
Committees of the Royal Hospital for Sick Children, Glasgow, and the 
Department of Psychology, University of Stirling. The children's mean phe 
levels were: pre-treatment 1893 Jimolll (SO 523), 0-5 years 351 Jimol/l (SO 
86) and 6-10 years 474 Jlmolll (SO 165). Mean age at entry was 12.60 years 
(SO 2.10) and mean IQ (WISC3-UK) was 100.94 (SO 10.71). 
Dietary supplements 
Non-phe supplements were individual children's usual low phe amino acid 
mixture: either XP Maxamaid or PK Aid 3. High-phe supplements were these 
products with phe added to a value found in first-class protein. A" products 
contained balanced mixtures of amino acids and were supplied by Scientific 
Hospital Supplies International Ltd., 100 Wavertree Boulevard, Liverpool, L7 
9PT, UK. The high-phe supplements were specially developed so as to be 
facsimiles of the regular treatment products in visual appearance, smell, taste 
and texture. 
Neuropsychological test battery 
The neuropsychological battery consisted of eight tests measuring between 
them selective attention, verbal memory, visuo-spatial memory and fine motor 
coordination. Individual tests were: Matching Familiar Figures (Cairns and 
Cammock, 1978), Rey Verbal Learning (Rey, 1941), Digits Forwards 
(Wechsler, 1992), Paired-Associate Learning (Wechsler, 1987), Corsi Block-
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Tapping (Kolb and Whishaw, 1996), Rey-Davis Manual Labyrinth (Zangwi/l, 
1946), Purdue Pegboard and hole-type Steadiness Tester (Campden 
Instruments Ltd, King Street, Sileby, Loughborough, LE12 7LZ, UK). The 
measures were not specifically selected for their sensitivity to executive 
function, a cognitive domain associated with prefrontal activity which has 
been hypothesized by Welsh (1996) and others as being susceptible to the 
supranormal phe concentrations found even in treated PKU. However, error 
scores on Matching Familiar Figures are regarded by some authors as 
indicative of executive function disorder (Pennington and Ozonoff, 1996) and, 
being a three-dimensional maze that requires a systematic search strategy, 
the Rey-Davis Manual Labyrinth satisfies the theoretical criteria for a test of 
executive ability (Kelly et al., 1996). Including breaks, the complete battery 
took between 40 and 60 minutes to administer. 
Group allocation 
Patients were randomly allocated to one of two groups. Group One consisted 
of ten patients, Group Two of six. The groups did not differ significantly in 
chronological age, sex ratio, la, pre-treatment phenylalanine level, age at 
diagnosis and start of treatment. Dietary control during treatment was 
assessed by calculating individual median annual phe levels over the first ten 
years of life (Rupp and Burgard, 1995). A group by year-of-Iife ANOVA of 
these data revealed no significant between-group effect, the mean phe levels 
over the period for Group One being 414 Jlmolll (SO 86) and for Group Two 
410 Jlmolll (SO 89), and no significant interaction. A significant within-group 
effect was found (F= 5.24, df9/117, P< 0.001), indicating deterioration of 
dietary control over time for the sample overall. There was thus good 
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evidence that the groups' dietary compliance during the first ten years of 
treatment was comparable. 
Procedure 
The study conformed to a triple-blind, single-crossover, repeated measures 
design with baseline, first experimental and second experimental phases. 
Circulating phenylalanine was manipulated by means of the protein-substitute 
supplement rather than by natural food intake. The experimental period 
lasted six months, switching of conditions occurring half-way. Both groups 
remained on their usual low-phe dietary regimen throughout. During the 
baseline phase, both groups took their customary non-phe protein 
supplement. For the three months of the first experimental phase, the ten 
patients in Group One continued with their non-phe supplement, but for the 
three months of the second experimental phase were given a supplement 
with added phe. They were designated the La/Hi Group. The sequence for 
the six patients in Group Two was the reverse. They were given a supplement 
with added phe for the first three month phase and their customary non-phe 
supplement for the second. They were designated the Hi/Lo Group. The 
perceptually identical non-phe and added-phe protein supplements were 
coded by the manufacturers for individual patients so that the children, their 
families and the research staff were unaware of the product being given 
during any particular phase of the study. 
Phe levels were measured using high pressure liquid chromatography at 
baseline, at the end of the first three-month experimental phase and at the 
end of the second. The neuropsychological battery was repeated on the 
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same three occasions. Pre-test familiarization, test instructions and the test 
administration sequence were standardized. Biochemical and psychological 
testing during illness was avoided. All the children resumed their usual 
treatment on completion of the second experimental phase. 
Results 
Blood phe levels recorded at baseline and at the ends of the first and second 
experimental periods were subjected to ANOVA (BMOP2V), which revealed 
significant group (F= 7.98, df1/14, P< 0.05), phase (F= 8.91, df2l28, P< 
0.01) and interaction (F= 17.98, df2l28 , P< 0.001) effects. The highly 
significant interaction term confirmed the intended experimental manipulation. 
The analysis also showed that the Hi/lo Group's overall phenylalanine levels, 
irrespective of dietary condition, were significantly lower than the lo/Hi 
Group's. Figure 12 shows mean phe levels with SOs for each group as a 
function of experimental phase. 
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Figure 12. Mean (SD) blood phenylalanine levels in Jlmol/I at baseline (1) 
and end of first (2) and second (3) manipulation periods for Group One (Lo/Hi) 
and Group Two (Hi/Lo). The group x phase interaction was significant (P < 
0.001 ). 
Performance on the neuropsychological tests was quantified by time in 
seconds to complete the Purdue Pegboard, the number of contacts between 
stylus and hole on the Steadiness test, and number-correct raw scores on the 
remainder. Results from each of the eight tests were analyzed separately by 
ANOVA, the interaction term providing an index of a possible phe-related 
crossover effect. Table 13 shows means and standard deviations for tests and 
conditions. None of the between-group or interaction terms was significant at 
P < 0.05. Similarly, within-group terms were non-significant except for Ray 
Verbal Learning (F = 14.06, df 2128, P < 0.001) and Paired Associate 
Learning (F = 4.69, df 2/28, P < 0.05). The results from these two tests 
indicated gradual improvement over time in the performance of the group as a 
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whole irrespective of phe-Ievel and suggested a practice effect with repeated 
testing. In view of the Hilla Group's lower overall pherwlalanine levels, test 
scores after the first and second supplement manipulations were subjected to 
ANCOVA with baseline phenylalanine as the covariate, but again no 
significant interactions emerged. 
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Supplement Manipulation 
Test Group Baseline 1st phase 2nd phase 
1) Matching Figures Lo/Hi 6.30 (1.42) 7.00 (1.16) 6.80 (1.40) 
Hi/Lo 5.67 (1.03) 5.33 (1.51) 6.00 (1.41 ) 
2) Rey Verbal Lo/Hi 49.80 (3.94) 54.00 (3.09) 55.00 (4.74) 
Hi/Lo 43.67 (8.45) 49.50 (8.19) 50.33 (5.32) 
3) Digits Lo/Hi 10.10 (1.73) 10.30 (1.49) 10.40 (1.90) 
Hi/Lo 9.50 (2.66) 8.50 (2.95) 8.67 (1.75) 
4) Paired Associates Lo/Hi 27.30 (1.70) 25.90 (2.13) 27.40 (2.63) 
Hi/Lo 25.00 (3.10) 24.83 (2.86) 27.00 (1.27) 
5) Block Tapping Lo/Hi 7.90 (1.52) 7.20 (1.69) 8.30 (1.89) 
Hi/Lo 8.00 (1.79) 7.67 (2.50) 7.83 (1.47) 
6) Rey Labyrinth La/Hi 16.50 (3.92) 16.70 (2.95) 15.70 (3.09) 
Hi/Lo 15.00 (4.69) 14.33 (5.35) 15.50 (3.39) 
7) Pegboard (s) Lo/Hi 160.40 (8.45) 162.00 (12.32) 155.90 (13.15) 
Hi/Lo 154.33 (11.98) 154.17 (16.15) 152.83 (16.50) 
8) Steadiness Lo/Hi 21.20 (9.81) 17.20(10.89) 15.20 (9.73) 
Hi/Lo 16.00 (6.87) 24.67(14.05) 13.50 (5.47) 
Table 13. Results of neuropsychological tests in relation to group and 
experimental supplement manipulation. Means and SDs are number-correct 
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scores except for Pegboard which are seconds. High scores indicate good 
performance except for Pegboard and Steadiness where the reverse pertains. 
Group x phase interactions were uniformly non-significant. 
Discussion 
Crossover effects on test performance as a result of experimentally 
manipulating phenylalanine would have been reflected in the interaction 
terms of the analyses. However, as none was significant, it appeared that 
medium-term changes in phenylalanine were not affecting either motor 
control or verbal and spatial information-processing as measured by the 
neuropsychological battery. 
At the end of the two three-month periods of induced 
hyperphenylalaninaemia, the subgroups' average levels of 1355 J.1mol/l and 
1008 J.1mol/l respectively were below those of many children with classical 
PKU who have discontinued diet and thus may not have provided a realistic 
simulation of normal levels after treatment cessation. For this reason, it would 
be incautious to conclude that the results unequivocally indicate age 10 as a 
safe time to stop dietary treatment as far as neuropsychological function is 
concerned. Nonetheless, Frankenburg et a/., (1973) raised the average phe 
level to 2400 J.1mol/l in their subjects but found no adverse effects at the end of 
a three-week challenge period. 
The results agree well with those of Halvorsen et a/., (1989) who allowed 23 
PKU patients of similar age to those reported here natural protein up to the 
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point where blood phe levels reached 1200 J.1mol/l. These authors reported 
no changes in their subjects' IQ or neuropsychological status after three years 
of the liberalized regime. 
The neurotoxic mechanism by which excessive phe disrupts CNS 
development is poorly understood but, in untreated PKU, high phe levels 
appear to impair myelin, neurotransmitter and synapse formation (Hommes, 
1991). Maturation of the CNS is largely complete by 10 years of age 
(Davison, 1973). Following treatment of PKU until this age, three months is 
probably too short a phe-Ioad time-scale to potentiate changes in myelin 
turnover that would be reflected in functional indices such as 
neuropsychological measures. However, according to Guttier and Lou 
(1986), neuropsychological effects of the faster temporal dynamics of 
neurotransmitter biosynthesis might have been expected in the present 
sample within the manipulation period adopted. The fact they were not seen 
suggests that neuronal circuitry underlying verbal and spatial memory, fine 
motor coordination and selective attention was not affected by transient 
hyperphenylalaninaemia. However, the battery was not exhaustive and other 
psychological functions, not assessed, may be more vulnerable. 
Following a suggestion by Lou et al., (1985), Diamond (1994) proposed that 
excessive phe impairs dopamine synthesis in the prefrontal cerebral cortex 
which results in malfunction of executive programs governing attention, 
response inhibition and set maintenance. We found neither covariance 
between transient hyperphenylalaninaemia and attention or impulsivity as 
measured by the Matching Familiar Figures Test, nor deficient three-
dimensional maze learning, another purported executive function, on the Rey-
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Davis Manual Labyrinth. Nonetheless, short-term worsening of performance 
on executive tasks involving complex, speeded decision-making has been 
reported in older patients in whom phe was manipulated by supplement 
(Clarke et al., 1987) and by diet (Pietz et al., 1993). Though Griffiths et al., 
(1995) found no effect of post-treatment hyperphenylalaninaemia of three or 
more years duration on the Rey-Davis task in subjects who had good dietary 
control until age 10, their data did show a non-significant trend (P < 0.07) 
towards impairment on Matching Familiar Figures. In our current research 
programme, we are exploring the particular issue of whether executive 
functions are adversely affected by elevated phe levels in treated PKU. 
Our findings on the Matching Familiar Figures Test are at variance with those 
of Davis et al., (1986) though the two studies differ in design. Davis and her 
colleagues reported that Matching Familiar Figures discriminated averagely 
intelligent, treated PKU children from controls. However, they did not 
correlate phe levels with performance, thus failing to clarify whether the 
constructs of impulsivity and short attention span that the test purports to 
measure were associated with high historical or circulating phe. Our results 
suggest that temporary changes in circulating phe are not associated with 
these behaviours. 
Neuromotor deficits have been reported in seven post-treatment PKU adults, 
a sample representing less than 0.5 per cent of the total United Kingdom 
National PKU Register (Thompson et al., 1990). Only two of this number 
were treated early and remained well-controlled up to the same age as our 
patients. Three were developmentally retarded and one had epilepsy. As 
treatment factors and IQ were heterogeneous in this group, comparability with 
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ours was poor. In our early and continuously treated patients, we found no 
evidence of tremor or incoordination as a temporary, phe-related crossover 
effect. 
Our results agree with those of Pietz et a/., (1995) who studied the immediate 
effects of a single oral dose of L-phe in a carefully selected group of eight 
adults with classical PKU who were treated early. These authors reported a 
steep rise in blood phe and a delayed rise in brain phe concentrations in their 
patients, but no impairment of attention or fine motor skill as measured by 
neuropsychological test performance during a 20-hour post-load period 
compared with pre-load baseline. A similar lack of attentional dysfunction 
following an acute phe load has been reported by Realmuto et a/., (1986), 
whose nine- to 20-year-old sample was closer in age to ours. 
Conclusion 
Our findings suggest that elevation of blood-phe concentrations to between 
1000 and 1300 J,tmol/l on average for three months does not adversely affect 
verbal and spatial memory, motor coordination and selective attention in 
treated children with classical PKU whose intelligence is normal and who 
have been maintained on diet until and beyond the primary school period. 
These findings imply that the nervous system may be sufficiently protected 
against hyperphenylalaninaemia by the age of 10 or thereabouts and may not 
be susceptible to hypothesized neurotransmitter effects. However, the 
influence of longer-term exposure to excess phe on information processing 
remains to be researched, especially in relation to rapid decision-making and 
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sustained attention. It is important that patients with varying degrees of dietary 
control are followed up across the life span before a definitive statement is 
made about the optimal age for stopping treatment or whether dietary phe 
restriction should be a lifetime recommendation (Medical Research Council, 
1993b). 
Commentary 
A central purpose behind conducting neuropsychological studies of PKU is to 
determine whether subtle deficits revealed by neuropsychological tests in 
younger subjects might represent markers for later, perhaps more severe, 
impairments (Woolf, 1979). The oldest PKU patients who were detected by 
the mass newborn screening methods devised by Guthrie and subsequently 
treated are barely 30 years of age at the time of writing. Though older treated 
patients exist, they were generally identified and treated because of being 
younger siblings of children with PKU in whom the disease was diagnosed 
following behavioural signs of mental retardation. This post-3~ group - apart 
from being very small in number and often late or poorly treated - are still less 
than 45 years old as it was 1953 before Bickel published the first 
demonstration of an effective dietary treatment. Thus we know nothing about 
the intellectual outcome of treated PKU in late middle-age onwards. 
The value of conducting experimental challenge studies such as the one 
described above is in identifying phe-sensitive marker variables at an early 
stage that might have some predictive validity. In particular, psychological 
processes that are found to react adversely to temporary 
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hyperphenylalaninaemia in well-treated PKU might represent early risk 
indicators of later dysfunction should dietary treatment be relaxed or 
discontinued. After reviewing 21 published studies of neuropsychological 
measures in treated PKU, Waisbren et al. (1994) concluded that motor speed, 
speech, language, memory and basic logic were generally unaffected. By 
contrast, she and her co-authors found evidence for deficits in abstract 
reasoning, problem solving and executive functions. Executive functions are 
inherent in all purposeful behaviour and subsume planning and foresight (the 
guidance of actions by internal representation rather than by external 
stimulation), attentional deployment (selective and sustained) and self-
restraint (response inhibition). The term is often used interchangeably with 
'prefrontal lobe function' (Stuss, 1987). 
The negative findings of the present study are consistent with Waisbren et 
al. 's view that non-executive functions are not subject to disruption by 
excessive phe. The results only partially agree with a recent report by 
Weglage et al. (1996). These authors found a similar lack of association 
between concurrent phe and digit recall in 11-year-old children, whereas 
performance on the Stroop and a test similar to Matching Familiar Figures 
was impaired. Their sample's test levels ranged between 85 and 1709 Jlmolll 
and thus were comparable, at least with the Lo/Hi Group's on challenge. Of 
the six cognitive tests in the battery, five were measures of memory and 
learning. Thus, a methodological weakness of the study was its failure to 
achieve a better balance between discriminant tasks such as memory 
measures and supposedly phe-sensitive tasks such as measures of executive 
function that may be differentially depressed by hyperphenylalaninaemia. 
Matching Familiar Figures and the Rey Labyrinth came closest to the criteria 
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for being classified as executive function tests. In failing to show a phe effect, 
they weakened the executive dysfunction theory, but further research is 
required to settle this question. A comprehensive and validated test battery 
suitable for assessing executive skills in children remains to be developed 
{Ke"y et al., 1996}. The Stroop and Wisconsin Card Sorting tests, choice 
reaction time and mazes hold some promise of being able to reveal subtle 
executive disturbance in treated PKU but often studies on which such claims 
are based are characterized by small samples that are heterogeneous for 
age, treatment history and intellectual status {Waisbren et al., 1994}. The 
present study could not be criticized on these counts, but would have been 
improved by the inclusion of more tasks thought to be indicative of executive 
activity. 
In a study very recently published, Burgard et al. {1997} compared two groups 
of early-treated adolescents on simple reaction time and de Sonneville's Dot 
Pattern Test {de Sonnevi"e, 1993}. The Dot Pattern Test is a speeded, 
decision-making task involving response suppression and purports to 
measure executive function. Burgard et al. found no difference in the level of 
sustained attention, as quantified by this task, between a French PKU group 
who had stopped treatment abruptly at 5 years and a German PKU group who 
had continued with the phe-restricted diet. No effect was found despite a 
large, though not statistically tested, difference in mean concurrent phe levels: 
1272 J,1molll for the French patients and 588 J,1molll for the German patients. 
With mean ages of 13.6 and 13.1 years and mean las of 103 and 101 
respectively, these groups were thus similar in age and 10 to the present 
sample. Furthermore, the British children were comparable with the French 
during the high-phe experimental phase and with the German during the low-
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phe phase. While the children in the present sample were rendered 
hyperphenylalaninaemic for only three months, the French children had been 
subjected to high dietary phe levels for eight years on average but, 
nothwithstanding this prolonged period of exposure, showed no neurotoxic 
effects on measures of executive function. Burgard et al.'s results therefore 
appear to support the conclusion of the present study that a point is reached 
in middle childhood at which the eNS can tolerate high circulating phe levels. 
However, a note of caution about Burgard et al.'s study needs to be sounded 
as their samples were neither homogeneous nor matched for severity of PKU. 
In the French sample, three of the nine children had mild (Type 2) rather than 
classical (Type 1) PKU (Guttier, 1980); in the German sample there was one 
Type 2 child. The relatively large proportion of non-classical children in the 
French sample may have diluted the effect of many years of 
hyperphenylalaninaemia and thus the non-significant test results may have 
been an artefact of sample factor differences. 
An obvious anomaly in the design of the present study was the unequal 
subgroup numbers. This imbalance arose because of the method of group 
assignment adopted by the Project Director. A pure (heads/tails) 
randomization rather than an alternate allocation (random sequence, then 
odd/even) procedure was used to decide group membership. Partly because 
the rest of the research team were blind to the categories to which individuals 
had been assigned and partly because of a lack of communication between 
team members, this quirk did not emerge until after the final phase when the 
codes were broken. The analysis package (BMDP 2V) was able to handle 
unequal distribution totals but the large standard error inherent in the data 
from the smaller (n=6) Hi/Lo Group would have lowered the statistical (i.e. 
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inferential) power of the ANOVA (Gravetter & Wallnau, 1992). 
A matched pairs design would have been preferable, especially in view of the 
significant difference between the groups in overall phenylalanine level. The 
lower mean phe levels shown in every condition by the Hi/Lo Group appeared 
to be the result of a combination of small subgroup size (n=6) and three 
exceptionally we "-controlled children being allocated to this group by the 
simple randomization procedure. These three subjects had low mean lifelong 
phe levels of 360, 362 and 327 Jlmolll respectively. 
A sma" criticism that could be leve"ed at the biochemical aspect of the study 
is the absence of intermittent phe-Ievel data during the experimental phases. 
Intra-individual diurnal fluctuation in phe concentrations is beginning to be 
recognized as a potentially troublesome phenomenon in PKU research. For 
instance, Rylance et al. (1996) reported a range of 130 to 280 Jlmolll in a 
group of 11 patients whose plasma phe concentrations were monitored for 24 
hours. The group x condition interaction term was highly significant when 
subjected to ANOVA, thus vindicating the intended manipulation of the 
independent variable. However, the single phe readings taken at the end of 
each phase may not necessarily have been representative of average levels 
during the three-month experimental periods, only of levels pertaining during 
neuropsychological testing. It is conceivable that the significant between-
group difference in phe could have arisen out of subjects in the Hi/Lo Group 
systematically and temporarily reducing dietary phe intake more than the 
Lo/Hi Group immediately prior to hospital attendance for examination. There 
is no evidence for this kind of deception by the subjects in the smaller group 
and individual differences in general dietary control or even genotype are 
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more likely explanations. Nevertheless, the simple expedient of gathering 
data from regular Guthrie tests throughout the duration of the experiment 
would have illuminated whether end-of-phase phe figures were 
representative of the phases in their entirety. 
The use of the interaction term in the ANOVA should have permitted phe 
effects to be identified irrespective of differences in group baseline phe levels. 
A minor weakness in the argument for relying on the interaction term to reveal 
a dynamic relationship between phe and neuropsychological function, 
however, is whether absolute phe levels are indeed factors in the equation 
that can be dismissed as irrelevant. The possibility of a threshold effect has to 
be acknowledged where an adverse influence of elevating phe level only 
occurs when the baseline level surpasses a certain point. This is conjecture 
and there is no evidence for such a mechanism in treated PKU. In untreated 
PKU, when very high phe levels similar to those achieved in the present study 
by the Lo/Hi Group (i.e. > 1200 J.1mol/l), are maintained from infancy until 
adulthood, a qualitative change appears to occur in the extent and location of 
white matter abnormalities in the brain (Malamud, 1966; Pearsen et al., 1990). 
But the treated form of the disease in which experimental 
hyperphenylalaninaemia is imposed after the great majority of eNS 
maturation is complete and the untreated form cannot reasonably be 
compared, given the fundamental differences in onset and duration of high 
phe levels that delineate the two. 
A further shortcoming of the experiment was its failure to incorporate a return-
to-baseline condition. Such an addition would have been eminently 
practicable as, unlike the adults in the dietary resumption pilot study 
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described in Chapter Five, all the children continued with their low-phe diet 
and were returned to their normal phenylalanine-free amino acid supplement 
on conclusion of the second manipulation period. A final administration of 
the test battery after a further three months of normal treatment might have 
provided extra data on the reversibility of phe effects or, in the case of 
negative results, additional support for the null hypothesis. The sequence of 
conditions would continue to represent a single crossover model as in Figure 
13. While this is a less effective demonstration of reversal effects than a 
double crossover model, it is ethically more acceptable and would shed a little 
more light on the neurotransmitter theory of treated PKU, the theory positing 
dynamic yet temporary and reversible alterations in rapid information 
processing as a function of phe level fluctuation in late childhood and 
adolescence (Lou et al., 1987). 
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Practice effects bedevil repeated measures designs and their control 
necessitated the adoption of a crossover design (Stuart-Hamilton, 1996). 
Altemative control procedures such as preliminary asymptoting of 
performance would have been feasible on the two motor tasks, Pegboard and 
Steadiness, but not on the remainder as this approach would probably have 
resulted in stimulus material being transferred to long-term memory and thus 
being arguably less vulnerable to transitory neurochemical effects (Claridge, 
1970). The employment of parallel test forms was not an option unless 
detailed preparatory work was undertaken. Though stucturally equivalent 
forms for Matching Familiar Figures, Rey Verbal Learning, Digits Forwards, 
Paired Associates could have been constructed, equality of content and 
facility level could not have been achieved without extensive psychometric 
standardization. The Corsi Block Tapping and Rey Labyrinth tasks tap recall 
of novel information (spatial positions). While the apparatus, for these tasks 
could not have been altered without changing their intrinsic demand 
characteristics, alternative stimulus sequences could have been devised. 
However, assumptions about replicability could not have been made without 
preliminary empirical studies on test-retest reliability (Walsh, 1989). 
The tests included in the neuropsychological battery were not norm-
referenced for children and information about their individual psychometric 
features such as construct validity was scant. Furthermore, they were 
uniformly laboratory tests whose results could not be readily translated into 
everyday psychological functioning. Finally, they were exclusively either 
cognitive or motor in nature and thus unable to throw light on any personality 
changes that might have occurred in response to raised phe concentrations. 
These shortcomings were not recognized at the planning stage of the study 
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but became evident once it was under way. In order to make good possible 
deficiencies in their psychometric soundness, ecological validity and 
coverage of personality variables, a further set of tests was introduced, the 
subjects being given these at the end of the first and second experimental 
phases. This additional battery was not prepared in time to be included when 
the initial baseline measures were made using the neuropsychological tests. 
The chapter which follows describes a subsidiary study in which results on IQ, 
everyday memory and problem behaviour tests were compared with 
manipulation of the phe variable. 
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Chapter 7 
MANIPULATION OF PHENYLALANINE BY AMINO ACID 
SUPPLEMENT: IQ, EVERYDAY MEMORY AND PERSONALITY 
OUTCOME 
Background to study 
In the previous study, the effects of the independent variable, phe 
concentration, were investigated under three conditions: baseline, first 
experimental manipulation and second experimental manipulation. In the 
present study there were two only, the baseline phase being omitted. The 
subjects, group allocation and procedure were the same, but the following 
tests were given at the end of the first and second three-month experimental 
phases in addition to the neuropsychological battery. As before, the same 
measures were repeated on retest. 
The aim of the study was to explore whether transitory elevation of phe level 
in older treated PKU children would affect cognitive functioning as evidenced 
by changes in la, everyday memory as measured by the Rivermead 
Behavioural Memory Test (Wilson ef al., 1991) and behaviour disorder as 
rated by the children's parents on a modified version of the Rutter Scales 
(Rutter ef a/., 1970). A perennial difficulty with the interpretation of 
neuropsychological test results, such as those derived from the study reported 
in Chapter Six, surrounds their ecological validity. Positive or negative 
findings on laboratory-style tests may not translate readily into obvious 
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practical consequences or identifiable shortcomings in everyday commerce 
with the world (Taylor, 1988; Griffiths, 1996) and may fail to provide a firm 
foundation on which to build a convincing argument to put before patients and 
their families for dietary discontinuation or prolongation. Thus, we selected 
the Rivermead measure whose ecological validity is purportedly good - or at 
least which was constructed in the spirit of relating item content to real-life 
tasks. Furthermore, we realized that the experimental format of the study with 
both parents and children being blinded to the supplement condition 
presented us with a valuable opportunity to collect data on the subjective 
judgements of the patients and their carers about which supplement - high or 
low phe - was being administered. To our knowledge, no previous study had 
asked such a basic question, despite the history of experimental manipulation 
of phe in PKU research extending back over 20 years (Frankenburg et al., 
1973). 
A short-form of the Wechsler Intelligence Scale for Children, 3rd UK Edition 
(WISC3-UK) was given. This comprised two subtests from the Verbal Scale -
Similarities and Vocabulary - and two subtests from the Performance Scale -
Block Design and Object Assembly. This tetrad of subtests was chosen for 
being representative of verbal and spatial cognitive functions and for its high 
correlation wirh Full Scale IQ, at least in terms of subtests from the WISC-R 
standardization. Applying McNemar's formula, the part-whole correlation 
coefficient is +0.943 {Sattler, 1974}. 
The Rivermead Behavioural Memory Test (RBMT) is a fairly new measure for 
children that is little known outside the UK. The philosophy underlying its 
creation is that the preponderance of existing psychometric instruments 
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devised to quantify memory are clinical or laboratory tasks that use artificial 
stimuli and have little bearing on successful day-to-day adjustment to the real-
life world. Hence, the authors believe, there is a need for information about 
whether patients are able to meet everyday demands on memory, such as 
remembering appointments and people's names and faces. The strength of 
the RBMT, its authors claim, lies in its ecological validity, a concept alluded to 
by Cole and Bruner (1971), but articulated in detail by Brooks and 
Baumeister (1977) who, taking the field of mental handicap as an example, 
called for a move towards more naturalistic studies and, in general, applied 
psychological research with more environmentally and socially relevant 
objectives than those of the traditional laboratory. Stuart-Hamilton (1995) 
defines ecological validity as a 'term describing a study which is a realistic 
simulation of a real life event or which tests skills used in real life'. The RBMT 
consists of seven main items: recalling names, recognizing faces, locating a 
hidden object, remembering a story, recognizing pictures, learning a route 
and recalling a message. There are also temporal and spatial orientation 
items. Immediate and delayed recall of route learning and message recall is 
tested. For children over 10, the overall score is norm-referenced. No parallel 
forms exist. 
To the author's knowledge, this is the first time an attempt has been made to 
investigate memory for everyday stimuli in treated PKU by means of the 
RBMT. 
Several reports have suggested that treated PKU may be associated with 
poor psychosocial adjustment. Smith et al. (1988) gave teachers the Rutter 
scales to complete on 544 eight-year-old children from the UK National Study 
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cohort. Overall, the PKU children were rated significantly higher for neurotic 
and hyperactive behaviours than controls, though not for anti-social and 
aggressive behaviours. In an uncontrolled study of patients on the US 
Collaborative Study's register, Holtzman et al. (1986) found parental ratings of 
problem behaviours to be highest for children with early dietary cessation, but 
so was loss of 10. Above average psychiatric symptomatology, including 
hyperactivity, was found in a strictly treated group from the German 
Collaborative Study at the age of 13, but disturbed behaviour was unrelated 
to historical phe levels (Burgard et al., 1994). Distractability, passivity and 
impersistence emerged as PKU-related personality variables from a 
questionnaire study by Schor (1983) but, again, these traits did not correlate 
with either historical or concurrent phe levels. 
While there is evidence that, as a diagnostic category, treated PKU carries 
with it an elevated risk of mild maladjustment compared to age standards, a 
key research issue is the underlying reason. Given the onerous nature of 
dietary treatment and the pressures compliance exerts on both patient and 
carer, it is simplistiC to assume a direct link between phe level and personality 
development. In the untreated condition, uncontrolled circulating phe 
appears to potentiate a deviant personality that is typified by hyperkinesis, 
temper tantrums and self-punitive acts (Wood et al., 1967), but these 
immature behavioural characteristics are common in numerous mentally 
handicapping conditions (Heaton-Ward & Wiley, 1984) and may not be PKU-
specific. Much of the behavioural deviance reported in treated PKU may be 
iatrogenic, the chronic and burdensome treatment itself carrying with it the 
potential for peer and family conflict, feelings of alienation in the patient and, 
of course, the ever-present fear in the parents of damaging the child's 
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intellect. 
In an early study of children treated until at least five years of age, Chang and 
Fish (1976) found the opposite to what would be predicted by the 
hyperphenylalaninaemia hypothesis. Paradoxically, children in their sample 
who were treated the longest showed the highest frequency of problem 
behaviours, this result providing some support for the view that dietary 
prolongation may be accompanied by the negative side-effect of 
accumulating stress. In a later study (Chang et al., 1983), these authors 
argued that unstable behaviour associated with treated PKU may be due to 
non-phe factors such as parental education and implied that, when treatment 
is continued after the age of seven, the risk of intellectual deterioration 
declines to near-zero but the risk of emotional disturbance rises considerably. 
The value of observing problem behaviour parameters during phe 
manipulation in older treated children lies in the potential power of such a 
model to provoke change by challenge and thereby establish whether a 
dynamic relationship exists between phe and behavioural deterioration when 
treatment administration factors are held constant. It is worth remembering 
that the contemporary treatment of PKU by dietary restriction is inherently a 
behvioural methodology that requires, for its success, the formation of atypical 
feeding and eating habits on the part of the parent and the patient. Raising 
phe by supplement allows these habits to remain unmodified and thus the 
design falls into the univariate category where any systematic change in 
personality can reasonably be attributed to phe and not extraneous variables. 
The theoretical rationale for considering that hyperphenylalaninaemia in 
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treated PKU may influence personality functioning is the assumption that 
certain central aspects of individuality such as adherence to moral codes, self 
control and concentration are dependent on the integrity of the prefrontal 
cortex. The bulk of evidence for this view derives from clinical research on 
patients with damage to the anterior area of the brain who subsequently 
exhibit the typical frontal lobe syndrome of disinhibition, poor foresight and 
lack of moral restraint (Walsh, 1978). There is no suggestion of such a 
dramatic personality change being occasioned by hyperphenylalaninaemia in 
treated PKU subjects, but Welsh (1996) has recently proposed that more 
subtle - and also temporary and reversible - signs of the syndrome could 
arise, the underlying mechanism being disruption by phe of the dopaminergic 
system in the prefrontal cortex. 
Introduction 
Classical phenylketonuria (PKU) is operationally defined as blood 
phenylalanine (phe) levels consistently in excess of 1200 /lmolll after the first 
week of post-uterine life (Koch & Wenz, 1987). Sustained 
hyperphenylalaninaemia during the early years of life is neurotoxic and 
almost invariably results in severe intellectual impairment (Berman et al., 
1968). The effect is irreversible (Marholin et al., 1978). The pathogenesis of 
mental retardation in untreated PKU is unclear. Poor dendritic arborization 
and reduced synaptic spine density are characteristic (Bauman & Kemper, 
1982). The neuropathological mechanism is assumed to be a disturbance of 
myelination (Bick et al., 1991), elevated levels of circulating phe during the 
vulnerable period of cerebral maturation appearing to compromise neuronal 
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conduction by reducing myelin turnover (Hommes, 1991). Neurotransmission 
may also be affected. The metabolic block in PKU provides a theoretical 
basis for a neurotransmitter hypothesis as dopamine, serotonin and 
norepinephrine deficiencies are consequential on the failure or partial failure 
of phenylalanine hydroxylation to tyrosine (Vorhees et al., 1981). 
The devastating effects of hyperphenylalaninaemia in infancy are well-
established, however its effects on the mature nervous system in treated PKU 
following dietary cessation require ongoing research. While myelination is 
largely complete by early adolescence, elevated phe levels may adversely 
affect neurotransmitter activity in the short-term and such changes could be 
manifested in subtly impaired cognitive and behavioural functioning (Guttier & 
Lou, 1986). Current treatment recommendations are for dietary restriction to 
be implemented within the first month of life and maintained until at least 10 
years of age with control well within the 120 to 600 J,lmolll range (Legido et 
al., 1993). Briefly challenging the CNS with phe following a treatment regime 
that meets these criteria and measuring concomitant psychological function is 
a methodology that can illuminate treatment and theoretical issues in PKU 
such as age for dietary discontinuation and, indirectly, neurotransmitter 
depletion. Temporary deterioration of psychological function in response to 
transient hyperphenylalaninaemia might suggest premature cessation of 
treatment and imply short-term, but probably reversible, neurotransmitter 
deficiency. 
In a prototype study, Frankenburg et al. (1973) experimentally manipulated 
phe intake in a small group of six non-retarded, treated PKU children aged 
four to five years, measuring adverse behaviours such as withdrawal, short 
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attention span and emotional lability in relation to two high-phe challenges. 
These authors noted a short-lived deterioration in behaviour coincident with 
onset of challenge but no sustained effect over three weeks of exposure to 
phe. Clarke et al. (1987) conducted a similar study with nine adolescents with 
IQs below 90 who had discontinued treatment between two and eleven years 
of age, returning them to a protein-restricted diet before imposing a high-phe 
challenge for four to five weeks. A neuropsychological battery failed to detect 
psychological changes following alterations in phe except for slight increases 
in choice reaction-time. Together, these studies suggest that widespread 
behavioural and cognitive deficits are not consequent on temporary 
elevations in phe. Also, the lack of circumstantial evidence for short-term 
neurotoxic effects implies that a neurotransmitter mechanism may not be 
involved. However, while both studies adopted a triple-blind approach, they 
suffered from methodological shortcomings. For instance, Clarke et al. (1987) 
did not incorporate a cross-over design to control for practice effects, neither 
sample conformed to current US and UK treatment recommendations of 
maintaining diet until at least 10 years of age (Azen et al., 1991; Medical 
Research Council, 1993a) and Frankenburg et al.'s (1973) findings may have 
been contaminated by confounding variables. 
To establish whether temporary hyperphenylalanaemia in PKU results in 
diminished psychological functioning when the disorder is treated according 
to contemporary standards, we simulated a period of temporary dietary 
cessation in an early and continuously treated sample of 10 to 16 year-old, 
non-retarded children with classical PKU. We experimentally manipulated 
phe intake over two successive three-month blocks, inducing 
hyperphenylalaninaemia in one of these, and measured cognitive and 
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behavioural outcome. A triple-blind crossover design was adopted to control 
for subject, parent, experimenter and practice variables. Psychological 
measures included short-form la, everyday memory and problem behaviours. 
We also asked parents and children to judge which condition (low or high 
phe) had been imposed. 
Method 
Subjects 
A recruitment meeting attended by families with children who met the 
inclusion criteria of early and continuously treated classical PKU was held at 
which a presentation of the study was made by a senior clinician. The pupose 
and methodology of the study were fully explained and parents and children 
discussed details and concerns with the research team. Thereafter, individual 
families were given a few days in which to consider their decision, prior to 
formal consent being sought. 
Three families declined to participate, leaving a final sample of 16 children, 
ten boys and six girls. All had classical PKU (i.e. phe > 1200 Ilmol/l following 
neonatal screening) and had been continuously treated from early infancy. 
The target therapeutic range for the first ten years of life was 120 to 600 
Ilmol/l, some degree of dietary relaxation occurring thereafter. None had 
neurological or psychiatric disorder. On entry to the study, the median 
chronological age of the sample was 11.48 years (range 10.83 to 16.42), the 
median phe level 507 J.lmolll (range 209 to 1236) and the median Wechsler la 
101 (range 89 to 124). Concurrent phe and la were not significantly 
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correlated (r= -0.21, p = n.s.). 
Each child was randomly allocated to one of two groups. Group One 
consisted of ten patients with a median chronological age of 12.17 years on 
admission to the study (range 10.83 to 16.42). Group Two consisted of six 
patients with a median age of 11.29 years (range 10.83 to 14.67). The 
groups' age distributions did not differ statistically (U = 20, P = n.s.). There 
were six males and four females in Group One (60% male), four males and 
two females in Group Two (67% male). The mean IC for Group One at the 
outset of the study was 104.90 (SO 10.09), that for Group Two 99.67 (SO 
8.71). This difference was non-significant (t= 1.05, P = n.s). The mean pre-
treatment phenylalanine level for Group One was 2070 Jlmol/l (SO 449) and 
for Group Two 1597 JlmoVI (SO 540). This difference was also non-
significant (t = 1.90, P = n.s.). The median age at diagnosis was 16 days for 
both groups (range: Group One, 14 to 25; Group Two, 10 to 40) which was 
non-significant (U = 29, P = n.s.). The median age for initiation of treatment 
was also 16 days for both groups (range: Group One, 15 to 25; Group Two, 11 
to 40) which was similarly non-significant (U = 26, P = n.s.). The groups were 
thus matched for chronological age, sex, IC, pre-treatment phenylalanine 
level (severity), age at diagnosis and age at start of treatment. 
Following the recommendations of Rupp and Burgard (1995), median annual 
phe levels were taken as indices of dietary control (IDCs). Each child's IDCs 
over the first ten years of life, i.e. up to the age of the youngest child in the 
sample, were averaged and the distributions subjected to ANOVA, although 
one patient from Group One had to be omitted because of incomplete 
historical data. No significant between-group effect was found (F = 0.01, df 
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1/13, P = n.s.), the mean IDC over the ten years for Group One being 414 
/lmol/l (SD 86), that for Group Two 410 Ilmol/l (SD 89). A significant within-
group effect was found (F = 5.24, df 9/117, P < 0.001), indicating deterioration 
of dietary control over time for the sample overall (see Figure 14), but no 
interaction (F = 1.54, df9/117, P = n.s). The groups' dietary control during the 
first ten years of treatment was therefore comparable. The sample as a whole 
could be regarded as well-controlled, average IDCs falling within the 
recommended 120 to 600 Ilmol/l therapeutic range in operation at the time. 
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Figure 14. Mean indices of dietary control (IDCs) with standard errors. 
Groups One (n=10) and Two (n=6) over first ten years of life. See text for 
analysis. 
Apparatus 
1) Intellectual function ing was quantified by a short-form version of the 
Wechsler Intelligence Scale for Children (WISC-3 UK) comprising the 
Similarities, Vocabulary, Block Design and Object Assembly subtests (Sattler, 
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1982). 2) Everyday memory was assessed by the Rivermead Behavioural 
Memory Test. The adult version was chosen as no differences in level of 
periormance between a sample comparable in age to ours and the normal 
adult population have been reported by its authors (Wilson et al., 1991). The 
Rivermead contains tasks that measure memory for names, pictures, places, 
times, faces, routes, commands and stories. It purports to possess greater 
ecological validity than laboratory-style measures of memory. 3) Ratings of 
parents' perceptions of problem behaviours were obtained from a 20-item 
adjective checklist based of the Rutter Scales (Rutter et al., 1970). Each item 
in the Problem Behaviour Checklist was a word or phrase such as anxious, 
destructive, forgetful, unable to concentrate, lacking in energy, clumsyand so 
on. Parents rated each descriptor on a five-point Likert scale ranging from 
Not at al/ through Slightly, Moderately and Considerably to Extremely. 
Checklists were headed with standardised instructions. 4) Parents' and 
childrens' judgements of what dietary regime had been imposed were 
obtained by the forced-choice question Do you think you were given the low 
or high phenylalanine supplement over the past three months? 
Procedure 
The protocol for the study was based on a triple-blind, crossover design with 
repeated measures, each subject acting as their own control. In each group 
phenylalanine intake was experimentally manipulated over a six-month 
period, switching of conditions occurring at the half-way point. Both groups 
adhered to their normal restricted-protein dietary regime throughout the six 
month study period. For the first three months, however, the children in Group 
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One received their customary low-phenylalanine supplement but for the other 
three months a high-phenylalanine supplement. This group was designated 
the Lo/Hi Group. The children in Group Two received the reverse: a high-
phenylalanine supplement for the first three months and their customary low-
phenylalanine supplement for the remainder. This group was designated the 
Hi/Lo Group. 
High phenylalanine intake was achieved by replacing the patients' usual low 
phenylalanine protein supplement with a formula identical in bulk, 
composition, appearance, taste and texture but with half the tyrosine content 
replaced by phenylalanine. Thus, the experimental product was the 
children's customary amino acid, carbohydrate, mineral and vitamin 
supplement but with phenylalanine added and tyrosine reduced to give an 
identical volume. Dietary restriction was otherwise invariant before and 
throughout the study and individual children remained on diet and took their 
daily supplement as usual, the only difference being that, during the first 
three-month phase for the Hi/Lo Group and during the second three-month 
phase for the Lo/Hi Group, the supplement contained phenylalanine 
equivalent to the average daily intake of someone without PKU. Both the 
children's usual formula and the experimental product were prepared and 
coded by Scientific Hospital Supplies (UK) Limited, 100 Wavertree Boulevard, 
Liverpool, L7 9PT. Neither the children, their parents, nor the researchers 
knew which product was being administered until testing was completed. The 
key to the code was kept by a senior member of the hospital medical staff. 
WISC and Rivermead data, parents' ratings on the Problem Behaviour 
Checklist and parents' and childrens' guesses about the supplement were 
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gathered during the week before crossover at the end of the first three-month 
period. The testing was repeated during the week before the end of the 
second three-month period. The same parent who completed the first 
Checklist and made the first guess also responded the second time. On the 
second occasion, parents and children who wished to change their first guess 
were allowed so to do (their second guess then becoming the opposite). 
Parents and children made their guesses independently of each other. The 
Problem Behaviour Checklist was headed with standardised instructions for 
parents who were asked to rate their child's behaviour as they saw it over the 
immediately preceding week. The testing sequence was standardised to 
control for order effects. 
Blood samples were collected at the end of each three-month period on the 
morning of the day of testing. Phe levels were established by high pressure 
liquid chromatography. All subjects returned to their restricted diet and 
normal protein supplement immediately on conclusion of the second three-
month experimental period. 
Results 
Phe levels were measured in JlmoVI. Analyses of the WISC subtests were 
based on scaled scores and analysis of the Rivermead test on standard score 
totals, high scores on both representing good intellectual and memory skills 
respectively. Individual item-ratings on the Problem Behaviour Checklist were 
coded on a 0 to 4 scale (zero for absence of the problem) and these figures 
totalled to give a score out of 80, high scores representing maladjustment. 
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Table 14 shows both the independent variable (phe level) and dependent 
variables (psychological test and rating scores). All were analysed by ANOVA 
(BMDP 2V), the between-group factor being group allocation (Lo/Hi or Hi/Lo), 
the within-group factor phase of dietary manipulation (1 st or 2nd) and the 
interaction term the cross-over effect. Significant interactions would have 
supported the hypothesis that systematic changes in phe affect intellect, 
memory and behaviour. According to the theoretical model, wIse and 
Rivermead scores should decline with rising phe, and Problem Behaviour 
scores increase. 
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Dietary manipulation ANOVA 
Test Group 1st: Mean (SD) 
Phe: One 836.90 (396.06) 
Two 1007.67 (217.54) 
Sim: One 
Two 
Voe: One 
Two 
BD: One 
Two 
OA: One 
Two 
11.70 
10.17 
9.80 
7.50 
10.50 
9.50 
10.90 
9.83 
(2.00) 
(2.04) 
(1.32) 
(2.26) 
(1.72) 
(2.59) 
(2.13) 
(3.31 ) 
RBMT: One 22.30 (2.06) 
(3.93) Two 20.67 
PBC: One 7.20 (7.98) 
Two 10.67 (10.01) 
2nd: Mean (SD) Term F p 
1354.50 (291.87) 
515.00 (236.14) 
11.90 
11.17 
9.80 
8.50 
9.10 
8.67 
13.00 
10.67 
22.50 
20.50 
(3.11) 
(2.48) 
(2.70) 
(2.43) 
(2.89) 
(2.16) 
(2.94) 
(1.50) 
(1.51 ) 
(3.94) 
15.80 (18.90) 
5.67 (2.42) 
Between 7.49 
Within 0.01 
Interaction 23.79 
0.02 
n.s. 
0.00 
Between 0.96 n.s. 
Within 1.12 n.s. 
Interaction 0.50 n.s. 
Between 3.26 n.s. 
Within 0.82 n.s. 
Interaction 0.82 n.s. 
Between 0.39 n.s. 
Within 6.06 0.03 
Interaction 0.39 n.s. 
Between 2.63 n.s. 
Within 3.23 n.s. 
Interaction 0.60 n.s. 
Between 2.07 n.s. 
Within 0.00 n.s. 
Interaction 0.08 n.s. 
Between 0.40 n.s. 
Within 0.24 n.s. 
Interaction 3.49 n.s. 
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Table 14. Cross-over effects on independent variable (phenylalanine level) 
and dependent variables (psychological tests). Phe levels, and WISC 
(Similarities, Vocabulary, Block Design and Object Assembly), Rivermead 
(RBMT) and Problem Behaviour Checklist (PBC) results as a function of 
dietary manipulation and group. df1/14 throughout. Alpha-level 0.05. 
A highly significant interaction between dietary phase and group was found 
for blood phe levels (Table 14), indicating that phe differed according to the 
supplement taken and that manipulation of the independent variable was as 
intended. For the sample as a whole, overall phe levels did not differ over 
time. However, the significant between-group term indicated that, during the 
course of the experiment Group One's overall phe level was higher than 
Group Two's (mean, Group One: 1095.70 Jlmol/I; mean, Group Two: 761.33). 
Except for the Problem Behaviour Checklist which showed a non-significant 
trend (p= 0.08), none of the interaction terms for the psychological variables 
was significant, suggesting that intellectual and memory test scores and 
behavioural ratings were not changing conSistently in a similar manner to phe 
levels. None of the major terms in the analyses of the psychological tests was 
significant, except for the within-group F-ratio on Block Design. This statistic 
revealed a reliable difference in performance on retest for the entire sample, 
irrespective of dietary condition. The second mean (8.94) was less than the 
first (10.13): a counter-theoretical effect in terms of practice as familiarity 
would have resulted in the opposite. A secondary analysis of Rivermead raw 
(unweighted) scores also yielded non-significant F-ratios (Between 3.46, df 
1/14, P = n.s.; Within 0.01, df1/14, P = n.s.; Interaction 0.07, df1/14, P = n.s.). 
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The proportion of parents and children whose guesses about the dietary 
regime agreed with actuality and with each other are shown as percentages 
in Table 15, chance level being 50 per cent. On a binonomial test, in Group 
One (n=10), nine or more parents and children (90 per cent) guessing 
correctly would have been required for statistical significance at p < 0.05; in 
Group Two (n=6) all six (100 per cent) would have had to have been correct; 
and for the sample as a whole (n=16) the number would have had to have 
been 12 (75 per cent). The data confirmed that neither the parents, nor the 
children in Groups One and Two, nor the sample as a whole reliably guessed 
which phe supplement had been administered. Likewise, inter-observer 
agreement, as measured by the proportion of concurring parents' and 
childrens' judgements, was random. 
Group 
One 
Two 
All 
Parent 
40% 
67% 
50% 
Child 
60% 
33% 
50% 
1/0 
40% 
50% 
44% 
Table 15 Guesses about dietary manipulation. Per cent correct judgements 
of parents and children and inter-observer (1/0: parent-child) agreement for 
Groups One and Two and complete sample. Chance level 50 per cent. 
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Discussion 
The results showed that changes in 10, everyday memory and behaviour 
ratings did not parallel significant elevation ~.nd reduction of blood phe levels 
over three-monthly periods of experimental dietary manipulation. These 
negative results corroborate those of Frankenburg et al. (1973) and Clarke et 
al. (1987). Though restricted in size by availability of patients, the sample in 
the present study was nonetheless homogeneous for severity and treatment 
factors and, collectively, the three studies provide evidence that temporarily 
raising phe in treated, classical PKU does not produce a measurable 
neurotoxic effect, at least as reflected in tests of psychological performance. 
Of the three studies, the exposure period of the present study was the longest. 
However, despite being subjected to three-months of elevated phe levels, the 
groups did not show adverse test scores at the end of these periods. A 
limitation of the research design was that psychological measures were not 
taken immediately following onset of the high phe phase. Frankenburg et al. 
(1973) found behaviour ratings worsened briefly at this time, suggesting rapid 
reaction of the eNS to the change in phe before stabilising 10 days later at 
baseline levels. Our findings cannot attest to the validity of this phenomenon, 
but no parent reported sudden deterioration in their child's functioning on 
administration of the high phe supplement either at the time or in retrospect. 
Furthermore, the brief behavioural disorder noted by Frankenburg and his 
colleagues may have been due to illness rather than phe as the two factors 
were confounded in four of their six subjects. 
The two experimental groups were matched for demographic, treatment and 
10 variables. However, they differed in overall phe level during the course of 
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the study, Group One being on average 334.37 Jlmol/I higher than Group Two. 
Better dietary control in Group Two may account for this discrepancy. Greater 
phenylalanine hydroxylase activity is probably not an explanation as historical 
phe levels did not differ between the groups. Though the between-group 
factor for phe was statistically significant, this finding would not materially 
affect the interpretation of the outcome data in relation to phe as analyses 
centred on the ANOVA interaction term. A difference in favour of Group Two 
might have emerged had concurrent phe been influencing test performance, 
but it is noteworthy that none of the between-group terms for the psychological 
measures was significant. 
It could be argued that the WISC, Rivermead and Rutter Scales represent 
psychometric instruments that are insufficiently sensitive to detect subtle phe-
related cognitive and behavioural changes. Waisbren et al. (1994) concluded 
that a small body of evidence exists pointing to executive cognitive functions 
possibly being specifically impaired in treated PKU. Executive functions 
include self-programming, foresight, sustained attention and set maintenance, 
and are associated with the prefrontal lobes. While the tests selected do not 
measure these skills directly, attentional and behavioural control are 
necessary substrates of all and, if adversely affected by phe, might have led 
to lowered performance scores. Similarly, impaired executive function such 
as attention deficit or hyperactivity might reasonably be expected to have 
been revealed in disordered behaviour, but this was not registered on the 
Problem Behaviour Checklist. In further support of the case for executive 
functions being uninfluenced by transient phe, Clarke et al. (1987) used an 
extensive neuropsychological battery consi~ting of several measures of 
executive function such as the Trail Making, Stroop and Verbal Fluency tests 
Chapter 7: Page 166 
and failed to find a relationship. The Rivermead was chosen for its ecological 
validity as it purports to measure everyday memory as opposed to laboratory 
performance. Its lack of sensitivity to elevated phe provides some confidence 
that recognition and recall skills required in daily living seem not to be 
impaired. 
Perhaps the most striking result was the inability of the children to identify from 
their subjective state what phe condition had been imposed. Likewise the 
parents' random guessing about the nature of the phe supplement from the 
children's general demeanour reinforces the view that elevated phe was not 
potentiating any discernable change. Some parents and children were 
adamant they knew the supplement administered but, as around half were 
wrong, their convictions did little to alter the picture of non-discrimination. 
The experimental, within-subject, crossover design adopted here is a 
powerful investigative methodology, yet no significant findings emerged. 
Absence of deleterious psychological effects from transitory 
hyperphenylalanaemia in classical PKU following 10 or more years of 
treatment adds some weight to the idea that the eNS may be sufficiently 
robust to withstand a relaxed or fully liberalized diet shortly after the first 
decade of life, though no firm statements can be made about age for 
cessation of treatment on the basis of a three-month monitoring period. A 
universally acceptable clinical policy on age for treatment discontinuation has 
not been formulated. Nonetheless, evidence is beginning to converge on 10 
to 12 years as an age level beyond which risks to IQ and psychosocial 
functioning from prolonged hyperphenylalanaemia appear to diminish 
dramatically (Azen et al., 1991; Beasley et al., 1994). A three-month 
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challenge to the eNS by high circulating phe levels may be too short given 
the insidious nature of neurological deterioration in PKU and that a lengthier 
period of exposure may be required to provoke measurable cognitive and 
behavioural change. However, support for this view was not forthcoming from 
a recent study of longer-term consequences of diet discontinuation (Griffiths 
et al., 1995). In this study, deleterious effects on mental and motor functioning 
of three or more years exposure to phe after treatment till age 10 were not 
clearly evidenced. 
Guttier & Lou (1986) characterized PKU in terms of level of CNS maturation, 
dichotomizing the condition into juvenile and adolescent forms. In the 
juvenile form, hyperphenylalanaemia almost invariably produces mental 
retardation. In the post-dietary adolescent form, hyperphenylalanaemia is 
hypothesized by these authors as producing subtle neuropsychological 
defects. The idea of a Idiet discontinuation syndrome' was not bome out by 
the findings of the present study. All the children experienced a state of 
sustained phenylalanine intoxication but did not show accompanying 
impairment of psychological functioning. The theory that phe disturbs 
myelination in the immature nervous system has already gained some 
empirical support (Bick et al., 1991; Cleary et al., 1994), but the notion that 
post-treatment hyperphenylalanaemia in adolescence produces sufficient 
disturbance either in myelin or neurotransmitter biosynthesis to generate 
cognitive and behavioural abnormalities (Lou et al., 1985) is more 
contentious. The negative findings of the present study are essentially in 
keeping with the arrested neuronal growth hypothesis of PKU (Bauman & 
Kemper, 1982), a corollary of which is that neurological structures that are 
permitted to reach maturity by the artificial creation of a low phe environment 
Chapter 7: Page 168 
are subsequently spared when that environment reverts to its natural high-
phe state. 
Conclusion 
The results did not suggest a dynamic relationship between level of 
circulating phenylalanine and psychological functioning in children with 
classical PKU over the age of 10 who were treated early and continuously. 
An absence of medium-term hyperphenylalaninaemic effects does not imply 
no adverse long-term consequences. However, well-controlled children who 
discontinue diet at age 10 and subsequently are exposed to high phe 
throughout adolescence or early adulthood do not appear to show significant 
deterioration in cognitive and motor ability (Schmidt et al., 1987; Griffiths et 
al., 1995). The question of whether subtle disturbance of executive function 
occurs in relation to phe level (Weglage et al., 1996b) remains open and 
needs further research before a definitive policy statement can be made about 
treatment discontinuation in PKU. 
Commentary 
In an early report, Smith et al. (1973) described a downward shift in the la 
distribution of 24 treated PKU patients, the mean for the group being 93 
instead of the expected population norm of 100. A later analysis of data from 
the UK PKU Register appeared to confirm the conclusion that, as a diagnostic 
cateory, treated PKU appears to be characterized by lower than expected la, 
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discrepancies below the norm of around seven points being found at ages 
four to 14 years in a cohort of 375 born between 1972 and 1978 (Smith et al., 
1990a). In the present study group, slippage of 10 was not found. The mean 
10 of 100.94 (SD 10.71) did not differ significantly from the population mean of 
100 (Z= +0.09, P= N.S.), suggesting that the experimental sample was drawn 
from a different population than those patients in the 1970s cohort. 
Consistently higher lifetime phe concentrations of between 100 and 200 
~molll in the UK Collaborative Study probably account for the 10 mismatch. 
Thus, while it may be true that 10 in a large random sample of PKU subjects 
falls short of normative expectations, a sample carefully selected for strict phe 
control in the early years of life can develop intellectually in a way that is 
indistinguishable from normal. 
Progressive reductions in the recommended upper phe-Ievel limit of the 
therapeutic range in early childhood have been made over the years to the 
point where the proposed German ceiling is now 240 ~mol/l for the birth to 10-
year period. While in reality few patients have been able to attain the 
previous goal of keeping levels below 360 J.Lmol/l (Weglage et al., 1993), it is 
nonetheless important for research samples to be selected for what is 
considered to be near-optimal control. If, by so doing, normal intellectual 
development can be demonstrated as the outcome, the rationale for strict 
recommendations is fortified and principles underlying patient management 
procedures thereby justified. 
In attempting to resolve the issue of whether deviant personality deviant or 
frank psychopathology might be accompaniments of treated PKU, there is 
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some convergence between the findings of the present study and those of 
Weglage et al. (1996a). Weglage and his colleagues in Munster investigated 
psychosocial adjustment in a group of treated children with classical PKU 
whose average age, IQ and treatment history were similar to ours. The mean 
age of the Munster children was 10.00 years and their mean IQ 96. Their 
mean age for starting diet was 17 days and mean annual phe levels rose in a 
linear fashion from around 240 JlmoVI in infancy to around 480 JlmoVI at age 
10. Weglage et al. tested this group on a self-report personality questionnaire 
(PFK 9-14) akin to the Children's Personality Questionnaire (Cattell, 1959), 
but found no significant abnormalities compared with population standards, 
nor a sex difference or a correlation between test scores and lifetime phe 
levels. The self-report approach differs from the parent rating scale we 
adopted. Nonetheless, neither method yielded data indicating that personal 
adjustment in well-controlled older children might be a function of previous 
phelevel. 
A matter of concern in the present study's findings, however, is the pattern of 
group x phase mean differences on the Problem Behaviour Checklist. 
Though failing to achieve statistical significance, the mean rating for both 
groups during the high phe phase was twice that of the rating during the low 
phe phase. The exact probability for the interaction f:.ratio of 3.49 (df1/14) is 
0.08 and suggestive of a non-significant trend. The small sample size would 
not warrant a more liberal alpha level. Nonetheless, the question arises as to 
whether a larger sample with similar results might have raised the power of 
the test to beyond the range of rejection. 
Little is known about factors determining adjustment outcome in treated PKU. 
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Weglage et al. (1996a) also reported personality data from on-diet adolescent 
samples and found a striking difference in both self-evaluations and parent 
ratings of psychosocial problems between the adolescents and the primary 
school children despite their treatment histories being comparable. By the 
age of 14, the patients were describing themselves as excessively retiring, 
diffident, introverted, inhibited, repressed, cautious and passive in relation to 
age norms; and parents were using terms like lover-protected' and Irestricted' 
to describe their upbringing. Weglage et al. concluded that these signs of 
maladjustment could most likely be attributed to a combination of negative 
attitudes towards the rigorous diet, with its potential for creating peer-group 
isolation, and the stress of puberty. The argument was not altogether 
compelling, however, as he and his coworkers also found that social and 
emotional problem scores correlated negatively and significantly with dietary 
control. It will take further research to parcel out dietary and attitudinal factors. 
There is a moral and clinical imperative to finding a solution as they each lead 
to diametrically opposed management policies. If poor dietary control in later 
childhood is the culprit, then prolongation of the strict diet would be required. 
However, if the early beneficial effects of diet later become iatrogenic, so long 
as intellect is not compromised, prolongation of diet into adolescence may be 
counter productive for personal stability and social adaptation. 
Apart from personality measures such as the above and occasional 
educational measures (Fishier et al., 1987; Weglage et al' l 1993), few if any 
studies have incorporated tests that have high ecological validity, the great 
majority relying on laboratory instruments. While it may emerge that a limit-
testing, laboratory approach such as choice reaction-time is necessary to 
detect phe effects in the mature organism (de Sonneville, 1991), how these 
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might translate into daily living and interaction with the routine world remains 
to be defined. Arguably, the Rivermead Test includes a number of tasks that 
mimic those of everyday life but, despite being performed by a eNS bathed in 
circulating phe exceeding of 1000 /lmol/l, these functions did not appear to 
suffer in consequence. 
In further support of the view that elevated phe levels are harmless in the short 
to medium term during the later stages of CNS maturation were the random 
subjective judgements of the patients and their parents about the condition 
imposed. As with the ecological validity approach, this is a new· if obvious· 
extension to previous experimental research in PKU and one whose results 
might cause clinicians and patients to pause over interpreting symptoms of 
malaise as phe-related phenomena. This brings PKU management and 
research into the domain of attribution theory (Jaspars et al., 1983). Given the 
present results, clinicians might be wise to be cautious about accepting older 
patients' constructions when they attribute problems of cognition or 
adjustment to high phe levels. In the current climate of alarm about loss of 
dietary control in adulthood (Sullivan, 1996; Koch, 1997), there is a risk of 
singling out phe as the causal factor without appyling Occam's razor and 
looking for Simpler explanations such as personal adequacy or changes in 
external circumstances. 
Experimental methodologies can only be short to medium term in their 
influence for ethical reasons. However, the oldest individuals amongst the 
post-screening, treated PKU population are now nearing the end of their third 
decade of life and opportunities will continue to grow for long-term follow-up 
of basic treatment questions. 
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In the meantime, knowledge about the optimal phe level for clinicians and 
parents to aim for during treatment remains limited and warrants continuing 
research. The Medical Research Council's Working Party on PKU (Medical 
Research Council, 1993a) recommended lowering the upper limit during the 
pre-school years from 600 JlmoVI to 360 Jlmol/l, but the empirical foundation 
for this change in policy was only weakly articulated in a companion paper 
(Medical Research Council, 1993b). The rationale for a reduction in early phe 
levels from the more relaxed figure of 600 JlmoV to the current 
recommendation of 360 JlmoVI was largely based on findings from 10 studies 
(Smith et al., 1990b). However, neuropsychological studies of children with 
varying degrees of dietary control have raised the particular question of 
whether phe levels during treatment previously considered harmless might 
adversely affect prefrontal executive function (Welsh et al., 1990). It is this 
issue that is addressed in the following two chapters. 
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Chapter 8 
ASSOCIATION BETWEEN PHENYLALANINE CONTROL DURING 
TREATMENT AND EXECUTIVE FUNCTION 
Background to study 
The first instance in the literature of the notion that treated PKU may be 
associated with a specific deficiency in cognitive functioning was a report by 
Anderson et al. (1969). After matching for age, sex and la, these authors 
found that 10 children with classical PKU achieved significantly worse results 
than controls on an adaptation of the Continuous Performance Test (Rosvold 
et al., 1956). The Continuous Performance Test is a vigilance measure that 
requires the subject to respond to designated target stimuli presented 
discretely and sequentially within a context of distractors. The orthodox 
version employs the letter X as the target signal, the letter A as a priming or 
alerting signal and other letters of the alphabet randomly interspersed as 
noise; thus, the subject's objective is to identify, usually by pressing a key, as 
many AX combinations in the stimulus series as possible and reject all others. 
Instead of letters, Anderson et al. used pictures and found that the PKU 
children's overall hit-to-miss ratio was poorElr than the comparison group's as 
was the slope of their performance decrement curve. They interpreted these 
results as evidence for impaired attention span in PKU but failed to explain 
the finding either on a priori grounds or by correlating task parameters with 
historical or concurrent phe levels in an endeavour to demonstrate a direct 
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biochemical effect. This omission is a serious one as their sample was 
heterogeneous for treatment factors: four subjects had come off diet between 
the ages of seven and twelve, one was treated very late and another never. 
These last two were, respectively, mildly and severely mentally handicapped. 
Despite this study's limitations in regard to the representativeness of its 
sample, it raised an important issue. Hitherto, it had been assumed that 
excess phe gave rise to global intellectual dysfunction, but Anderson et al. 
suggested that more subtle deficits might a!"ise in the treated condition. This 
concern was largely overlooked until the mid-eighties when several studies 
on the theme of specific cognitive impairment in treated PKU were published. 
Pennington et al. (1985) tested a group of six early-treated PKU children aged 
10 who had all terminated diet at six years of age and found they had 
particular problems with concept formation as measured by the Wisconsin 
Card Sorting Test, a difficulty often associated with damage to the frontal lobe 
of the brain (Duncan, 1986). The same year, Lou et al. (1985) described three 
adolescents whose simple reaction times ir:tcreased while indicators of 
serotonin and dopamine decreased following dietary cessation, suggesting a 
possible inverse relationship between phe on the one hand, and 
neurotransmission and information processing on the other. Guttier and Lou 
enlarged on this theory the next year, proposing that subtle 
neuropsychological deficits might accompany dietary cessation in late 
childhood and adolescence (Guttier & Lou, 1986). They reasoned that 
biosynthesis of dopamine, serotonin and norepinephrine would be adversely 
affected by hyperphenylalaninaemia in post-treatment PKU in a similar way to 
that found in the untreated disease and that functional disorders such as rapid 
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decision-making would accompany changes in neurotransmitter metabolism. 
A corollory of Guttier and Lou's (1986) theory is that neurotransmitter changes 
due to elevated phe concentrations and their attendant neuropsychological 
impairments are reversible by dietary regimen. Again using simple reaction 
time to gauge information-processing speed, Lou et al. (1987) investigated 
the influence of elevated phe levels by means of a repeated-measures 
design. They first measured reaction times in nine classical PKU patients 
aged 15 to 24 years while off diet then re-measured times after returning the 
group to diet. The mean score for the off-diet condition was 254 milliseconds 
and for the on-diet condition 245. From these results, the authors concluded 
that reducing post-treatment phe levels is psychologically beneficial and that 
high circulating phe in late adolescence and early adulthood 'impairs mental 
function' (sic). However, apart from being an over-generalization from a 
single, lOW-level index of cognition (i.e. reaction time) to intelligence overall, 
such a statement was not warranted by their data. Although no analysis was 
provided, raw scores were published and a correlated t-test by the author 
yielded a non-significant difference (t= 0.46, df9, P= n.s.). 
A common fault in PKU research where matched control-group designs are 
employed is a failure to test the matching variables for non-significance. Such 
a weakness undermines the conclusion of Brunner and Berry (1987) who, like 
Anderson et al. (1969), used the Continuous Performance Test to quantify 
sustained attention in a group of 22 well-treated PKU adolescents. These 
workers devised a computerised version of the AX test (see also Halperin et 
al., 1991) and gave it both to the patients and those of their siblings who were 
closest in chronological age. This procedure resulted in an age discrepancy 
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of three years between the groups, the mean age of the PKU group being 
16.4 years and that of the sibling controls 13.4 years. Brunner and Berry 
reported no significant difference in hit, miss or false alarm scores on the 
Continuous Performance Test and concluded that the study furnished no 
evidence for hyperdistractibility in treated PKU. However, they made no 
mention of the risk of a Type II error and the possibility that the increased age 
of the PKU subjects might have neutralised the influence of the phe factor on 
test outcome. A simple test (e.g. Wilcoxon) of the age discrepancy between 
the experimental and control group would have sufficed. Had a reliable 
difference been found, ANCOVA could have provided the necessary statistical 
control for the confounding factor. 
A study of the executive dysfunction theory by Welsh et al. (1990) illustrates 
the need for careful control of independent variables. She and her 
colleagues succeeded in matching a four-year-old, on-diet, PKU group with 
controls on age and WPPSI IQ but not on socio-economic status. When the 
groups were given tasks considered by the authors to be indices of executive 
ability and the results analyzed by ANCOVA with socio-economic status as 
the correlated variable, thumb-and-finger sequencing, semantic fluency and 
performance on the Tower of Hanoi task were significantly worse in the PKU 
children. Visual search and recognising familiar pictures were not. Therefore, 
when account was taken of possible confounding variables and the fact that 
the PKU children were tested while still on diet, some support for the 
executive dysfunction theory emerged. Further weight was given to the idea 
by the finding that a composite test score correlated negatively with mean 
lifetime phe level (r= -0.62, P< 0.05). 
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Welsh et al.'s study provided some of the best empirical evidence thus far that 
specific cognitive deficiencies might arise even in well-controlled PKU. The 
authors argued that the deficit was indicative of dysfunction in the frontal 
cortex of the brain, the tests which showed maximum disturbance being those 
most associated with motor sequencing, planning and set maintenance. They 
speculated that a biochemical deficiency centring on the fronto-cortical 
dopamine system underlay the cognitive impairment. This line of reasoning 
was theoretical and derived from the knowledge that, as the metabolic block 
in PKU occurs at that point in the pathway between phe and tyrosine, 
concentrations of metabolites beyond the block such as dopamine should be 
depleted. 
While Welsh et al.'s dopamine account was purely conceptual and a priori, 
physiological data were collected by Diamond et al. (1994) from a rat study 
which suggested a link, possibly mediated by neurochemical changes in 
frontal cortex, between hyperphenylalaninaemia and maze performance. 
Diamond et al. injected an experimental group of rat pups with phe to a level 
six times that of normal at four days post partum, maintaining this regime on a 
daily basis until sacrifice around 50 days. In addition to injecting phe, these 
workers administered the PAH inhibitor alpha-methylphenylalanine. 
Experimental animals were compared at intervals with placebo controls on 
immediate and delayed alternation behaviour in aT-maze. 
Diamond and her colleagues found only weak signs of impaired T-maze 
performance in infant pups, but stronger evidence for both immediate and 
delayed response inaccuracies in the juveniles, suggesting a cumulative phe 
effect over the developmental period. Biochemical analysis of brain 
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monoamine levels at biopsy yielded only one finding: a reduction of 
homovanillic acid in the experimental animals confined to the medial 
prefrontal cortex. Homovanillic acid is a metabolite of dopamine and thus a 
marker for activity in dopaminergic neurone systems. Norepinephrine 
(noradrenaline) showed no effect of hyperphenylalaninaemia. 
As a conclusion to this comparative study, Diamond et al. provided both a 
theoretical account of the possible neurochemical and neuropsychological 
effects of elevated phe levels on brain function and a waming about 
acceptable phe levels during dietary therapy in humans. She and her co-
authors suggested that excess phe has a. selective negative influence on 
prefrontal cortex and specifically disrupts the dopamine system. Tyrosine is 
the immediate precursor of dopamine. In their view, tyrosine depletion, which 
is a direct consequence of PAH deficiency, results in dopamine reduction 
which, in turn, has maximal adverse effects on the prefrontal cortex because 
this area of the brain is especially rich in dopaminergic neurons. The 
behavioural outcome of a shortage of dopamine is malfunction of executive 
processes such as self-programming, sequencing and impulse inhibition. 
Almost coincident with the rat study report, Diamond published the results of a 
parallel study into human PKU in which she claimed to have found evidence 
for previously accepted phe levels during treatment having a specific and 
malign influence on executive cognition (Diamond, 1994). Such a conclusion 
understandably generated consternation amongst clinicians managing the 
treatment of patients with PKU and the debate continues as to what phe levels 
might be considered safe at given ages throughout the developmental period. 
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In her single-authored studyPhenylalanine levels of 6-10 mg/d/ may not be 
as benign as once thought, Diamond (1994) made a case for reducing the 
upper limit of the therapeutic range. Until the early 1990s, and especially in 
the United States, 600 Jlmol/l had been the generally agreed safe ceiling for 
phe during infancy and the pre-school years of treatment. (To convert mg/dl 
into /lmol/l, multiply by 60.) Diamond's evidence was derived from scores on 
two tests: Piaget's Alnot 8 task and a simplified Stroop measure. 
The Alnot 8 task follows a delayed, two-choice, alternation paradigm in which 
subjects are required to uncover a hidden toy in one of two wells on two 
consecutive trials; upon success, the side of hiding is switched and 
performance quantified by error (i.e. perseveration) scores. This task is 
similar to the delayed response technique used to study frontal lobe 
functioning in monkeys (Diamond & Goldman-Rakic, 1986). It purports to 
reveal the ability to inhibit the stronger response tendency and to reflect 
maturation of behavioural control systems in the frontal cortex (Kelly et al., 
1996). Diamond modified the traditional Stroop test by replacing the colour-
word interference stimuli with pictures of the night sky, to which subjects had 
to respond with the word day, and with pictures of the sun, to which subjects 
had to respond with the word night. Thus, the stronger response had again to 
be suppressed. 
Compared with control subjects, treated PKU children aged between six 
months and seven years did poorly on the Alnot 8 and the Stroop-like tasks, 
but were not significantly different on six discriminatory tasks of spatial 
discrimination, recognition memory, visual comparison, delayed non-
matching to sample, global-local decision-making and line bisection. 
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Diamond interpreted these findings as indicative of dopamine-related, 
prefrontal impairment along with selective sparing of the temporo-parietal 
cortex, despite treatment parameters in her largely pre-school PKU sample 
conforming to phe levels recommended at the time. 
The impact this paper has made on thinking about phe control in early life is 
disproportionate to its substance. The acceptability of the conclusion is 
marred by the fact that no numerical data or statistical analyses were reported, 
nor IQ measures to allow the reader to determine whether the PKU and 
control groups were matched for general intelligence. Furthermore, Diamond 
did not provide a breakdown of test performance by age, saying only that 
three PKU subgroups were tested: infants, toddlers and pre- and early primary 
schoolers. The importance of this omission is that the report states that each 
subgroup was tested on a different number of measures at different intervals 
without making it clear whether the pattern of apparent impairment was 
consistent at each age level. Finally, no correlational data were presented to 
support the conclusion that the cognitive deficiencies were directly associated 
with elevated phe concentrations. 
In view of these methodological shortcomings, and the last-mentioned in 
particular, we embarked on a study of the executive dysfunction hypothesis in 
which neuropsychological test performance in a group of treated 10 to 13 
year-old children with PKU was correlated with annual phe concentrations 
across their lifetime and with concurrent levels. Our study strove to establish 
clearly the relationship between the independent variable, phe, and cognitive 
and personality outcome following an extensive treatment period. We 
selected experimental tests considered to be sensitive to impairment of the 
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prefrontal area of the brain and discriminative tests considered to be sensitive 
to posterior impairment in order to investigate the possible specificity of 
cognitive deficits. We also added a personality profile measure in an 
endeavour to extend knowledge about whether putative prefrontal cognitive 
impairment translates into personal and social maladjustment in treated PKU. 
Introduction 
A safe upper limit for circulating phenylalanine (phe) during dietary treatment 
of classical phenylketonuria (PKU) in early childhood has yet to be 
established (Lancet, 1991). During the seventies and eighties, 600 J.1mol/l 
was widely accepted in the USA and UK (Schuett & Brown, 1984; Smith et 
al., 1973). The recommended pre-school level has since been revised 
downward in the UK (Medical Research Council, 1993a) and Germany 
(Burgard, 1994) to 360 J.1mol/l. Findings from IQ (Beasley et al., 1994) and 
neuropsychological studies have provided indirect support for these changes 
(Waisbren et al., 1994). Pennington et al. (1985) and Welsh et al. (1990) 
claimed that executive skills - attention, planning, creativity and response 
inhibition - are especially vulnerable to elevated phe levels and Diamond 
(1994) specified that, in the early years of life, phe-Ievels in the range 360 to 
600 J.1mol/l may be especially harmful to the development of executive 
function. Her results suggested that infants and young children with phe 
levels in this range perform badly on executive tasks, but not on those of 
perception and memory. She proposed that executive functions are primarily 
mediated by the prefrontal cortex and that neurotransmission in this area of 
the brain is particularly susceptible to dopamine depletion (McDowell, 1996), 
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deficient dopamine being a consequence of the blockage in the metabolic 
pathway between phenylalanine and tyrosine. 
We investigated the executive dysfunction theory by means of a correlational 
study in which we tested a group of 10 to 13 year-old children with classical 
PKU on a battery of neuropsychological and personality measures. We 
selected children in whom individual dietary control in early life had varied 
around present UK recommendations, median annual levels for individuals in 
the first five years of life having ranged from 120 to 810 J.1moVI and in the next 
four years from 120 to 900 J.1moVI. At the time the study was conducted, levels 
ranged from 141 and 1053 J.1molll. According to the theory, we hypothesized 
an inverse relationship between phe and performance on executive tasks, but 
not on non-executive tasks. In addition, on the assumption that personality 
disorders such as inattention, poor self-regulation and impulsivity reflect 
prefrontal lobe dysfunction (Hinshaw, 1994), we hypothesized a direct 
relationship between phe and measures of these variables. 
Method 
Subjects 
The sample consisted of fifteen children (10 boys,S girls) from the West of 
Scotland PKU Register. All had peak blood phenylalanine levels in the post-
natal period above 1200 J.lm 0 III (mean 1805, SO 591). Each had been 
diagnosed and placed on a low phe diet during the first four weeks of life 
(mean 12.07 days, SD 5.01). They were continuously treated thereafter. 
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Blood phe was measured by high-pressure liquid chromatography using an 
amino acid analyser. The mean lifetime phe level for the group was 411 
~mol/I (SO 178): 355 ~mol/I (SO 144) for the first five year period and 480 
~mol/I (SO 193) for the second four year period. At the time of psychological 
testing, mean phe (concurrent level) was 547 ~mol/I (SO 270). The index of 
dietary control (IDC) adopted was the median value of each subject's annual 
phenylalanine readings (Rupp and Burgard, 1995). Figure 15 shows mean 
IDCs with standard deviations for ages 1 to 9. The mean age of the sample 
when tested was 12.13 years (SO 1.21) and the mean IQ was 105.47 (SO 
8.64). 
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Figure 15. Dietary control during first nine years of life (n=15). Annual Index 
of Dietary Control (IDC) means and standard deviations (see text for 
explanation of IOC derivation and analysis). 
Executive function tests 
Executive functions were assessed by four tests: Mazes, Stroop, Letter 
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Cancellation and Design Fluency. The Mazes subtest from the WISC-3UK 
(Wechsler, 1992) was chosen as a measure of planning, the Stroop of 
response inhibition, Letter Cancellation of sustained attention and Design 
Fluency of creativity (Beaumont, 1983). The Stroop test was the orthodox 
word-colour interference version, the number-correct score being recorded 
(Stroop, 1935). The Letter Cancellation Test was a visual search task for 21 
target letters irregularly located in an array of 1050 random distractor letters, a 
time limit of two minutes being set and hits per minute scored (Neisser, 1967). 
The Design Fluency test required construction of different designs from two 
curved and two straight pieces of plastic, the number of non-repeated designs 
created in three minutes being recorded (Griffiths, 1991). 
Non-executive function tests 
Non-executive functions were assessed by four tests, representing 
phonological, visual, tonal and verbal memory respectively: Digit Span from 
the WISC-3UK, Benton Visual Retention (Benton, 1974), Seashore Rhythm 
(Seashore et al., 1960) and Rey Verbal Learning (Rey, 1941). Memory tests 
were chosen as control measures because of their relative immunity from the 
effects of prefrontal lesions (Beaumont, 1983). Benton VRT Forms C and D, 
with 10 second presentation and immediate recall, were given and the 
number correct out of 20 recorded. Sections A, Band C of the Rhythm subtest 
of the Seashore Measures of Musical Talents were administered to give a 
total-correct score out of 30. The 12-word list from the Rey Verbal Learning 
Test was presented repeatedly five times and the total number recalled out of 
60 recorded. 
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Psychosocial functioning 
Maladjustment was measured by the child and adolescent forms of the 
Devereux Scales of Mental Disorders (Naglieri et al., 1994), these parent-
report questionnaires containing 110 items about overt behaviour rated on a 
5-point Likert scale. The six scales - Conduct, Attention, Anxiety, Depression, 
Autism and Acute Problems - are factor-based and norm-referenced. 
Devereux forms were completed by one of the children's parents on the day of 
testing and T-scores derived for the total scale and the six subscales. 
General procedure and design 
Subjects were tested individually and given standardised instructions. Pre-
training was given to ensure understanding of demand characteristics. Tests 
were presented with executive and non-executive measures alternating in the 
following sequence: Mazes, Digit Span, Letter Cancellation, Rey Verbal 
Learning, Design Fluency, Benton VRT , Stroop and Seashore Rhythm. The 
study conformed to a correlational design, though comparisons with non-PKU 
population norms were possible for Mazes, Digit Span and the Devereux 
Scales (Z-tests). 
Results 
One child obtained a maximum score on the Stroop test and two on the 
Benton, otherwise floor and ceiling effects were absent. 
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Phenylalanine control was determined by analysing annual IDC distributions 
over the first nine years of life, this being the period for which complete 
historical phe data were available for every subject (see Figure 15). One-way 
analysis of variance was highly significant (F=3.57, d.f. 8/126, P<0.001), 
indicating a gradual worsening of dietary control. In the first five-year period, 
one child's IDCs in Years 3 and 4 were 810 and 720 Ilmolll respectively, the 
others' staying between 120 to 600 Ilmolli. Between Years 6 and 9, about 
three-quarters maintained IDC levels below 600 Ilmol/l, but some among the 
remainder occasionally reached 900 Ilmoi/i. 
To provide a historical measure of dietary control, annual cumulative IDes for 
the first nine years of life were calculated for each child. These data and 
concurrent levels were correlated with each of the psychological variables. 
Scaled scores were used for the WISC Mazes and Digit Span tests, T-scores 
for the Devereux Scales and raw scores for the rest. High scores on the 
cognitive tasks represented good performance, high scores on the personality 
measures maladjustment. The age range of the sample was 3.58 years. Test 
performance was not positively correlated with age except on Design Fluency 
(/!:::0.57, d.f. 13, P<0.05, Spearman, one-tailed). Partial correlations with age 
as the controlled variable were therefore performed on data from this test 
(Daniel, 1990). 
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Year of life and concurrent pbe leyels 
2 3 4 5 6 7 8 9 Cone 
I~sts 
WISC Mazes (E) 0.05 0.17 0.11 0.04 0.10 -0.03 -0.06 -0. 12 -0.11 -0.29 
Stroop (E) -0.30 0.03 0.08 0.21 0.13 -0.03 ·0.01 -0.03 -0.01 -0.11 
Letter Cancellation (E) 0.02 0.11 0.20 0.21 0.15 0.22 0.05 0.12 0.10 -0.06 
DeSign Fluency (E. P) -0.24 -0.31 -0.40 -0.42 -0.42 -0.39 -0.39 -0.46- -0.45- -0.19 
WISC Digits (NE) 0.14 -0.21 -0.26 -0.28 -0.38 -0.41 -0.35 ·0.38 -0.31 -0.03 
Benton VRT (NE) -0.35 -0.21 -0.11 0.12 0.23 0.24 0.21 0.22 0.23 -0. 13 
Seashore (NE) 0.13 0.16 0.21 0.23 0.11 -0.02 0.01 -0.04 ·0.05 -0. 18 
Rey Verbal Leaming (NE) -0.10 -0.15 -0.31 -0.33 -0.25 -0.20 -0.23 -0.27 -0.05 -0. 18 
Devereux Total 0.14 0.13 0.30 0.35 0.35 0.31 0.26 0.29 0.28 0.01 
Conduct 0.12 0.22 0.43 0.42 0.40 0.32 0.24 0.28 0.30 0.09 
Attention 0.19 0.16 0.37 0.48- 0.49- 0.49- 0.46- 0.49" 0.48- 0.13 
Anxiety 0.28 0.18 0.09 -0.04 -0.09 -0.11 ·0.13 -0. 11 -0. 14 -0.12 
Depression 0.13 0.15 0.39 0.45 0.38 0.31 0.22 0.25 0.25 -0.03 
Autism -0.08 -0.19 -0.17 -0.11 ·0.06 ·0.07 ·0.09 ·0.05 -0.04 -0.14 
Acute Problems ·0.00 0.04 -0.04 ·0.01 0.14 0.17 0.21 0.22 0.21 0.02 
,.. P<0.05, one-tailed 
Table 16. Correlations and partial (P) correlations between annual and 
concurrent phenylalanine levels, and cognitive and personality variables. (E) 
denotes executive task, (NE) non-executive task. df13 throughout. 
Table 16 shows correlations and partial correlations between annual 
cumulative IDCs for Years 1 to 9 and concurrent phe level, and the cognitive 
and personality measures. Pearson tests were used for normalised scores, 
Spearman tests for raw scores. Coefficients were non-significant except for 
positive correlations between Year 4 to Year 9 phe levels and Devereux 
Attention (P<O.05), and negative correlations betwen Year 8 and Year 9 phe 
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levels and Design Fluency (P<O.05). Subsidiary analyses revealed non-
significant correlations between mean lifetime phe (Years 1 to 9), mean pre-
school phe (Years 1 to 5), mean school-age phe (Years 6 to 9) and all the 
psychological measures except for Devereux Attention which correlated 
significantly with mean lifetime phe (r=0.48, df 13, P<0.05) and mean pre-
school phe (r=0.49, df 13, P<0.05). 
The positive correlations for Devereux Attention were in the theoretically 
predicted direction. However, regression analyses of Attention and IDes for 
Years 4 to 9 isolated one subject whose score was an outlier and whose 
dietary control worsened between three and four years of age when her 
parents divorced. When this child was removed from a secondary analysis, 
coefficients between Attention and phe for Years 4 to 9, lifetime and pre-
school phe were non-significant. Thus, the apparent association may have 
been due to a third factor, marital disharmony, affecting both phe-Ievel and 
adjustment in a single subject whose data biased the group result. The 
negative correlations for Design Fluency were also as predicted but, in a 
matrix of 150 statistics (Table 16), two significant coefficients are well within 
chance expectations. 
Mean Mazes and Digit Span scaled scores were 9.13 and 9.80 respectively. 
This difference was non-significant and neither test was significantly 
discrepant from the population norm of 10. 
Phe-related differences between executive and control tests provide a critical 
test of the executive dysfunction hypothesis. However, Pearson coefficients 
for Digits-Mazes difference scores and historical phe levels were unifonnly 
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non-significant, as was the coefficient for concurrent phe level. 
The mean overall T-score (population mean 50, SD 10) for the Devereux 
Scales was 48.47 (SD 7.64). Mean T-scores with standard deviations in 
brackets for the subscales were: Conduct 49.60 (6.96), Attention 51.00 
(10.08), Anxiety 46.60 (6.33), Depression 50.73 (14.25), Autism 48.80 (8.26) 
and Acute Problems 46.93 (3.65). Z-test comparisons with population norms 
revealed none as significantly different. 
Discussion 
When chance and confounding factors were taken into consideration, results 
from correlational analyses and normative comparisons failed to provide 
support for the executive dysfunction hypothesis. Median annual phe levels 
in the first five years of life between 120 to 810 IlmoVI, in the next four years 
between 120 and 900 IlmoVI and concurrent with psychological testing 
between 141 and 1053 J.1mol/l were not clearly associated with later executive 
impairment or behavioural maladjustment. 
The Design Fluency test entails the production of novel spatial pattems and 
may be a task that is especially sensitive to prefrontal cortical impairment 
(Jones-Gotman & Milner, 1977). Success depends on intact executive 
functions such as set maintenance, ideational creativity and inhibition of 
previous responses. Despite this apparent construct validity, Design Fluency 
performance was not associated with concurrent phe level. The two 
significant correlations between Design Fluency and historical phe levels are 
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consistent with possible phe-related non-verbal fluency effects reported by 
Mazzocco et al. (1994) and Griffiths et al. (1995), however these isolated 
findings may be random. At P<0.05, in a matrix of 150, eight significant 
coefficients would be expected by chance. Including the Design Fluency 
correlations, this was exactly the number found (see Table 16). 
Sma" sample size and the absence of a control group were methodological 
weaknesses of the study, though these were partly offset by within-subject and 
population comparisons, none of which indicated either a general or specific 
neuropsychological or personality disorder. The lack of a positive association 
between norm-referenced Digits-Mazes difference scores and concurrent phe 
was particularly counter-theoretical because Diamond's (1994) 
neurotransmitter model explicitly predicts executive dysfunction as a 
consequence of elevated phe level, the underlying mechanism proposed 
being the reduction of prefrontal dopamine by phe. 
Arguably, conduct disorder and personal disorganization are manifestations 
of executive dysfunction in the personality domain. Neither Conduct, Acute 
Problems nor any of the other Devereux subscale scores differed significantly 
from population norms. These findings, which imply that the sample was not 
maladjusted, contrast with those of Smith et al. (1988) who reported elevated 
anxiety and hyperactivity in eight-year-old PKU children. However, in their 
group, abnormal behaviour was predominantly associated with low IQ and 
pre-school phe levels above 600 J,1mol/l. The absence of evidence for deviant 
personality development in the present study concurs with the findings of 
Weglage et al. (1994). 
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The neuropsychological test results are also consistent with those of 
Stemerdink et al. (1994) who found neither executive function nor memory 
deficits in a Dutch classical PKU sample with a comparable mean lifetime 
phenylalanine level of 381 Jlmoi/i. The present results differ from those of a 
recent German study by Weglage et al., (1996) who reported a negative 
correlation between concurrent, but not lifetime, phe and Stroop performance. 
Though the German sample's yearly IDes were only slightly higher (476 
Jlmol/l on average), as was its mean concurrent level (583 Jlmol/l), the lack of 
agreement may be accounted for by a considerably greater phe range and 
higher upper limit (85 to 1709 Jlmol/l). These authors also chose digit span as 
a control (non-executive) measure and, like the present study, found it to be 
neither developmentally abnormal, nor affected by lifetime or concurrent phe 
levels. 
The present study does not disprove the executive dysfunction theory, but 
casts doubt on whether subtle impairment of mental ability or personality 
arises when average phe levels in the pre-school period are kept between 
200 and 400 Jlmoi/i. Mean pre-school IDCs for the children in the present 
sample were close to 360 JlmoVI the lower limit of the range considered 
unsafe by Diamond (1994) and the figure currently recommended in the UK 
as the upper limit for phe control in the birth to five period (Medical Research 
Council, 1993a). De Sonneville et al. (1990) found that patients with historical 
phenylalanine levels below 570 Jlmol/l performed normally on a task involving 
sustained attention and response-inhibition, whereas those with levels above 
did not. This finding and those of the present study add weight to the view that 
when phe levels in early life are kept well below 600 Jlmol/l, widespread 
deleterious effects on later cognitive functioning and adjustment do not occur. 
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Many studies of executive disorders in treated PKU are based on patients 
who discontinued treatment early or whose dietary control was exceptionally 
poor or unreported. In raising the issue, Pennington et al. (1985) found 
executive skill deficits at age 10 in a small sample of six patients. Though 
treated early, this group had discontinued treatment at six years of age. 
Nowadays, dietary restriction until 10 is considered desirable (Griffiths et al., 
1995) or even for life (Beasley et al., 1994). Welsh et al. (1990) reported an 
inverse relationship between phenylalanine and executive tasks in a group of 
11 four-year-olds, but even by this age some patients were returning 
phenylalanine levels in excess of 600 J,lmolll and one was recorded at 1074 
J,lmolll. Mazzocco et al. (1994) found no reliable evidence for deficient 
executive functioning in early-treated, school-aged PKU children but failed to 
document historical and concurrent phe levels, making it impossible to 
translate this finding into recommendations for phe control during treatment. 
In settling the executive dysfunction issue, it is essential that studies clearly 
document treatment parameters, such as age of treatment onset and 
cessation, and quantify phe levels, rather than use categorical descriptions, 
and that further research is undertaken into the neuropsychological effects of 
phe levels above and below the 360 J,lmol/l limit currently recommended in 
the UK for the pre-school period. 
Commentary 
In the entire corpus of research on treated PKU, there is no evidence for a 
threshold effect of phe control on intellectual functioning (Beasley et al., 
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1994). That is to say, there does not appear to be a clear value for the 
concentration of phe in blood below which CNS damage does not occur and 
above which it does. This implies that research studies into how phe control 
influences behaviour should adopt correlational (or pseudo-correlational 
designs such as ANOVA) wherever possible. This was the rationale for the 
correlational approach adopted in the present study. Diamond (1994) 
eschewed the correlational method in favour of a control group method in her 
study. However, lifetime phe data for her subjects, either for the group as a 
whole or for each subgroup, should have been presented and related to test 
outcomes. By so doing, the influence of historical and task-concurrent phe on 
executive function could have been determined in the fashion achieved by the 
present study. 
Because of the apparent lack of a threshold effect, any figure that is 
recommended as a target for phe control at a given age will only be a 
guideline. What is well-recognized is the dynamic relationship between age 
and blood phe concentrations. For a given level of circulating phe, 
neurological damage will be greater the younger the child, the age factor 
being especially potent in infancy (Berman et al., 1968). Age is presumed to 
reflect maturity of the eNS, and myelination in particular, so even moderately 
elevated phe levels will create more disruption to neuronal growth in the early 
weeks or months than the same levels in later childhood (Hommes, 1991). A 
possible reason for the disagreement between the findings of the present 
study and those of Diamond (1994) might lie in the poorer degree of control of 
her infant subjects or her group as whole in their early years compared with 
ours. She has acknowledged this possiblity (Diamond, 1995) but, in the 
absence of published phe-control data in her study, the comparability of the 
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two sets of findings is compromised. 
The phe control of the Glasgow patients in infancy and during the pre-school 
period was probably very close to a realistic optimum, though above current 
guidelines for the upper limit of the therapeutic range as currently laid down in 
the UK and Germany of 360 JlmoV for the pre-school years. Weglage et al. 
{1993} have already hinted that the recommended targets may be idealistic, 
reporting that most patients cannot adhere to the German Paediatric Society's 
guideline of maintaining phe levels below 360 Jlmol/l until age 10. 
The degree of phe control achieved by Weglage et al.'s (1993) sample 
compared with the subjects in the present study was slightly worse. The table 
below shows mean indices of dietary control (median phe level per annum) 
for the Glasgow sample compared with the German sample at years 1, 5 and 
10. The discrepancy in the figures provides some justification for the 
supposition that the Glasgow subjects were reaspnably representative of the 
wider population of striclty treated PKU children. Individual patients who 
consistently achieve blood phe levels below 360 JlmoVI in the early years of 
life are rare. The sample in the present study only averaged levels around 
this figure. However, this pattern may be typical and closer to realistic levels 
of good dietary control than the target figures currently promulgated. 
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Scotland (Glasgow, n = 15) 
Germany (Munster, n = 34) 
1 
348 
436 
Year of life 
5 
444 
461 
10 
470 
648 
Table 17. Mean Index of Dietary Control, Glasgow versus Munster patients. 
The mean IQ in Weglage et al.'s sample was 93.6 while that of the present 
sample was 105.47. Thus, the German PKU group was below the population 
norm for IQ while the Scottish group was above. The difference in favour of 
the Glasgow group may be attributable to the overall better dietary control of 
the Scottish children. Given that the Scottish children had las that were at 
least normal (and, if anything, slightly above) and that no convincing evidence 
was found either for specific executive deficits or a relationship between 
cognition generally and historical or concurrent phe, then these findings 
suggest that a satisfactory degree of dietary control was achieved by the 
Glasgow patients throughout the treatment age range. 
It is a robust finding that, despite pressure from clinicians to the contrary, phe 
levels in treated PKU rise throughout childhood. Nonetheless, as the risk of 
CNS damage probably diminishes with age, this inexorable trend may be of 
little consequence in later childhood. The results of the present study might 
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be indicating that, so long as low phe levels in early life are maintained, a 
satisfactory intellectual outcome later on can be obtained. It is highly 
noteworthy that the average phe level for the group in the present study 
dipped to about 250 J,lmolll in the second year of life (see Figure 15). This 
may be an important characteristic of the sample that should not be 
overlooked. It is tempting to speculate that long-term intellectual benefit may 
be maximized if phe levels in infancy are kept even further below the 360 
J,lmolll mark presently recommended. The Medical Research Council's 
Working Party on Phenylketonuria (Medical Research Council, 1993a) 
advised that this target should be aimed at for the pre-school years but there 
may be a case for setting a lower target for infancy (i.e. years 1 to 2). 
In attempting to establish numerical upper limits for the therapeutic range that 
will yield an acceptable intellectual outcome, it is salutory to recognize that 
even a figure as low as 360 J,lmolll still represents a level of phe circulating in 
the blood that is six times the norm for the healthy population (Hsia, 1967) and 
that there is a strong correlation (r= 0.91, P < 0.01) between blood and brain 
phe (Pietz et al., 1995). Thus, a potent case exists for reducing phe in infancy 
on theoretical grounds, because this is the developmental period when the 
CNS is most vulnerable; and also on practical grounds, because this is when 
diet can be influenced and manipulated most readily by caretakers. It is 
interesting that in Germany at the present moment there is a proposal to 
reduce the recommendation for the first 10 years of life to phe-target levels of 
between 40 and 240 J,lmolll (Burgard, personal communication), though these 
figures have not yet been formally adopted as national treatment policy. 
A criticism of the present study is that no control group was built into the 
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design. This omission was partly redressed by the use of norm-referenced 
tests, i.e. WISC Digits and Mazes, and the Devereux Scales. However, the 
, addition of a control group matched for age, sex and general ability would 
have aided interpretation of the findings and would have provided an extra 
safeguard against making a Type" error. A further criticism is that a measure 
of decision-making involving sustained attention was not included. In their 
review of the neuropsychological literature in relation to treated PKU, 
Waisbren et al. (1994) concluded that the kinds of tasks emerging in recent 
research that seem most sensitive to hyperphenylalaninaemia are those 
executive functions based on speed of information processing, such as choice 
reaction time. 
With these considerations in mind, my colleagues and I constructed a control-
group study to explore the frontal executive hypothesis further by means of a 
speeded vigilance task which was a modification of the Continuous 
Performance Test first described by Rosvold et al. (1956) and discussed at the 
start of this chapter. 
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Chapter 9 
EXECUTIVE FUNCTION MEASURED BY VARIANTS OF THE 
CONTINUOUS PERFORMANCE TEST 
Background to study 
When designing this study, we decided to employ the orthodox AX version of 
the continuous performance test (CPT) as described in Chapter Eight 
because of the poorer than normal response decrement curve found in PKU 
by Anderson et al. (1969). However, as two subsequent investigations 
(Realmuto et al., 1986; Brunner & Berry, 1987) based on the original format 
yielded equivocal data, we incorporated a variant of the CPT which increased 
attentional demands in an endeavour to increase the sensitivity of the 
instrument. 
Realmuto et al. (1986) compared two off-diet adolescent groups on a 
computer-mediated version of the standard CPT (Klee & Garfinkel, 1983), one 
of which was given a phe-Ioaded supplement and the other a placebo. The 
phe-Ioaded group's average concentrations increased to above 2100 J.lmol/l 
five hours after dosage while the placebo group's remained steady at around 
1200 J.lmolll. Despite the temporary elevation in circulating phe, the 
experimental group showed no reliable change in either hits, errors of 
omission (misses) or commission (false alarms) on the CPT. Nonetheless, 
reaction times increased by 200 msec in the phe-Ioaded group and statistical 
analysis showed a trend towards some loss of information processing speed. 
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In a CPT study a year later, a similar, though at P = 0.14, very weak trend was 
found by Brunner and Berry (1987) on the miss-rate variable of an AX-type 
computerized task. In their study, off-diet, and therefore 
hyperphenylalaninaemic, adolescent PKUs made twice as many such errors 
as sibling controls. 
The tenuous link between phe concentrations and performance on the CPT 
suggested by these studies begged the question whether a true vigilance 
deficiency exists but was not being revealed by the CPT because of 
insufficient sensitivity in the instrument. Thus, the standard AX paradigm 
chosen by Realmuto et al. and Brunner'and Berry may have been too dull a 
tool for detecting inattention, especially in older PKU patients, and hence led 
these authors to make a Type II interpretive error. 
Pursuing this line of reasoning, in the study reported below we took the 
computerized CPT as our measure of executive functioning but, in addition to 
the conventional AX version, increased task difficulty by the simple expedient 
of inserting a distractor stimulus (random letter) between the warning signal 
(letter A) and the target (letter X). This manipulation imposes additional 
demands on executive functions as the subject not only has to maintain a 
more complex mental set during execution of the task, but has a higher risk of 
failing to inhibit erroneous responses. In other words, in the A?X version an 
impulsive response to the next stimulus aftn: the prime would always be 
scored as an error, whereas in the orthodox AX version there is a chance of 
the immediately succeeding stimulus being a target and therefore an 
impulsive response being registered as a hit rather than an error. 
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We designated the standard AX version of the CPT the one-back test to 
denote the serial position of the prime in relation to the target and the new 
A?X version, with its heavier attentional and memory demands, the two-back 
test. 
To this author's knowledge, the two-back paradigm has not been used as a 
neuropsychological methodology in PKU research, nor was it mentioned by 
Corkum and Siegel (1993) in their review of task variables in thirteen CPT 
studies of various issues and populations. 
The lack of a control group in the study reported in Chapter Eight and the lack 
of a correlational analysis in Diamond's (1994) seminal study are 
methodological deficiencies. These were remedied in the design of the study 
that forms the core of this chapter by testing healthy, matched controls in order 
to illuminate the effect of diagnostic category on one-back and two-back CPT 
performance. Also, within the PKU group, dietary control factors were 
quantified and related to outcome on the CPT in an endeavour to clarify 
whether the therapeutic range currently recommended in the United Kingdom 
(Medical Research Council, 1993b) confers protection against executive 
disorder. 
Introduction 
Uncertainty prevails about whether subtle cognitive deficits are associated 
with treated phenylketonuria (PKU, McKusick 26160) in childhood. While it is 
universally accepted that loss of 10 can be minimized by implementation of 
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dietary prophylaxis as early as possible in the neonatal period (Barclay & 
Walton, 1988; Legido et al., 1993), questions remain about the optimal age for 
cessation of the low phenylalanine diet and the maximum level of circulating 
phenylalanine (phe) allowable at different ages during treatment (Smith et al., 
1990; Editorial, 1991; Medical Research Council. 1993a). Following the 
introduction of mass newborn screening for PKU in the late sixties (Guthrie. 
1996). an upper limit for the therapeutic range of 600 Jlmolll was widely 
accepted. especially in the United States (Williamson et al .• 1981). However. 
this figure has been challenged by Diamond (1994) who concluded that it is 
too high to prevent disorders of executive function in infants. toddlers and 
young children and that such groups are especially vulnerable because 
executive impairments may not be detectable by traditional intelligence tests. 
Executive functions are higher. goal-directed mental activities that are 
organizational and supervisory in nature and heavily dependent on good 
attentional control. They entail planning, selecting or maintaining complex 
behavioural routines, often in novel contexts (Kelly et al .• 1996). Pennington 
and Ozonoff (1996) argued that executive functions in children are mediated 
by the prefrontal cortex of the brain as they are in adults and hypothesized 
that. where frank neurological damage is absent. deficits in executive 
functions may reflect dopamine depletion in this area. Welsh (1996) 
proposed that executive functions may be specifically at risk of impairment in 
treated PKU. The theoretical rationale she put forward for this view was that 
reduced tyrosine availability resulting from hepatic phenylalanine hydroxylase 
deficiency adversely affects dopaminergic neurotransmitter systems and. as 
the prefrontal dopamine system is especially sensitive to decreased tyrosine, 
executive dysfunctions would result. Accordingly. she argued, impairment of 
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executive functions represents a cognitive marker for tyrosine imbalance and 
would be seen in neuropsychological tasks involving planning, response 
inhibition and flexibility of thought and action. She drew upon empirical 
evidence from Davis et al. (1986), Pennington et al. (1985) and Welsh et al. 
(1990) to support the idea that executive functions may be impaired at least in 
young (i.e. preschool) children with treated PKU. 
We tested the executive dysfunction hypothesis by means of a control-group 
study of primary school-age children with classical PKU who were treated 
early and whose mean phe concentrations for the preschool years remained 
close to 300 flmoi/l. Our aims were threefold: a) to establish whether 
executive skill was specifically deficient in this group compared with healthy 
children, b) to determine whether preschool or lifetime phe predicted later 
executive capability, and c) to investigate the relationship between task-
concurrent phe and executive function. We chose the Continuous 
Performance Test (CPT) as the dependent experimental measure as it fulfils 
the criteria of a typical executive function task in having the intrinsic demand 
characteristics of sustained attention, set maintenance, decision-making and 
inhibition of competing but erroneous responses (Corkum & Siegel, 1993; 
Benton, 1994). 
The prototype version of the Continuous Performance Test (Rosvold et al., 
1956) is a vigilance task that requires the subject to respond rapidly to the 
target letter X when immediately preceded by the priming letter A. 
Conventionally, the AX letter-combination is randomly located in a series of 
distractor letters. We designated this the one-back version to denote the 
position of the priming stimulus in relation to the target. In order to increase 
Chapter 9: Page 204 
the attentional demands of the task, we also employed a two-back version in 
which a distractor letter was interpolated between the priming and target 
stimuli. Clearly, n-back variations of this task are possible but, given that 
some of the children were only five years of age, we limited the priming letter 
to two serial positions back from the target to avoid possible floor effects. 
Method 
Subjects 
Eleven children (six boys and five girls) with Type 1 or 'classical' PKU (Guttier, 
1980) made up the experimental sample. They were identified from the West 
of Scotland PKU Register as having had pretreatment phe levels in excess of 
1200Jlmolll and as having been treated early (median day of life = 13, range 
1 to 47) and continuously until the time of the study. None of the PKU children 
was mentally handicapped (mean IQ = 108.71, SO 12.30). Individual PKU 
subjects were paired with healthy controls, seven boys and four girls, from the 
normal primary school population on chrono!ogical age and receptive 
vocabulary, the latter being considered a non-executive ability that correlates 
highly with globallQ (Sattler, 1974). The median age of the PKU group was 
8.83 years (range 5.11 to 11.92) and that for the control group also 8.83 
(range 6.17 to 12.75). The age distributions did not differ significantly at the 
0.05 alpha level (W = 29, N = 10, P = n.s., Wilcoxon). Receptive vocabulary 
was measured by the British Picture Vocabulary Test (Dunn et al., 1982), the 
standard score mean for the PKU group being 104.64 (SO 14.62) and that for 
the controls 101.45 (SO 15.40). This difference was not statistically significant 
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(t = 1.47, df 10, P = n.s., correlated). Postcode-derived deprivation categories 
were used as an index of social class (Carstairs & Morris, 1992). The modal 
,value on a 1 to 7 scale for the PKU group was 4 and that for the controls 3, 1 
meaning least deprived. The groups were thus matched on size, 
chronological age and receptive vocabulary, and very closely matched on sex 
and social class. Pairing on age and vocabulary was achieved at the 
expense of an equal sex ratio, but gender has not been consistently 
demonstrated as a factor underlying intellectual outcome in treated PKU (Koff 
et al., 1979). 
Measurement of phenylalanine 
Historical and task-concurrent plasma phenylalanine concentrations were 
measured by high pressure liquid chromatography. For individual PKU 
children, the annual median value was taken as the index of dietary control 
(Rupp & Burgard, 1995). Figure 16 shows mean indices with standard 
deviations for the first five years of life for the group as a whole. The mean 
preschool (birth to age five) phe-Ievel for the group was 342 Jlmolll (SO 126), 
the mean lifetime level 341 Jlmolll (SO 125) and the mean task-concurrent 
level 388 Jlmol/l (SO 127). 
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Figure 16. Historical phe-Ievel profile for PKU sample. Mean phe 
concentrations for first five years of life. Error bars are standard deviations. 
Executive function task 
A modification of the AX format of the CPT was adopted as a measure of 
executive function (Rosvold et al., 1956). Ail Acorn Archimedes 310 personal 
computer was programmed in BASIC to deliver the stimuli which were upper-
case letters of the alphabet, 7 mm high, placed centrally in a square frame 
with 38 mm sides. The frame was permanently displayed in the centre of the 
monitor screen throughout the test. Subjects sat at a distance of 
approximately 50 cm from the screen. The onset-offset duration for all stimuli 
was 500 msec and the interstimulus interval 1000 msec. 
In the one-back version of the task, there were 560 stimuli. A target was 
defined as the letter X immediately preceded by the priming letter A. There 
were 80 targets in total, the subject being required to make a keyboard 
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response as quickly as possible to the presentation of an X contingent upon 
an A. The entire stimulus sequence was subdivided into four blocks of 140. 
Randomly spaced within each block, there were 20 targets (AX combinations), 
10 false primes (A not followed by X) and 10 false targets (X not preceded by 
A), the intervening stimuli being random letters of the alphabet. A hit was 
defined as a response to an AX pair made during the immediately succeeding 
inter-stimulus interval and false alarms as responses to single A and X stimuli 
made during the same interval. Reaction time for hits was measured in 
centiseconds from the onset of the X stimulus in an AX pair to the depression 
of the space bar on the computer keyboard. 
The parameters of the two-back task were identical to the one-back except 
that a distractor letter was interposed between the A and the X, the target 
combination becoming A?X instead of AX. Thus, the priming letter was two-
back in the sequence from the target letter. Each task took 14 minutes from 
beginning to end. Losier et al. (1996), in a review of 26 studies employing the 
CPT with children, found the following modal values and ranges (in brackets): 
stimulus duration 200 msec (50-800), inter-stimulus interval 1500 msec (800-
4000), time on task 12 minutes (9-27) and number of trials 350 (300-600). 
Thus, the settings chosen in the present study were within conventional limits 
and generally close to the mode. The number of trials (i.e. stimulus 
presentations) was the one parameter deliberately set at an above average 
level. The rationale for this decision was to raise the attentional demands of 
both versions of the task and, by compounding the extra difficulty of the two-
back task with already protracted attentional maintenance, thoroughly test for 
weaknesses in vigilance performance. The program automatically recorded 
on-task performance and reported hit and false alarm totals and mean 
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reaction times for the one-back and two-back tests separately as we" as a 
block-bY-block breakdown. 
Non-executive function task 
Forward recall of digits was selected as a non-executive, discriminative task 
on theoretical and empirical grounds. Immediate repetition of digit strings is a 
function strongly associated with posterior rather than prefrontal cortex 
mediation (Walsh, 1978) and short-term memory deficits for phonological 
information are not characteristic of treated PKU (Waisbren et al., 1994). The 
test comprised two- to nine-long strings of the digits 1 to 9 ordered randomly. 
There were five trials at each level, each containing a different digit 
combination, making 40 in total. Individual digits were presented at a rate of 
one per second by means of an audio tape-recorder. An untimed oral 
response was required from subjects. A simple binary scoring scheme for 
success and failure was imposed. The discontinuation criterion was three or 
more failures within a five-trial level. The score recorded for each subject was 
the total number of trials correct out of 40. 
Design and procedure 
The study conformed to a matched groups design. The test order for 
individual subjects was standardized, the one-back CPT being given first 
followed by the British Picture Vocabulary Scales, the two-back CPT and lastly 
recall of digits. Data were collected from subjects during a single session 
which had rest breaks between but not within test items. As many pretest 
practice trials were given for both versions of the CPT as were necessary to 
Chapter 9: Page 209 
convey the task requirements to individual subjects. 
Approval for the study was obtained from the Glasgow Royal Hospital for Sick 
Children's Ethics Committee and permission granted by the local education 
authority to test the control children. Informed consent from the children and 
their carers was obtained by means of an explanatory letter. 
Results 
The dependent variables for the one-back and two-back CPT were hit rate, 
number of false alarms and mean reaction time. Though the CPT program 
registered reaction times in centiseconds, these are reported below in 
milliseconds for ease of comprehension. Results for each version were 
analyzed by two-way ANOVA (Minitab) for group and time effects. 
One-back continuous performance test 
The overall mean hit rate out of 80 for the one-back CPT was 72.18 (SO 7.17) 
for the PKU group and 69.70 (SO 10.5) for the controls. The group effect was 
non-significant {F = 0.41, df 1120, P = n.s.} as were the time-on-task (F = 0.65, 
df 3/20, P = n.s.) and interaction effects (F = 1.47, df 3/20, P = n.s.). At 8.36 
{SO 7.24}, the overall mean false alarm frequency for the PKU children was 
less than that of the controls at 15.80 {SO 19.50}, but the group difference was 
not statistically significant (F = 1.42, df 1120, P = n.s.) and neither was the time 
factor {F = 0.13, df 3/20, P = n.s.}, nor the interaction term (F = 0.55, df 3/20, P 
= n.s.). The overall mean reaction time in milliseconds for the PKU group was 
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499 (SO 81) and that for the control group 462 (SO 92). Again the group 
effect was non-significant (F = 1.00, df 1120, P = n.s.) and no significant effects 
were found for time (F = 0.20, df 3/20, P = n.s.) or the interaction (F = 0.29, df 
3/20, P = n.s.). 
Two-back continuous performance test 
On the two-back version, the overall mean hit rates for the PKU and control 
groups were very similar at 64.55 (SO 7.54) and 63.20 (SO 16.90) 
respectively, and the group effect was not statistically significant (F = 0.81, df 
1/20, P = n.s.). However, a highly significant time-on-task effect emerged (F 
= 7.22, df 3/20, P < 0.001), indicating a decrement in performance for both 
,groups as the task proceeded. The interaction term was also significant (F = 
5.50, df 3/20, P < 0.01). Mean block-by-block changes in detection of target 
stimuli forthe two groups are presented in Figure17 which shows a precipitate 
decline in performance on block 3 followed by recovery during block 4 for the 
PKU group, while the opposite pattern was displayed by the control children. 
No further significant results were obtained from the two-back test. The 
overall mean false alarm rate for the PKU group was 9.64 (SO 5.89) which 
was considerably less than the controls' of 25.8 (SO 33.1), though the 
difference was not significant (F = 1.87, df 1120, P = n.s.). No significant effects 
on false alarms were found for time (F = 1.73, df 3/20, P = n.s.) or the 
interaction (F = 0.91, df 3/20, P = n.s.). The overall mean reaction time in 
milliseconds for the PKU children was 509 (SO 72) and that for the control 
children 481 (SO 14), but the difference was non-significant (F = 0.34, df 1120, 
P = n.s.). Similarly, reaction times were not significantly affected by time on 
task (F = 0.18, df 3/20, P = n.s.) or the interaction between group and time (F 
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= 0.42, df 3/20, P = n.s.). 
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Figure 17. Mean hit rate per consecutive block of 140 trials on the two-back 
CPT. Illustrates significant performance decrement and group x time 
interaction. Between group factor was non-significant. 
Digits forwards test 
The mean score out of a maximum of 40 on the recall of digits test for the PKU 
group was 18.45 (SO 4.70) and for the control group 20.91 (SO 4.64). The 
difference between the distributions was not significant (t = 1.91, df 10, P = 
n.s., related). 
Correlational analyses 
As expected, within both groups there were significant correlations at P < 0.05 
(df 9, Pearson) between chronological age and one-back hits (PKU, r = 0.62; 
control, r = 0.77), one-back reaction time (PKU, r = -0.68; control, r = -0.75), 
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two-back hits (PKU, r = 0.86; control, r = 0.69), two-back reaction time (PKU, r 
=-0.75; control, r=-0.60) and digit recall (PKU, r=0.81; control, r=0.65), 
,thus vindicating the use of a matched controls design. Only false alarms 
showed inconsistent correlations with age (one-back: PKU, r = -0.66, P < 0.05; 
control, r = -0.25, P = n.s.), (two-back: PKU, r = -0.48, P = n.s.; control, r =-0.64, 
P<0.05). 
Within the PKU group, there were no significant correlations between any of 
the one-back or two-back measures or digits forwards and mean lifetime phe 
concentrations. A similar pattern of non-significance emerged for correlations 
between the outcome variables and mean phe concentrations for the first five 
years of life and task-concurrent levels. Mean lifetime and concurrent phe 
level were highly positively correlated (r = 0.89, df 9, P < 0.001). Interestingly, 
in the PKU group, only two-back hits (as opposed to false alarms and reaction 
time) and digit recall correlated significantly (r=0.84, df 9, P <0.01) and in the 
control group only one-back hits and digit recall (r = 0.72, df 9, P < 0.05), this 
inconsistent pattern of inter-test correlation suggesting poor concurrent 
validity and providing some evidence that the experimental and control tasks 
represented different cognitive domains. 
Discussion 
The results from this sma"-sample study failed to support the view that 
continuously treated PKU in middle childhood is characterized by specific 
executive dysfunction, at least as gauged by the ability to sustain attention 
and decision-making, when average phe concentrations in the preschool 
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period are kept around the 300 JlmoVI mark. Neither the one-back nor the 
two-back versions of the CPT differentiated children with classical PKU who 
were treated early from healthy children of similar age and verbal ability in 
terms of target detection, inhibition of incorrect responses or speed of reaction 
to targets. Both CPT variants required prolonged periods of concentration 
and the case for the two-back version being the more taxing was 
strengthened by the finding of a significant vigilance decrement curve on this 
measure. Despite the increased attentional demands of the two-back test, no 
between-group differences emerged. Thus, it appeared that the on-diet PKU 
children could concentrate or, conversely, resist distraction as well as their 
non-PKU counterparts. 
The significant interaction term in the analysis of the two-back, hit-rate data 
could not be ascribed to the above average phe levels that typify even treated 
PKU. (The non-PKU fasting norm falls within the 35 to 100 Ilmol/l range 
(Smith & Brenton, 1995).} Figure 17 shows the means conforming to a 
crossover rather than a divergence pattern centring on block 3. While the 
PKU group's hit rate fell suddenly during this block compared with both the 
within-group trend established during blocks 1 and 2 and the performance of 
the controls, it recovered and indeed surpassed that of the controls during 
block 4. 
The significant time effect found for hit rates on the two-back version of the 
CPT for both groups (Figure 17) clearly demonstrates the kind of temporal 
performance decrement curve customarily found in vigilance tasks 
(Mackworth, 1969). From this evidence, it is tempting to conclude that the two-
back version of the CPT may be more sensitive to progressive failure of 
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attentional mechanisms than the one-back version and hence should be used 
whenever there is a need to explore subtle impairments of sustained 
attention. However, as the two-back version was confounded with test order 
and may have been more subject to general fatigue effects, the general 
superiority of this format as an investigative tool needs to be further examined. 
The earliest example of the CPT being incorporated into PKU research 
methodology was a study by Anderson et al. (1969) who reported poorer hit 
rates and more errors than matched controls in a group of 11 PKU children. 
However, all their subjects were diagnosed before the advent of mass 
neonatal screening and their sample was extremely heterogeneous for 
treatment variables and 10. Compared with our homogeneous group, two had 
never been on diet; three commenced later than one, six and eleven years of 
age respectively; and, with only one exception, the remainder began when 
they were more than two months old. The sample mean IQ was 77 and two 
subjects were severely mentally handicapped. 
The present study concurs with those of Mazzocco et al. (1994) and 
Stemerdink et al. (1994) in finding no significant executive function deficits in 
school-age subjects with early treated PKU. It extends these authors' work by 
relating performance on executive and non-executive tasks to lifetime, 
preschool and concurrent phe concentrations. As no significant correlations 
emerged between either historical or recent phe levels and executive or 
indeed non-executive function, it is a reasonable conclusion that the range of 
dietary control observed by the patients in our sample may have been 
protective against both global and specific cognitive deficits. 
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The results vindicate the policy adopted in the United Kingdom some years 
ago of aiming to reduce phe concentrations in the preschool period to below 
360 /lmolll (Medical Research Council, 1993b). At 342 /lmollll, our subjects 
succeeded in maintaining their preschool average within this guideline. 
Though the group's standard deviation for the period was 126 /lmoVI, this 
degree of variance did not yield a phe-control effect in outcome correlations. 
Poor self-management and conduct disorder may exemplify executive 
dysfunction in the personality as opposed to the cognitive domain. 
Nonetheless, Weglage et al. (1996a) found no correlation between preschool 
phe and scores on a questionnaire measure of behavioural adjustment at 10 
years of age in a group of 58 treated PKU children. The German children's 
average indices of dietary control between birth and five were close to ours at 
around 360 /lmoVI. Thus, Weglage et al.'s negative result regarding 
personality functioning provides further evidence for 360 /lmol/l being not only 
an attainable and realistic preschool target for phe control but one which does 
not appear to have demonstrable adverse consequences in the short-term. 
In contrast to both the present study and their personality findings, Weglage 
et al. (1996b) reported significantly poor attention in 11-year-old, PKU 
subjects who were treated early compared with matched controls. These 
authors also found significant correlations between concurrent phe and 
attentional measures. In keeping with our data, they found no group effect on 
digit recall or associations between historical phe control and attention. As 
measures of attention, Weglage and his colleagues used the Stroop Task and 
the Test-d-2. The contradictory findings of the two studies may relate to the 
differential sensitivity of the instruments to phe. However, the older German 
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children had slightly poorer historical and considerably worse concurrent phe 
control {see Table 18}. As average pre-school and school-age phe levels for 
our subjects fell within current UK guidelines of 360 and 480 J,lmolll 
respectively and no evidence for executive impairments was found, the case 
for the suitability of these benchmarks is strengthened. 
Lifetime 
Mean 
Present study 341 
Weglage et al. 476 
Concurrent Present study 388 
Weglage et al. 583 
so 
125 
144 
127 
377 
Range 
224-600 
279-818 
193-562 
85-1709 
Table 18. Treatment parameters of patients in the present study (n = 11, 
median CA = 8.83 years) compared with those studied by Weglage et al. 
{1996b} (n = 20, median CA = 10.92). Data are phe concentrations in J,lmol/J. 
Knowledge is presently scant about the effects of longer-term exposure to 
elevated phe concentrations on executive skill in adolescence and beyond 
(Zetterstrom, 1995). Nonetheless, in a control group study, Griffiths et al. 
{1995} found no evidence for deficits in measures of executive function such 
as letter cancellation, verbal fluency and three-dimensional maze leaming in 
patients who terminated diet abruptly at age 10 and who were 
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hyperphenylalaninaemic for three or more years thereafter. 
Research into the executive dysfunction question would be served by further 
studies of infant PKU subjects in an endeavour to replicate Diamond's (1994) 
findings and animal studies are needed to explore the prefrontal dopamine 
model (McDowell, 1996). All studies of treated patients should integrate 
results from outcome measures with historical and concurrent phe levels. 
Further research using comparable measures on progressive age groups with 
well-defined treatment histories is needed before a definitive statement can 
be made about the executive dysfunction issue and optimal phe levels at 
different stages in the life cycle. 
Commentary 
The term 'executive function' is of fairly recent origin, its provenance being the 
work of Stuss and Benson (1985). However, the concept dates back to the 
19th century and localizationist theories about the role of the frontal lobes in 
cognition. Nowadays, 'executive' and 'frontal lobe' function are viewed as 
interchangeable, though it is important to recognize the metaphorical 
character of the 'frontal lobe' description (Pennington & Ozonoff, 1996). Far 
from being silent, the prefrontal cortex is now regarded as the seat of man's 
highest intellectual feats and the centre of creative, adaptive and purposeful 
behaviour (Hebb, 1945). Its activities are probably most closely linked to what 
Cattell (1971) described as fluid as opposed to crystallized intelligence. In 
essence, the cortex anterior to the central sulcus is responsible for the 
application of skill and knowledge, in constrast to the cortex posterior to this 
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division which is primarily devoted to input and storage of information. The 
acquisition of knowledge involves interaction between the two functionally 
distinct anterior and posterior regions (and, incidentally, provides the basis of 
a neuropsychological model for Piaget's developmental theory of 
epistemology). 
Because of the organizational and metacognitive nature of executive 
functions, they remain not only difficult to define in the abstract but even more 
elusive to capture psychometrically. For instance, operationalizing executive 
constructs like creativity, foresight and flexibility of thought as tasks with 
quantifiable outcomes poses special problems compared with, say, 
measuring non-executive functions such as defining words or completing 
pictures. In general, assessment is presently better served by instruments 
measuring crystallized rather than fluid intelligence (Duncan, 1995). One 
reason is historical and to do with the dismissal of frontal function as being of 
minor significance by Hebb and Penfield in the forties. but principally the 
imbalance is due to controversy both now and in the past about what 
constitutes a valid measure of prefrontal activity. 
From studies of impulsivity and perseveration in frontally damaged patients, 
some consensus has emerged that the ability to maintain mental set over 
time, resist distraction and inhibit maladaptive responses is a hallmark of 
many executive functions (Welsh & Pennington, 1988). Thus, the Continuous 
Performance Test, which was originally devised by Rosvold and his 
colleagues to discriminate neuropathological from non-organic disorder, has 
quickly found a central place in armoury of measures purporting to tap 
executive disorders. Because of its vigilance format, the CPT is nowadays 
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seen as a measure of sustained rather than selective attention and having a 
particular value in the diagnosis and monitoring of attention deficit disorder 
. (Schachar et al., 1993). 
Neither of the studies of executive dysfunction by Anderson et al. (1969) and 
Diamond (1994) furnished sufficiently detailed data about phe levels in their 
PKU subjects to enable an analysis of whether a threshold value, either 
historical or concurrent, was identifiable above which attention and impulsivity 
were affected and below which were not. Thus the question remains largely 
open as to whether, when a certain level of circulating phe is reached, specific 
executive disorders are potentiated and, if so, what that precise point might 
be. 
The two-back version of the CPT promises to be a useful tool for exploring this 
question. Indeed, with flexible programmable testing systems such as 
SuperLab (Haxby et al., 1993), not only can the effect of altering stimulus 
variables such as duration or interval be studied but also that of increasing 
task difficulty. The elicitation of a vigilance decrement curve during a 
sustained attention task such as the CPT is usually taken as an index of 
validity. Task variables such as stimulus duration, inter-stimulus interval, 
event rate and whether targets are sequenced rather than single have a 
powerful influence on slope of the curve (Schacher et al., 1988). In the 
present study, it is particulary noteworthy that only the two-back format yielded 
a significant decrement curve in the time allotted for testing. This begs the 
question whether a three-back paradigm would constitute an even more 
penetrating methodology for exploring the vigilance aspect of executive 
function in relation to phe level, though the likely interaction between task 
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difficulty and developmental level would have to be carefully controlled and 
floor effects avoided. 
The findings of the present study, with its well-controlled subjects, may be 
seen as corroborating Diamond's (1994) view, but they support more the 
corollory of her proposition, namely, that phe levels below 360 J.1molll are not 
harmful, than the proposition itself which states that those above are. A 
natural extension to the work described here would be a study based on a 
sample with poorer control, preferably in the range specified by Diamond as 
harmful of 360 to 600 J.1molll. To increase task difficulty and therefore the 
chances of limit-testing executive skills, a two-back or even three-back variant 
of the CPT could be employed. The clear hypotheses could then be tested 
that the performance decrement curves of healthy controls and PKU children 
with lifetime phe concentrations between 120 and 360 J.1mol/l would be 
indistingUishable, but that those of children with concentrations between 360 
and 600 J.1molll would show significant impairment. 
Another way of increasing vigilance task difficulty is to require subjects to 
respond selectively to targets and distractors. Thus, in addition to pressing a 
button when a target appears, they have to press another button in response 
to every distractor. This paradigm was adopted by de Sonneville who 
measured sustained attention by means of a Dot Pattern task in which the 
target stimulus was four dots and the distractors three and five dots. The 
positions of all the dots were random. Subjects had to press one of two 
buttons depending on their decision about the category to which the signals 
belonged and performance and reaction time were recorded automatically. 
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Twenty-two eight-year-olds with PKU achieved the same accuracy level as 
controls on this task but were significantly slower (de Sonneville et al., 1990). 
However, within the PKU group, significantly worse accuracy was shown by 
those with concurrent phe concentrations above 570 JlmoVI compared with 
those below whose performance was normal. These findings provided some 
support for Diamond's view that phe concentrations in excess of 600 Jlmol/l 
may be harmful but the study was marred by methodological flaws such as a 
failure to describe treatment variables fully, inappropriate statistical analyses 
(t-tests instead of ANOVA) and a mismatch between the PKU sample and 
controls on Performance 10. 
De Sonneville's Dot Pattern task was used as the investigative instrument in a 
subsequent experimental study in which 14 off-diet adults with PKU were 
returned to diet and finally taken off again (Schmidt et al., 1994). Figure 18 is 
adapted from the data presented in this report. The authors claimed 
covariance between on-task phe and attention, reaction times on the dot 
detection test decreasing when phe was lower, then increasing when phe 
returned to baseline levels. The difficulty with this interpretation is that, 
potentially, practice and familiarity were confounded with the high to low phe 
transition (phases 1 to 2) and fatigue and boredom with the low phe to high 
phe transition (phases 2 to 3). The simple expedient of testing the controls a 
third time in parallel with the PKU group under the high phe (return to 
baseline) condition would have helped resolve the interpretive problem. 
However, these data are curiously absent in the results section of the report, 
the reaction-time means for hits being presented as in Figure 18. 
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Figure 18. Mean reaction times for hits on de Sonneville's Dot Pattern task 
as a function of dietary phe manipulation. For PKU sample, Phase 1 is high 
phe, Phase 2 low phe, and Phase 3 high phe. Adapted from Schmidt et al. 
(1994). Illustrates absent datum point for controls during phase 3. 
Future research into the executive dysfunction issue would be better served 
by greater standardization of outcome measures and more careful definition 
of sample characteristics especially in relation to treatment variables. There is 
a great need for studies to be constructed from samples stratified for historical 
and concurrent phe control, although achieving large enough numbers for 
statistical analysis might necessitate collaboration and multi-centre data 
collection. 
The study described in this chapter and that reported by Diamond (1994) 
illustrate that executive skill may vary according to lifetime or task-concurrent 
phe level and that the findings from these two studies are not necessarily 
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contradictory but may reflect subtle neuropsychological changes that occur 
with progressively poor phe control. A threshold effect somewhere between 
300 and 600 Jlmolll is unlikely on theoretical grounds. A linear or curvilinear 
relationship between circulating phe and executive impairment is more likely, 
but something that remains to be clarified empirically. 
An alternative method of testing the prefrontal dopamine biosynthesis model 
would be to observe CPT performance in relation to artificially elevated blood 
phe levels in normal as opposed to PKU subjects. These could be provoked 
either by dietary ingestion of labelled phe or by intravenous infusion. If 
hyperphenylalaninaemia in humans generally depresses dopamine synthesis 
in the prefrontal area of the brain, such a phenomenon should occur in non-
PKU subjects when hepatic hydroxylation of phe to tyr is challenged to the 
point where the system becomes overloaded. Overloading would produce 
high blood phe concentrations. Though the blood-brain barrier diminishes 
cortical phe levels (Pietz ef al., 1995), the effects of overload should 
nonetheless be detectable in performance on measures such as the CPT if it 
is the case that, as Guttier and Lou (1986) proposed, dopaminergic neurone 
systems are functionally and temporarily compromised. 
To the author's knowledge, such a study has not been conducted. However, 
Lou ef al. (1987) adopted the opposite strategy of using large doses of tyr to 
counteract the hypothesized dampening effects of phe on prefrontal 
neurotransmitter metabolism in PKU. The results of tyr supplementation on 
continuous reaction times were equivocal with only the slowest showing 
improvement. The robustness of such an effect on neuropsychological 
performance remains seriously in doubt as it was not tested statistically by 
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Lou et al., nor has it been independently replicated. 
A further promising angle on the executive dysfunction question is the work, at 
present minimal, on late treatment of adult patients with PKU. Members of this 
population are mainly those mentally retarded adults, now generally into 
middle or old age, who were born before mass screening was initiated, or 
even before the possibility of treatment was demonstrated. They were never 
treated in infancy and the disease followed its natural course, resulting in 
severe intellectual impairment and usually institutionalization. A handful of 
case studies have been conducted to explore whether reducing dietary phe in 
untreated PKU can lead to behavioural improvement. There is no suggestion 
that introducing diet many years into the life cycle of the individual can reverse 
intellectual loss, but the dopamine-executivEl theory would suggest that 
lowering phe might dynamically ameliorate conduct disorder and poor 
impulse control. 
Guttier and Lou (1986) argued that, in untreated PKU, high phe 
concentrations decrease tryptophan in the CNS and interfere with the 
conversion of tyrosine into dopamine and norepinephrine, but that the 
temporal dynamics of these processes are short and reversible. 
Administering treatment late in PKU provides a test of this view and also of the 
executive dysfunction theory. The high level of comorbidity between attention 
deficit, conduct disorder and hyperkinesis is currently regraded by some as a 
marker for severe executive dysfunction (Moffit, 1993). Although frank 
attention deficit hyperactivity disorder is not commonly reported as a clinical 
feature of treated PKU, even when dietary control is weak, in the untreated, 
mentally handicapped patient poor self-control, oppositional behaviour and 
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impulsivity are frequent symptoms that may be attributable to 
hyperphenylalaninaemia and resultant deranged metabolism in prefrontal 
cortex. If reducing phe by dietary management mitigates these behaviours in 
untreated PKU, such a finding would provide indirect support for a frontal 
neurotransmission mechanism. 
At the time of writing, the balance of empirical evidence on this issue is, if 
anything, slightly against late treatment having beneficial behavioural effects. 
Harvey and Kirk (1995) reduced blood phe in a 30-year-old untreated male 
patient to around 300 /lmolll by dietary manipulation from a pre-diet level of 
1900 /lmoVI. They reported no systematic change for the better in behaviour 
during the on-diet period. Only slight improvement occurred following dietary 
inception, which may have been a Hawthorne rather than a phe effect. The 
case for social and material reinforcement being the active factor rather than 
phe was strengthened by the additional observation that the patient's 
behaviour also improved on return to his liberalized, and presumably more 
varied and palatable, normal diet. 
Three independent reports cited by Harvey and Kirk showed diet-related 
improvement in individual patients, while a further four, in addition to their 
own, did not. In the untreated patient, gross rather than subtle executive 
dysfunction is the norm. If research consistently shows that drastic reduction 
of blood phe in the untreated PKU population consistently fails to produce 
observable behavioural improvement, then the status of the metabolic theory 
of executive dysfunction must become severely diminished and its 
fundamental assumptions called into question. 
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Chapter 10 
OVERVIEW: TREATMENT AND POLICY 
Gene therapy or enzyme replacement therapy are theoretical alternatives to 
the current costly and time- and effort-consuming dietary method for 
preventing mental handicap in PKU. However, while the hope of developing 
a substitute for the missing enzyme was expressed over twenty years ago 
(Gearheart & Litton, 1975), it has yet to be fulfilled. The practicalities of 
enzyme replacement by means of orally administered medication have so far 
foundered on the problems of creating a satisfactory transport system and 
animal studies of techniques involving injection and implantation of active 
enzyme have failed (Danks & Cotton, 1987). Gene insertion therapy is now a 
real possibility and would represent a 'one-shot' or 'magic bullet' cure. The 
first disease being treated with gene therapy is adenosine deaminase 
deficiency and cystic fibrosis is another likely candidate (Batshaw & Perret, 
1992). However, the prospects for genetic remediation of the PAH deficiency 
in PKU are as yet impossible to gauge (Kent, 1994). Liver transplantation has 
never been seriously mooted as a treatment for PKU for ethical and practical 
reasons. There can be little moral justification for replacing a healthy organ 
whose functions aside from the manufacture of PAH are normal and in which 
the effects of PAH deficiency can be successfully circumvented by dietary 
adjustment. Furthermore, successful transplantation depends on availability 
and compatibility of donor organs and rejection of a vital organ such as the 
liver carries with it an unacceptable risk to the life of the patient. 
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For the foreseeable future, then, dietary prophylaxis, with all its demands for 
intra-familial social and behavioural reorganization, will remain the only 
practicable treatment option in severe PKU. In the 1950s, Bickel's method 
was truly revolutionary and the first instance in the history of medicine of the 
natural course of a neuropathic disease leading to mental retardation being 
halted. While it is broadly true to say that, as a therapeutic procedure, 
restriction of dietary phe is effective, refinement of the parameters of treatment 
must remain the goal of research. Taking an overview of the present state of 
knowledge about treatment factors in childhood PKU, it appears that dietary 
restriction of phe over the first decade of life produces diminishing intellectual 
benefit while the personal and social costs to the individual of adhering to the 
diet increase concomitantly. As demonstrated by meta-analyses such as 
those by Berman et al. (1968) and Hanley et al. (1971) on the relationship 
between age of treatment commencement and intellectual outcome, it is clear 
that the neurotoxic effects of phe are particularly savage in infancy and it is 
now universally accepted that treatment should begin as soon as is 
practicable in the neonatal period. However, there are signs that the issue as 
to when treatment may be safely terminated will become increasingly 
enmeshed with the issue of whether the harshness of the regimen justifies the 
cognitive outcome in the teenage years and beyond. Hence, risk-benefit 
analysis has more-and-more become the perspective on management of the 
adolescent and adult in recent years. This more complex question about the 
balance between the demands of continuing treatment and the profitability of 
so doing will foreseeably be the one that will exercise clinical research in the 
future. Data from across the life spans of individuals with PKU will 
undoubtedly be required to enable a definitive statement to be made about 
whether treatment cessation at any age is safe for the integrity of the CNS. 
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The studies in this volume were designed to illuminate the effects of the two 
remaining 'pure' treatment factors - age of cessation and degree of control - in 
those age groups from which satisfactory research samples can now be 
constructed, namely, school-age children, adolescents and young adults. As 
any derangement of mental and motor functioning at these developmental 
levels is likely to be subtle rather than gross (Guttier & Lou, 1986), a 
neuropsychological approach was adopted. The neuropsychological 
approach centres on the use of psychometric instruments that are known or 
suspected of being able to provide quantitative evidence about elementary 
aspects of brain function (Griffiths, 1989; Griffiths, 1996). While in the 1980s 
10 findings and in the 1990s MRI evidence made the most powerful impact on 
the shaping of treatment policy in PKU, the neuropsychological approach has 
gradually become more influential (Burgard, 1996). The principal reason for 
the move away from traditional 10 tests, with their high proportion of long-term 
or crystallized memory items, is the relative dullness of the latter in detecting 
the effects of subtle neurotoxicological and biochemical factors. The impetus 
in recent years has been towards the development of more sensitive 
neuropsychological measures many of which derive from clinical research on 
subjects with identifiable neurological lesions (Benton, 1994). 
Neuropsychological approach to treatment discontinuation Issue 
The treatment discontinuation study described in Chapter Three followed the 
approach of Brunner et al. (1987) in selecting neuropsychological as opposed 
to 10 measures. Control group comparisons were necessary as few 
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developmental neuropsychological measures are norm-referenced. Careful 
matching of experimental and control subjects yielded little in the way of firm 
evidence that three or more years of diet-induced hyperphenylalaninaemia 
led to neuropsychological deficit, this result providing additional support for 
the view that dietary liberalization at 10 years of age does not potentiate 
widespread cognitive impairment. However, 10 measures would have further 
contributed to knowledge about the intellectual consequences of lifting of the 
restricted diet and also about whether the off-diet group were deviant in 
relation to population norms, and it is a minor shortcoming of this study that 10 
data were not collected. 
The apparently phe-related poor Design Fluency finding in the treatment 
discontinuation study raised the question of whether executive functions might 
be specifically vulnerable to elevated and prolonged phe concentrations in 
post-treatment PKU. It was not possible to explore this issue further in 
subsequent discontinuation studies because of the change in policy adopted 
by the Glasgow clinic in the early ninties of encouraging children and 
adolescents with PKU to remain on a phe-restricted diet indefinitely. The 
negative results of the phe manipulation method reported in Chapters Five, 
Six and Seven, the further negative results from the correlational approach 
reported in Chapter Eight and finally the lack of a group effect in the control 
group study reported in Chapter Nine summate to undermine the notion that 
either global or specific intellectual deficit is an outcome in PKU when the 
disease is treated early and for at least a decade. Though, little is known 
about the influence of many years' exposure to high phe concentrations on 
neuropsychological test performance in adulthood after abrupt dietary 
cessation, sufficient numbers of older patients who voluntarily ceased dieting 
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in their teens should become available in the near future to permit treatment-
outcome research, probably on a multi-centre basis. 
Apart from the post-treatment study described in Chapter Three, the 
remainder all focussed on subjects who remained, at least nominally, on diet. 
The experimental studies reported in Chapters Six and Seven, though 
artificially elevating phe for longer than most of their kind, could not be said to 
have involved chronically extended hyperphenylalaninaemia. Nonetheless, 
the evidence from these studies was weighted against the adolescent period 
being one of CNS suspectibility to the malign effects of phe. The negative 
results derived from temporarily raising phe concentrations in adolescence 
lent further support to the view that the period of irreversible vulnerability of 
the CNS to phe was passed and suggested that a treatment policy of dietary 
liberalization or at least considerable relaxation may be pursued with impunity 
after the first decade of life. 
Selection of tests 
In retrospect, the omission of a choice reaction time measure in the 
neuropsychological test batteries employed in the studies described in 
Chapters Three, Six and Eight was a weakness as this variable appears to be 
the only one frequently associated with functional impairment in treated PKU. 
A meta-analysis by Burgard (personal communication) of 21 
neuropsychological studies in PKU reviewed by Waisbren et al. (1994) 
revealed highly conflicting results with evidence presented for and against a 
variety of cognitive and motor functions being impaired. However, abnormally 
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long response times on choice-reaction tasks emerged as a consistent feature 
across the groups studied, a mean increase of 111 msec for an increase in 
mean phe concentration of 966 J.1moVi being found. This increment in CRT is 
about half again the average for the normal population but has to be viewed 
against a very substantial rise in phe level. Deficiencies in CRT were 
apparently reversible by dietary restriction of phe and thus the incorporation of 
such a measure in the experimental manipulation studies described in 
Chapters Six and Seven would have possibly shed light on the temporary, or 
otherwise, nature of this phenomenon and perhaps added to the empirical 
foundation of the prefrontal dopamine theory. 
There is no standard choice reaction task, but de Sonneville's Dot Pattern 
Exercise (de Sonneville, 1993) and the Continuous Performance Task as 
used in Chapter Nine conform to a CRT paradigm in being both speeded and 
having a response inhibition component. The negative results from the one-
back and two-back variants of the CPT suggest that mean lifetime phe levels 
between 300 and 400 JimoVI may confer immunity to slowing of reaction time. 
However, a longitudinal study of patients who were well-controlled in early life 
would be necessary to establish if later loss of control leads to poorer speed 
of psychomotor responding. As a general point, little is known or even 
conjectured about what practical implications such a minor deficency might 
have for daily functioning. 
Taylor (1988) has argued that neuropsychological tests represent the 
sharpest tools for uncovering subtle intellectual deficiencies occasioned by 
brain disease. In PKU research, treatment outcome studies have 
incorporated a wide range of neuropsychological instruments. However, as 
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only choice reaction time appears to emerge as a consistently deficient 
function throughout the age range in treated patients, why then has the 
clinical community in recent years sided so strongly with the policy of dietary 
prolongation? The answer to this question can best be understood 
historically and, in particular, by viewing the apparently contradictory 
evidence furnished by 10, executive function and MRI studies. 
Background to treatment cessation policy: IQ, MRI and executive 
function studies 
In the absence of empirical knowledge about treatment duration, dietary 
cessation between four and six years of age was commonplace in the 1970s, 
especially in the USA (Schuett et al., 1980; Schuett & Brown, 1984). Above 
all, it was Cabalska etal.'s (1977) report describing average falls of 14 and 
11 10 points four years after treatment cessation at ages three and four 
respectively that caused a major revision of the policy to terminate diet in the 
preschool period. Others' findings (e.g. Koch et al., 1982; Seashore et al., 
1985) led to a gradual upward revision of the recommended age for treatment 
discontinuation. 
In England the policy, hitherto adopted on the grounds of caution rather than 
of science, had always been one of maintaining treatment until age eight 
(Smith et al., 1978). Only the French have been consistently out of step with 
the trend towards extending the treatment period. In France, the restricted diet 
was traditionally discontinued around age five. Saudubray et al. (1987) 
reported a mean 10 of 101 at 11 years in a group who discontinued at five 
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years of age and interpreted this finding as supporting the French policy 
which, by international standards, would now be regarded as excessively 
. early. Neverthless, though the mean IQ of his sample nearly equated with the 
population norm, standard deviations over the period increased from 10 to 21, 
suggesting that at least some children deteriorated coincidentally with 
hyperphenylalaninaemia in the primary school period. 
Treatment in Scotland was more conservative than that of England and 
certainly that of France in following a policy of abrupt cessation at 10 years of 
age. In Heidelberg, Germany, under Bickel's direction, strict diet was 
continued for as long as families could adhere to it and, when difficulties of 
compliance occurred, the diet was relaxed rather than fully liberalized. 
Worldwide controversy over age of treatment cessation was not settled by 
Waisbren et al.'s (1980) review of 19 outcome studies when diet was stopped 
between ages four and eight. Waisbren and her co-authors concluded that 
children's intellectual performance decreased in about half the studies while 
the others showed no change. Holtzman et al. (1986) analyzed IQ and 
scholastic attainments in treated children at age 10, some of whom stopped at 
six and others at eight, concluding that the recommendation be made to 
clinicians to maintain patients on diet until at least eight years of age. 
From the late seventies onwards there was thus emerging evidence for 
increasing the age for stopping treatment and that four to six years of age was 
too young to prevent later loss of 10. Taker. alone the IQ evidence might have 
led to a worldwide discontinuation policy that was in keeping with existing 
practice in Scotland of maintaining strict control until age 10. 
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Despite this apparent convergence of research opinion, in the late 1980s MRI 
studies showing abnormal brain structures become a second strand of 
evidence influencing commentators' judgements about what constitutes a 
safe age for treatment discontinuation. Villasana et al. (1989) were the first to 
report MRI anomalies in treated PKU, their subject being an 18 year-old who 
had been diagnosed and treated from birth. White matter changes were not 
diffuse but centred on the periventricular area. As the patient had 
discontinued diet at six, the complex of signs· an 10 of 81, fine motor 
incoordination, tremor and localized white matter lesions· implied that this 
was too early an age for cessation of treatment 
Shaw et al. (1990) corroborated the above findings. In a patient of similar age 
(19 years), they found posterior, periventricular abnormalites on MRI. 10 was 
slightly lower at 75. As treatment commencement was mildly delayed at six 
weeks and concluded early at six years, the abnormal neurological and 
intellectual outcome may again have represented a combination of treatment 
factors. In the same year, Pearsen et al. (1990) published the results from MRI 
scans of 14 patients with classical PKU, nine of whom were treated early and 
continued diet at least until age five. Again, white matter abnormalities were 
found principally in areas immediately posterior to the cerebral ventricles. 
The cerebral cortex (grey matter), basal ganglia, cerebellum and brainstem 
were unaffected. In this group study, no correlation was found, however, 
between severity of white matter abnormality and 10. Indeed, two cases with 
the worst-rated MRI abnormalities had lOs in the normal range. 
Abnormal MRI scans were obtained by Thompson et al. (1990) from a group 
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of seven classical PKUs that were heterogeneous for treatment variables. 
Later, in a larger group of 25, a" of whom were treated early and until at least 
seven, Thomson and his colleagues found periventricular and subcortical 
white matter lesions on MRI (Thomson et al., 1993). Severity was unrelated to 
age of treatment, dietary control after eight and 10. Time off diet was 
predictive, however, leading these authors to conclude that older patients on 
normal diet are at risk of CNS changes. 
Finally, neuropsychological test findings obtained by Pennington and his co-
workers pointed to the possibility of executive functions being specifically 
impaired in treated PKU (Pennington et aI., 1985; Welsh et aI., 1990). Though 
based on sma" samples that were heterogeneous for treatment history (see 
Chapter Eight), this view gathered momentum in the PKU community. Not 
only did it call into question the validity of IQ tests as phe-sensitive outcome 
measures but it concurred with the theory that prefrontal dopamine is 
selectively diminished even by the mildly elevated phe concentrations 
characteristic of treated PKU (Guttier & Lou, 1986; Diamond et al., 1992; 
Diamond & Herzberg, 1996). Perhaps more than any other, the report by 
Diamond et al. (1994) of an association between executive dysfunction and 
concentrations in the 360 to 600 JlmoVI range in the very early years of 
treatment led to concern, particularly in the USA, about reducing phe levels to 
below 360 Jlmolll in the preschool period. 
Dietary treatment policy In the UK 
In 1993 a working party of the UK Medical Research Council produced a 
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much-quoted report in which recommendations for dietary management of 
children with PKU were made explicit (Medical Research Council, 1993a). 
These included the following specific guidelines for all patients found to have 
neonatal, pretreatment phe concentrations above 600 J.1moVi. They have 
been widely incorporated into clinical practice throughout the UK at the time of 
writing. 
1) Treatment should begin within 20 days of birth. 
2) Phe concentrations should be kept above 120 J.1moVI irrespective of age, 
but below 360 J.1mol/l during the pre-school period, below 480 J.1mol/l until 
adolescence and below 700 J.1moVI thereafter. 
3) Restriction of dietary phe should continue until adult life. 
The importance of these recommendations for treatment policy was that they 
embodied a complete reversal of previous theory and practice in the UK. Until 
this time it had always been assumed that an age could be identified at which 
the nervous system became impervious to the harmful effects of 
hyperphenylalaninaemia and at which dietary restriction could therefore be 
stopped. This volte face in thinking was further bolstered by a report by 
Beasley et al. (1994) which went even further in recommending lifelong 
dietary restriction, a conclusion that was echoed by Potocnik and Widhalm 
(1994). The diet-for-life policy is one that has always been pursued in Eire 
(Naughten et'al., 1987) and in many parts of Holland (Slijper et al., 1988). 
Despite the opportunities for international comparisons, for example between 
the extreme positions of the Irish and the French, few such studies have been 
undertaken until very recently (e.g. Burgard et al., 1997). 
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The weakness of the 1993 MRC recommendations lay in a poor exposition of 
their rationale. A reappraisal of the la, neuropsychological, MRI and 
executive function evidence on which they were founded is needed and now, 
four years on, it is possible to review the recommendations in the light of the 
evidence presented above and that derived from other sources. 
Reappraisal of the evidence 
fQ data 
When longer follow-up periods of la outconle from national collaborative 
studies became possible, Levy and Waisbren (1994) conducted a second 
major review of the literature and concluded that there was little evidence for 
loss of IQ when diet is carried on until at least 10 years. Furthermore, Beasley 
et al. (1994) analyzed the UK Collaborative Study database and found that 
dietary control after eight years had little predictive value for la compared with 
before. In the same year, Potocnik and Widhalm (1994), after reviewing 12 
studies from the eighties and nineties, concluded more specifically that 
treatment termination at or near age 10 does not lead to subsequent 1055 of 
la. 
Having transformed their la data into up-to-date estimates to compensate for 
normative changes over the quarter-century or so during which test results 
were submitted from clinics throughout the UK to the Collaborative Study's 
headquarters (Flynn, 1984), Smith and her colleagues concluded that the 
period between eight and ten years of age appeared to be a time during or 
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after which the CNS was considerably less vulnerable to the neurotoxic 
effects of excess circulating phe than before (Smith et al., 1990a; Smith et al., 
1990b; Beasley et al., 1994). Earlier support for this view had been 
forthcoming from Cerone et al. (1986) and from the German Collaborative 
Study (Schmidt et al., 1987), the Heidelberg workers reporting an IQ range of 
108 to 124 in a well-treated adolescent PKU group who were permitted a 
relaxed - as opposed to a liberalized - diet at age 10. Abrupt cessation 
around 10 years of age rather than graduated reduction of phe restriction was 
a characteristic of a subgroup within the US Collaborative Study (Azen et al., 
1991), the mean IQ for these children being normal at 101 when tested on the 
WISC-R, which was restandardized in North America in 1974. 
Despite the lack of evidence for intellectual deficit following treatment 
cessation at the end of the first decade of life, the MRC Working Party 
formulated a policy for indefinite dietary continuation - as, paradoxically, did 
Potocnik and Widhalm (1994), despite having collated evidence to suggest 
the opposite! With hindsight, the principal reasons for this were undoubtedly 
the abnormal signs shown by MRI scans of the brain in treated PKU and the 
suspicion that executive functions were especially vulnerable to elevated phe 
concentrations. Following Villasana et al.'s (1989) seminal study, a 
succession of studies were published yielding evidence upholding the idea 
that even well-controlled levels of phe during the developmental period might 
lead to subtle white matter changes in subcortical structures (e.g. McCombe 
et al., 1992; Thompson et al., 1990; Thompson et aI., 1991; Toft et al., 1994). 
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MRldata 
These unusual MRI pattems were troubling for policy-making in relation to the 
management of PKU. The specificity and consistency of the results were 
highly relevant to the most widely accepted mechanism of neural damage in 
untreated PKU, namely dysmyelination (Hommes et al., 1982). Both human 
autopsy evidence (Malamud, 1966) and findings from the brains of PAH 
deficient mice (Hommes, 1994) suggested that hyperphenylalaninaemia in 
early life increases myelin turnover which is not compensated for by 
increased myelin synthesis. This in turn leads to loss of neurones and 
decreased connectivity and, since connectivity is the basis for complex 
behavioural organization, mental dysfunction results. 
The question arises, however, whether this neuropathological mechanism, 
which appears so devastating during foetal and infant growth in PKU, loses its 
potency when neural structures become mature. An extended period of phe 
restriction permits the eNS to myelinate and arborize in a non-hostile 
biochemical environment. If the mechanism is then allowed to operate, does 
it cause white matter abnormalities which have functional significance? White 
matter abnormalities so far found in treated PKU are indicative of changes in 
white matter water content that are suggestive of increased myelin turnover, 
but they tend to be subtle and localized. One of the firsts hints that these 
structural anomalies may be benign and of little clinical relevance came from 
Thompson et al., (1993) who reported finding no correlation between the 
degree of abnormality on MRI scans and 10 in a group of 25 early-treated 
subjects. 
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Corroborative evidence for a lack of association between neurological 
abnormality and intelligence was provided by an MRI study of 77 post-
. treatment adolescents and adults (Cleary et al., 1994). While every scan was 
abnormal, the extent of the abnormality correlated randomly with la, leading 
these authors to conclude that, although the brain in PKU after treatment until 
late childhood is typified by deviant MRI scans, the phenomenon may have no 
significance for intactness of cognitive function. 
Other reports of MRI data confirmed the essential picture, namely, that 
children treated early, well and until at least middle childhood (nine to ten 
years) show localized white matter abnormalities suggestive of disturbed 
myelination (Sick et al., 1991; Toft et al., 1994), but the clinical meaning of 
hyperintensity on the MRI scan and whether it translates into psychological 
malfunction remains unclear. The emerging view is that structural abnormality 
as gauged by the MRI scan may not imply a commensurate risk to 
intelligence. However, few studies of this issue using neuropsychological as 
opposed to 10 measures have been conducted so far. 
Lou et al. (1982) concluded that neurological lesions as revealed by MRI had 
few functional consequences. Results from a neuropsychological battery that 
comprised paired-associate learning, free-recall of word lists, digit span, digit-
symbol and trail-making were uniformly normal, though only nine of the 25 
subjects had stopped treatment. Warrington and James's Metric Figures Test 
was the sole exception, but the authors failed to correlate concurrent or 
lifetime phe with performance on this perceptual test. 
It is too early to dismiss MRI anomalies as being of no consequence in treated 
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PKU as the long-term effects of dietary cessation after the first decade are as 
yet largely unknown. Water density as revealed by MRI reflects white matter 
deposition which in tum reflects myelin synthesis. Given the demonstrated 
and rapid disruption of myelination in the immature brain by phe (Hommes, 
1991), an open-minded view is required about the possibility of this process 
continuing thereafter. For example, in the mature organism, slow and 
insidious phe-related myelin changes may occur and harmful effects arise 
over a more protracted time-scale than that observed in childhood. 
Executive test data 
The impact made by the executive dysfunction hypothesis on thinking about 
control of treatment variables in PKU is disproportionate to its empirical 
substance. Policy makers have perhaps too hastily latched on to the simple 
notion that mildly elevated phe concentrations potentiate subtle information 
processing deficits characteristic of prefrontal dysfunction without either 
appraising or weighing the supportive evidence. Unfortunately, thus far, the 
area is strewn with methodologically questionable investigations and 
contradictory findings. These problems were described in Chapter Eight. The 
publication by Diamond et al. (1994) has been influential in a way 
unwarranted by its content. More of an abstract than a report containing 
sufficient detail to permit replication, it lacks sample-matching data and an 
elementary analysis of the association between historical phe levels and 
performance on executive tasks. The study described in Chapter Eight strove 
to remedy these deficiencies and failed to provide confirmatory evidence of a 
link between phe concentrations that were three to five times greater than 
normal and executive and personality disorders. 
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In a subsequent study in which, instead of executive function, visual contrast 
sensitivity was measured as an index of dopaminergic functioning in the 
retinal as opposed to prefrontal neuronal systems, Diamond and Herzberg 
(1996) reported significantly impaired contrast sensitivity in 12 PKU subjects 
compared with healthy controls. However, even superficial examination of 
this report reveals the omission of historical phe data, thus making it 
impossible to relate outcome on the perceptual test with lifetime phe control. 
Furthermore, closer scrutiny shows that the effect may have been principally 
due to the controls having supranormal ability on the visual contrast test rather 
than the PKU subjects having subnormal ability. Thus, when average scores 
from the 12 PKU children in Diamond and Herzberg's sample were compared 
with those obtained by Scharre et al. (1990) from a similar-aged sample of 61 
healthy children, they were not consistently worse. 
In fairness to Diamond's position about phe concentrations in the 360 to 600 
J,lmolll range in the early years of life possibly having an adverse effect on 
development of executive function, the samples on which the studies in 
Chapters Eight and Nine were based had rather better lifetime phe control 
than this and individual readings either as a totality or a even a majority did 
not fall consistently within this band. These considerations emphasize the 
need for further work on the executive dysfunction hypothesis based on 
samples stratified for level of historical phe control. 
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Caveats about interpretations of studies 
Research findings in PKU rapidly affect parental perceptions of the disease 
and its management as organizations such as the National Society for 
Phenylketonuria in the UK are in close contact with their American and 
European counterparts and information about new developments is often 
shared and disseminated through magazines, conferences and websites. 
Particularly where studies of dietary continuation are based on samples of 
adolescent subjects, there is a danger of findings being misinterpreted by 
both commentators and parents. An example of ambiguity in findings leading 
to a risk of false conclusions being drawn is a study by Weglage et al. (1996). 
These authors found that early and continuously treated 10-year-olds with 
PKU showed no sign of psychosocial maladjustment, a piece of evidence that 
is in agreement with the lack of behavioural and personality deviance found in 
the 11-year-olds described in Chapter Seven. However, Weglage et al. 
discovered that the picture deteriorated in adolescence and that 14· to 16· 
year-olds with PKU were significantly maladjusted compared with healthy 
controls. In the younger group, correlations between phe and personality 
measures were non-significant but in the older subjects significant 
correlations emerged. The simplistic interpretation might be that the 
personality findings were manifestations of elevated phe and thus that loss of 
dietary control in adolescence leads to a decline in personal and social 
adjustment. Such a view would be in keeping with the executive dysfunction 
hypothesis. 
Correlation does not imply a causal relationship, however. A third factor might 
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have potentiated correlated changes in the other two. It is noteworthy that 
when Weglage et al. surveyed their adolescent sample, 77 per cent indicated 
difficulties with staying on diet and an enonnous 94 per cent wished to stop 
immediately. There were thus strong signs of conflict between the motivation 
of the clinicians and parents, on the one hand, and the teenage patients, on 
the other. Construing the correlation as a causal link between elevated phe 
and disordered conduct may be spurious. An alternative view is that negative 
and hostile attitudes towards the treatment might have generated both loss of 
control and a general hightening of maladjusted behaviour in many of the 
Weglage et al.'s mid-adolescent subjects. 
In instances such as this where interpretation is unclear and causal 
sequences are ambiguous, it is essential to seek corroboration. In the 
experimental manipulation studies described in Chapters Seven and Eight 
where subject, carers and researchers were blind to alterations in phe 
concentrations, no cognitive or personality effects were demonstrated, at least 
over three months. Thus, the theory that from early adolescence onwards phe 
directly affects psychological variables is weakened. The altemative view is 
that the turmoil of adolescence and puberty has widespread repercussions on 
adherence to diet and general behaviour and that opposition to dietary 
maintenance at this age results in both loss of dietary control and changes for 
the worse on indices of integration and adjustment. 
A further illustration of this point is provided by the correlational analyses 
performed on the data reported in Chapter Eight. A naive interpretation might 
be that phe was positively correlated with attention deficit. However, more 
thorough scrutiny revealed that a third factor, marital breakdown. appeared to 
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be influencing both phe control and concentration in one subject and that, on 
removing that subject from the analysis, the significant correlation 
disappeared. 
Overstating research findings and overgeneralizlng conclusions 
An example of lack of balance in evaluating research findings and of 
proclaiming a misleading message to the PKU community is provided by 
Koch et al. (1996) of the US Collaborative Study on PKU. These authors 
compared two early-treated groups, one of which maintained the phe-
restricted diet until 22 years of age on average while the other stopped at a 
little under eight years of age on average. The WAIS-R administered at age 
22 and 24 years respectively revealed a mean 10 of 104 (range 74 to 123) for 
the on-diet group and a mean 10 of 92 (range 69 to 116) for the off-diet group. 
Furthermore, 78 per cent of the on-diet subjects went to college compared 
with only 28 per cent of the off-diet group. Koch et al. concluded that these 
results affirmed the need for dietary phe restriction into adulthood. Koch at 
al. also implied that the earlier policy in the US or terminating diet at six years 
of age was misguided, the principal reason being cost to health insurance 
companies rather than clinical need, and argued that funds should be sought 
to support the provision of dietary supplements into adulthood. 
This strongly political message was published in a summary article by the 
American PKU Society's newsletter under the emotive title 'Off-diet young 
adults with PKU: lives in danger' and broadcast worldwide by Schuett on the 
Internet without criticism or commentary. While Koch at al.'s argument may 
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provide ammunition for pressure groups campaigning for better financial 
support for an expensive treatment (the cost of the PKU diet is currently about 
$5000 per annum), the reasoning behind the conclusion drawn for 
prolongation of the diet into adulthood is seriously flawed. 
First, no statistical test of the IQ group-difference was performed. Second, 
dietary cessation and control were confounded as the off-diet group contained 
six times as many subjects as the on-diet group who had phe concentrations 
above 1200 JlmoVI during treatment. Third, no attempt was made to correlate 
historical phe levels with adult IQ. And fourth, the authors failed to 
acknowledge the possibility that the non-phe factors, such as low parental IQ 
and education, which predispose PKU subjects to lower IQs may also 
predispose families to poor treatment compliance and early cessation of diet. 
Non-treatment factors 
The empirical studies described in earlier chapters focussed on treatment 
factors. However, non-treatment factors have a powerful influence on 
intellectual outcome in PKU and it is important when interpreting research 
findings that the two are clearly separated. Using multiple linear regression, 
Chang at al. (1983) demonstrated that parental IQ and educational level were 
significant predictors of IQ in the on-diet PKU child. Later, Legido at al. (1993) 
confirmed this finding. Moreover, these authors reported that parental IQ was 
the strongest predictor of IQ in the treated child. Few studies have quantified 
socio-economic status (SES) in families wit~ a PKU child. An exeption is 
Smith et al.'s (1990b) analysis of data from the UK collaborative study which 
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showed a strong effect of social class on 10, the most able children being 
associated with classes one and two in the Registrar General's scheme. 
Such a statistical manipulation is generally overlooked in research into 
treatment factors in PKU but the social background and educational status of 
parents deserve greater consideration as factors in the outcome equation. 
They clearly have no direct influence on metabolic processes and the issue is 
not that the intelligence of parents and offspring are generally positively 
correlated (for instance, Williamson et al. (1981) showed that matemallO 
predicts the 10 of PKU and non-PKU siblings equally well}. What matters is 
that parental ability probably dictates to some extent level of understanding of 
the condition, knowledge about biochemical mechanisms and appreciation of 
the constituents of dietary intake in both carers and patient which, in tum, may 
affect treatment compliance and the eventual neurological and psychological 
status of the child (Russell et al., 1988; Ferguson & Griffiths, 1997). 
Design of future research studies 
Over the years since the inception of newbom screening for PKU, arguably 
sufficient expertise has been amassed to identify mistakes made in research 
deSigns and to enable them to be avoided in the future. Research evidence 
accumulated thus far points to severity, age of treatment commencement, 
quality of early phe control and age of treatment cessation as being the four 
active phe-related factors that determine cognitive outcome in treated PKU. 
Operational definitions of these factors remain to be refined. In so doing, 
retrospective and prospective research designs must endeavour not to 
confound these factors or to control statistically for confounded effects if these 
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are unavoidable. 
One methodology for guiding future research into treatment factors is to 
concentrate on samples that are considered by contemporary standards to be 
optimally treated in order to establish whether recommended treatment 
practices are truly prophylactic. This approach would entail selecting groups 
of patients with PKU whose treatment conforms to criteria currently 
promulgated as optimal by different national bodies and comparing results on 
neuropsychological and personality outcome variables in such groups with 
those derived either from healthy controls matched for non-metabolic 
independent variables or from PKU comparison groups that differ only on the 
factor under scrutiny. Research procedures in PKU over the past thirty years 
have largely been based on between-group models - for instance, severity 
has been investigated by contrasting the intellectual performance of mildly 
hyperphenylalaninaemic children with that of classical PKUs (Costello at al., 
1994) - but comparison of optimally treated patients with non-PKU controls 
and sub-optimally treated controls largely remains to be done. This omission 
is understandable, not only because of the Circularity of the process, but also 
because German treatment recommendations were only made explicit in 
1990 (Stellungnahme APS, 1990) and British recommendations only 
published in 1993 (Medical Research Council, 1993a). American guidelines 
on treatment targets have never been formally announced. 
Such an approach would necessitate rather more careful selection of samples 
in future than perhaps has been the case in the past. An attempt to compile a 
sample based on present UK guidelines for optimal treatment was made in 
the CPT study described in Chapter Nine and executive dysfunction as 
Chapter 10: Page 249 
· , .. ,.~ ~s:·r· 
measured by sustained attention and decision-making was not found in this 
group. In general terms, the sample selection process entails operationally 
defining inclusion-exclusion criteria and is dependent on having detailed 
historical records available for potential subjects. Thus, computerized 
databases with serial test data, both biochemical and psychological, are 
highly desirable prerequisites for research. If not already established, existing 
clinical services could facilitate the development of local research datasets by 
immediate implementation of computer storage and analysis programs. 
One difficulty of applying the criteria currently recommended as the basis for, 
say, treatment policy in the UK is that control levels refer to ranges within 
which all phe readings for the individual patient ideally should remain. For 
instance, the therapeutic range at present recommended in the UK (Medical 
Research Council, 1993a) is 120 to 360 Ilmol/I for the pre-school period but 
an unresolved problem is a definition of what proportion of phe readings per 
unit of time falling within this range constitutes acceptable compliance with the 
standard. In the studies reported above, the annual median of phe readings 
was adopted as the index of dietary control according to the conclusions of 
Rupp and Burgard (1995), with means of annual medians calculated to 
summarize group or individual compliance during specified developmental 
periods or indeed over subjects' lifetimes. However, in studies where 
samples are compiled on the basis of their conformity with a broadcast 
standard, an index of compliance would be beneficial. In this way, a single 
value could represent the degree to which a sample of patients approximates 
to recommended parameters. Unfortunately, it would be difficult to escape 
incorporating an element into a formula for an index of compliance, such as a 
percentage threshold, the value of which would have to be set arbitrarily. 
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Dietary control, outcome and policy 
Despite the change in UK treatment policy, the reality of dietary control in 
treated PKU is that average phe levels drift inexorably upward. Figures 8 and 
14 demonstrate this phenomenon. Notwithstanding the current German 
policy of striving to maintain phe concentrations below 363 Ilmol/l up to the 
age of years, below 606 Ilmol/l until age 15 and below 909 Ilmol/l thereafter 
(Stellungnahme APS, 1990), Weglage et al. (1993) have shown that actual 
levels creep upward and generally surpass recommended limits across the 
age range. Figure 19 illustrates this trend. 
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Figure 19. Mean indices of dietary control for 34 Munster patients from birth 
to adolescence compared with German Paediatric Society's recommended 
upper limits. After Weglage et al. (1993). 
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It is important to recognise that the curve depicted in Figure 19 represents 
mean values. The fact of there being variation in phe control around these 
figures signifies that some patients have better control and others worse. 
Thus, although policy nowadays is for indefinite dietary continuation, research 
opportunities are nonetheless available for comparing outcome in poorly 
controlled groups with that in better controlled groups or for conducting 
correlational studies of historical phe and outcome as was done in Chapter 
Eight and in a cluster analysis study by Burgard et al. (1996). What may be 
lacking in the future is the opportunity that was exploited in Chaper Three of 
measuring the effect of a sudden change in the independent variable due to 
treatment cessation at a predetermined age. Experimental manipulation of 
phe, the method chosen in Chapters Six and Seven, is an alternative 
approach but one in which ethics dictate much shorter periods of 
hyperphenylalaninaemia. 
A paradox illustrated by Figure 19 is the failure by treatment policy-makers in 
PKU to recognize that in reality dietary control is lost over childhood in a linear 
fashion whereas recommendations for upper therapeutic limits are expressed 
as stepwise functions. It might be an objective of future practice to 
acknowledge this discrepancy and for clinicians to endeavour to construct 
treatment goals which better harmonize idealized and actual dieting 
behaviour. The difficulty with using stepped rather than a progressive phe 
targets in treatment is that, with the passage of time along a step, the trend will 
be for target and achieved phe levels to diverge. As they become more 
discrepant, there is a risk that motivation will be diminished. This is a 
'knowledge of results' or reinforcement phenomenon which could easily be 
counteracted by the practitioner adopting a target model that was linear or 
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curvilear across the age range. For instance, to reflect better what is now 
suspected about the toxicity of phe in relation to the maturity of the eNS, a 
negatively accelerated target curve could be adopted, the demands of which 
would be for very strict dietary control in infancy, minimal relaxation of phe 
restriction during the pre-school period, moderate relaxation during the 
primary school years and near-liberalization in adolescence and adulthood. 
In practice, targets could be expressed and adjusted annually as increasing 
acceptable phe levels so that given targets would be operative for given 
yearly ages. 
Aims of future research 
Three inter-related research areas are identifiable as extensions of the issues 
raised in the foregoing chapters. 
The first is the need fer follow-up neuropsychological studies of off-diet PKU 
adults who were treated early and strictly and who discontinued after the first 
decade. A lifespan developmental approach is required as there are as yet 
no grounds for making the assumption that lack of evidence for cognitive or 
motor deterioration in early adulthood implies protection from the neurotoxic 
effects of phe in middle or old age. Knowledge derived from charting the 
progress of this group would inform the Idiet-for-life' issue. 
The second is the need for independent studies to corroborate or annul the 
view that applying current treatment recommendations for dietary 
management, such as those formally articulated in the UK and in Germany, 
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will prevent concurrent or subsequent cognitive impairment. In particular, the 
question of the relationship between age level and therapeutic range in 
childhood needs further exploration in order ultimately to formulate policy and 
specify optimal limits. 
The third is the need for greater illumination of the executive dysfunction 
hypothesis. It remains unclear whether prefrontal functions are hyper-
sensitive to moderate elevations in phe level. For instance, there may be phe 
thresholds at varying ages at which specific impairment of executive functions 
arises. It is foreseeable that solution of the executive dysfunction problem will 
be hampered by lack of agreement about what psychometric instruments 
might be maximally sensitive to deficits in this domain or, more fundamentally, 
what exact cognitive operations fall under the rubric of 'executive function'. 
Conclusions 
The results of the studies reported above generally failed to support the 
theses: a) that cessation of dietary treatment for PKU at the end of the first 
decade of life leads to subsequent neuropsychological impairment, b) that 
temporary elevation of phe as an interruption to normal prophylactic therapy 
in adolescence produces immediate deficits in cognition and personality, and 
c) that specific disorders of executive function arise when phe concentrations 
are maintained within or close to limits currently advised in the UK. 
Arguably, negative findings constitute the most satisfactory outcome in 
preventive medicine. Restriction of dietary phe in PKU is designed to arrest 
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the natural course of a disease that otherwise would lead to severe mental 
impairment. The evidence obtained from the studies described here suggests 
that even subtle disorders of information processing can be avoided if 
circulating phe concentrations are kept at low levels in the early years of life. 
The findings concur with a small but growing body of neuropsychological 
evidence that derives from research studies that are characterized by careful 
quantification of treatment factors and background phe levels. Henceforth, 
research methodologies based on more rigorous control and separation of 
treatment factors than has been achieved in the past are desirable. 
The import of attributions made by patients and their families to phe should be 
viewed with caution by clinicians. Evidence was found that neither school-
age children nor their parents could reliably perceive artificially-induced 
hyperphenylalaninaemia on the basis of information stemming from 
subjective state or behaviour. 
The implications of the present research for treatment policy in PKU are that 
the case for lifelong phe restriction in patients with the classical form of the 
disease may be over-stated. The recommendation of the MRC Working Party 
on Phenylketonuria that dietary restriction of phe be prolonged into 
adolescence and adulthood may have been premature (Medical Research 
Council, 1993a). Data presented in this volume suggest that considerable 
relaxation of the restricted diet after the first decade of life may be acceptable 
and not deleterious to long-term cognitive and motor functioning. 
Furthermore, at the time they were published, the MRC Working Party's 
pronouncements on the optimal therapeutic range for phenylalanine 
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concentrations lacked a sound empirical basis and even precise age ranges 
for recommended concentrations were left unspecified. The results from the 
studies reported above suggest that adherence to the MRC guideline of 
maintaining concentrations within the 120 to 360 J.1mol/l band during the 
preschool period prevents neuropsychological dysfunction, at least in the 
short-term, but further evidence is needed about functional outcome in 
patients whose preschool phe control has strayed into the 360 to 600 J.1mol/l 
range or beyond during this period. 
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APPENDICES 
Appendix One 
Chapter Three - Post-treatment hyperphenylalaninaemia 
RAW DATA - PHENYLALANINE IDCs (j.J.mol/l) 
S Year of Life 
Post 
(Gp) 1 2 3 4 5 6 7 8 9 10 Diet 
PKU young, on-diet 
1 480 240 360 240 420 360 240 480 360 360 
2 360 660 480 360 540 300 540 
3 300 240 120 240 300 120 240 
4 360 180 120 120 120 
5 240 120 120 240 120 120 240 240 120 
6 600 300 240 360 480 240 
7 480 360 360 240 360 480 180 480 600 
8 360 360 540 540 360 480 
9 300 120 240 360 360 360 360 480 360 360 
10 480 240 240 240 360 360 600 360 420 
PKU old, off-diet 
1 480 240 260 300 280 260 440 520 520 540 1014 
2 240 240 260 300 280 240 480 480 480 480 773 
3 300 360 300 360 360 360 360 480 360 600 791 
4 100 100 120 150 120 120 240 240 240 480 720 
5 280 240 240 300 280 260 440 520 510 540 900 
6 480 240 240 360 360 120 480 480 480 480 1174 
7 300 240 240 180 120 180 240 240 360 480 900 
8 240 240 240 240 360 360 240 360 480 600 1200 
9 240 240 480 480 300 360 600 660 480 480 1204 
10 290 240 260 290 270 460 900 1200 1200 720 1200 
Appendices: Page 285 
Appendix Two 
Chapter Three - Post-treatment hyperp heny la Ian inaem ia 
RAW DATA - SEX, AGE & NEUROPSYCHOLOGICAL TESTS 
S Sex Age React Peg Match Letter Verb Des Rey Rey 
Time Trans Figs Cane Flu Flu Verb Lab 
(Gp) (MIF) (yrs) (sees) (sees) (0-10) (n/min) (n/3m) (n/3m) (0-75) (0-20) 
PKU young, on-diet 
1 M 9.75 2.11 63 7 5.00 29 12 54 13 
2 M 6.67 3.31 86 4 2.00 12 8 30 12 
3 M 6.42 3.31 114 5 3.73 8 16 26 4 
4 M 5.58 3.83 109 3 3.00 11 13 45 17 
5 M 8.83 2.56 77 7 3.25 28 14 37 15 
6 M 5.58 3.47 114 4 2.50 13 12 39 5 
7 M 8.50 2.53 68 4 3.00 18 13 41 9 
8 F 6.17 5.28 94 4 2.50 12 8 47 12 
9 F 9.42 2.95 67 7 3.25 33 10 46 4 
10 F 8.42 3.78 93 4 3.75 24 13 59 14 
CONTROL young 
11 M 9.75 2.97 66 7 3.75 20 7 55 18 
12 M 6.75 3.32 77 3 2.50 16 13 33 6 
13 M 6.33 2.81 74 6 2.00 20 13 39 9 
14 M 5.75 2.82 85 3 3.50 9 12 45 8 
15 M 8.75 2.46 61 6 4.75 23 15 47 18 
16 M 5.67 3.35 93 4 1.25 5 10 39 8 
17 M 8.50 2.09 63 7 6.39 29 14 51 18 
18 F 6.17 3.90 89 4 3.00 12 11 32 12 
19 F 9.33 2.56 59 4 3.75 38 13 49 17 
20 F 8.42 3.25 60 4 4.25 18 14 40 17 
PKU old, off-diet 
21 M 22.67 2.52 49 8 5.70 26 18 49 15 
22 M 18.83 2.40 48 6 4.50 37 20 50 9 
23 M 17.25 2.74 48 9 10.00 28 12 43 15 
24 M 28.42 3.27 47 6 8.20 42 19 45 17 
25 M 21.00 3.75 47 5 15.50 27 17 43 18 
26 M 22.33 1.70 46 6 5.00 32 16 51 9 
27 M 13.67 2.59 54 9 8.43 39 25 53 14 
28 F 13.58 1.57 60 8 4.75 48 17 61 19 
29 F 20.17 1.85 58 7 3.75 42 17 41 19 
30 F 23.67 1.32 58 8 7.81 17 21 31 10 
CONTROL old 
31 M 21.75 2.56 38 9 4.50 46 26 60 18 
32 M 17.75 1.39 48 9 12.90 48 27 49 16 
33 M 17.25 1.80 46 9 8.09 32 22 53 19 
34 M 27.92 2.79 47 10 19.60 41 22 55 16 
35 M 21.42 1.87 55 10 4.75 46 19 53 18 
36 M 21.42 2.77 50 10 12.74 43 27 61 18 
37 M 13.67 2.06 46 8 8.69 22 28 50 19 
38 F 13.58 2.20 48 6 3.00 28 20 42 17 
39 F 19.67 2.63 41 8 9.95 42 28 68 17 
40 F 24.17 1.96 50 9 13.33 41 26 60 18 
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Appendix Three 
Chapters Six and Seven - Experimental phe manipulation 
RAW DATA - SEX & AGE 
S Gp Sex Age 
(M/F) (yrs) 
1 1 F 12.17 
2 1 F 11.00 
3 1 F 16.08 
4 1 M 11.25 
5 1 M 12.17 
6 1 M 16.42 
7 1 M 16.25 
8 1 M 11.00 
9 1 M 13.75 
10 1 F 10.83 
11 2 M 11.25 
12 2 M 10.83 
13 2 F 10.92 
14 2 M 14.67 
15 2 F 11.63 
16 2 M 11.33 
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Appendix Four 
Chapters Six and Seven - Experimental phe manipulation 
RAW DATA - PHENYLALANINE IDes (J.tmolll) 
S Gp Year of Life 
1 2 3 4 5 6 7 8 9 10 
1 1 n/a n/a n/a n/a n/a n/a n/a n/a 360 420 
2 1 360 240 480 360 600 720 720 900 900 900 
3 1 480 480 360 180 360 480 360 360 360 240 
4 1 240 120 120 240 120 120 240 240 120 120 
5 1 480 240 360 240 420 360 240 480 360 360 
6 1 480 360 480 360 360 600 360 480 480 750 
7 1 120 240 360 360 360 480 360 480 480 720 
8 1 480 360 360 240 360 480 180 480 600 540 
9 1 240 360 720 420 420 600 900 540 600 900 
10 1 480 240 240 240 360 360 600 360 420 480 
11 2 360 240 240 360 600 480 420 600 480 480 
12 2 240 240 360 480 600 900 600 660 360 299 
13 2 360 360 810 720 480 600 540 660 600 720 
14 2 300 120 240 360 360 360 360 480 360 360 
15 2 300 120 240 360 360 360 360 480 360 360 
16 2 240 120 360 360 360 240 360 360 480 360 
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Appendix Five 
Chapters Six and Seven - Experimental phe manipulation 
RAW DATA - PHE CONCENTRATIONS x PHASE (Jlmol/l) 
Phase 
S Gp Baseline Low High 
1 1 472 614 844 
2 1 1217 1303 1875 
3 1 1064 1013 1285 
4 1 209 386 1345 
5 1 306 343 1558 
6 1 1008 1067 1516 
7 1 999 1074 1294 
8 1 1030 1109 1035 
9 1 1236 1047 1233 
10 1 687 760 1560 
11 2 471 396 1087 
12 2 507 868 902 
13 2 300 344 998 
14 2 459 455 741 
15 2 506 745 1385 
16 2 258 282 933 
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Appendix Six 
Chapter Six - Experimental phe manipulation 
RAW DATA - 'NEUROPSYCHOLOGICAL TESTS 
S Gp Matching Rey Digits Paired 
Figures Verbal Associates 
(0-10) (0-60) (0-16) (0-30) 
Base Low High Base Low High Base Low High Base Low High 
1 1 6 6 6 41 55 52 8 9 9 28 24 29 
2 1 3 4 6 52 57 56 8 8 8 28 29 24 
3 1 7 7 8 52 60 59 11 11 10 29 29 26 
4 1 7 8 8 54 55 50 8 8 10 30 30 30 
5 1 7 7 6 49 58 51 11 12 10 28 27 27 
6 1 8 8 8 54 52 57 11 13 13 28 28 24 
7 1 7 8 8 49 55 56 9 9 9 26 25 25 
8 1 5 5 5 46 55 43 11 11 11 25 21 23 
9 1 6 7 8 50 50 56 11 10 11 25 28 28 
10 1 7 8 7 51 59 55 13 13 12 26 28 27 
11 2 5 4 6 27 36 42 6 8 5 28 29 25 
12 2 7 6 6 47 50 50 8 8 7 23 21 26 
13 2 6 6 3 47 54 54 9 9 8 25 26 27 
14 2 6 5 4 43 47 44 10 7 7 28 29 28 
15 2 4 7 6 49 52 55 10 8 11 20 26 23 
16 2 6 8 7 49 57 58 14 12 13 28 28 23 
S Gp Block Rey Pegboard Steadiness 
Tapping Labyrinth 
(0-16) (0-20) {sees} {o--} 
Base Low High Base Low High Base Low High Base Low High 
1 1 6 7 5 18 19 16 152 153 162 31 1 9 
2 1 8 10 6 17 18 16 164 162 169 10 18 18 
3 1 11 11 11 19 19 20 146 129 131 21 5 3 
4 1 7 6 7 20 15 17 157 168 169 40 34 40 
5 1 6 6 6 15 15 15 153 141 159 32 11 14 
6 1 9 10 8 6 13 18 174 176 172 14 26 17 
7 1 9 10 8 18 20 16 167 159 169 14 9 16 
8 1 8 7 8 18 18 19 167 156 171 16 11 17 
9 1 8 9 6 17 9 10 160 157 154 19 11 14 
10 1 7 7 7 17 15 16 164 158 164 15 19 31 
11 2 9 9 8 15 20 11 159 180 180 29 13 35 
12 2 7 7 7 16 18 9 167 160 160 15 18 33 
13 2 5 7 3 7 13 7 143 146 146 10 4 9 
14 2 8 6 10 19 14 17 151 154 146 14 17 15 
15 2 9 8 9 13 17 19 139 131 131 17 18 13 
16 2 10 10 9 20 20 14 167 154 154 11 11 43 
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Appendix Seven 
Chapter Seven - Experimental phe manipulation 
RAW DATA - WiSe, Rivermead Memory & Problem Behaviours 
S Gp Similarities Vocabulary Block Object Rivermead Problem 
Design Assembly BMT Behaviours 
(1-19) (1-19) (1-19) (1-19) (0-90) (0-80) 
Low High Low High Low High Low High Low High Low High 
1 1 10 10 9 8 9 10 13 13 67.5 62.5 2 3 
2 1 13 12 11 10 9 7 8 17 56.5 59.0 25 58 
3 1 12 19 10 15 14 15 12 16 77.5 80.0 14 2 
4 1 12 12 10 11 11 11 13 16 66.5 63.0 2 15 
5 1 13 12 10 11 12 11 12 14 67.5 70.5 5 39 
6 1 11 11 11 9 9 6 10 8 72.5 57.5 1 4 
7 1 11 10 8 5 10 5 11 11 66.0 62.5 14 3 
8 1 10 10 8 8 10 8 10 11 60.0 64.0 4 4 
9 1 9 8 9 9 9 9 7 10 58.5 61.0 0 8 
10 1 16 15 12 12 12 9 12 9 78.0 85.0 5 22 
11 2 9 8 7 6 11 13 11 13 51.0 45.5 6 30 
12 2 13 10 10 5 10 9 9 4 64.0 59.0 3 3 
13 2 10 10 9 9 5 5 11 10 64.5 61.5 10 8 
14 2 8 9 5 6 10 10 13 9 59.5 59.0 4 3 
15 2 13 10 8 8 8 10 11 10 52.5 61.0 6 9 
16 2 14 14 12 11 8 10 9 13 67.0 71.0 5 11 
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Appendix Eight 
Chapter Eight - Executive Dysfunction, Correlational Study 
RAW DATA - Sex and Age 
0. 
S Sex Age 
(M/F) (Yrs) 
1 M 12.92 
2 M 12.50 
3 M 10.75 
4 M 10.50 
5 F 12.67 
6 M 10.50 
7 M 10.83 
8 M 12.83 
9 F 10.25 
10 M 13.83 
11 F 13.58 
12 F 12.58 
13 M 13.00 
14 M 12.67 
15 F 12.58 
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Appendix Nine 
Chapter Eight - Executive Dysfunction, Correlational Study 
RAW DATA - Annual Indices of Dietary Control 
IDC (J.1molll) 
S Yr 1 Yr 2 Yr3 Yr 4 Yr 5 Yr 6 Yr 7 Yr 8 Yr9 
1 360 240 240 360 600 504 420 600 480 
2 240 240 360 480 600 900 600 660 360 
3 360 120 360 480 600 720 900 600 822 
4 360 180 210 300 480 600 600 540 331 
5 360 240 480 360 600 720 720 900 900 
6 360 360 240 240 480 300 360 272 298 
7 240 600 600 360 480 240 540 360 408 
8 240 120 120 240 120 120 240 240 120 
9 360 360 360 540 360 540 480 562 523 
10 480 240 360 240 420 420 240 480 360 
1 1 300 120 240 360 360 360 360 480 360 
12 360 360 810 720 480 600 540 660 600 
13 240 120 360 360 360 240 360 360 480 
14 480 360 360 240 360 480 180 480 600 
15 480 240 240 240 360 420 600 240 420 
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Appendix Ten 
Chapter Eight • Executive Dysfunction, Correlational Study 
RAW DATA· Cognitive Variables 
S Mazes Stroop Cancel Des Flu Digits Benton Seashore Rey Verb 
(1-19) (0-36) (Hits/m) (Des/3m) (1-19) (0-20) (0-30) (0-60) 
1 12 31 10.0 15 6 20 24 47 
2 7 31 10.5 20 6 18 23 46 
3 12 34 8.0 14 9 20 26 45 
4 5 28 7.5 12 7 13 19 34 
5 6 31 7.5 15 10 15 21 41 
6 17 31 6.5 16 8 12 21 45 
7 10 35 10.0 14 6 19 26 44 
8 7 34 11.5 18 10 20 25 51 
9 7 36 8.0 12 12 19 28 40 
10 1 1 31 12.0 20 9 17 28 42 
1 1 6 35 11.0 18 10 18 25 45 
12 9 33 12.0 12 7 18 26 40 
13 12 32 3.5 26 19 15 26 37 
14 8 32 11.0 13 9 15 22 43 
15 8 32 6.5 21 19 15 29 48 
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Appendix Eleven 
Chapter Eight - Executive Dysfunction, Correlational Study 
RAW DATA - Personality Variables 
Devereux Scales of Mental Disorders (T-Scores) 
S Dev Tot Conduct AUent Anxiety Depress Autism Acute Pr 
1 59 54 60 48 64 65 58 
2 40 40 40 40 40 40 45 
3 45 42 58 41 41 44 49 
4 59 56 65 60 48 65 51 
5 51 58 52 48 58 44 46 
6 42 48 44 40 40 44 45 
7 46 49 47 49 43 45 49 
8 49 45 47 53 62 44 45 
9 42 44 47 41 40 47 46 
10 46 46 48 56 47 41 44 
11 42 44 44 40 40 50 45 
12 66 64 76 49 92 52 46 
13 46 55 43 40 43 59 44 
14 52 55 54 47 58 51 45 
15 42 44 40 47 45 41 46 
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Appendix Twelve 
Chapter Nine - Executive Dysfunction, Control Group Study 
RAW DATA - Sex, Age, British Picture Vocabulary Scales, Digits 
Forwards and Deprivation Category 
S Sex Age BPVS Digits DEPCAT 
(M/F) (Yrs) (Std Sc) (0-40) (0-7) 
PKU Group 
1 M 11.92 125 22 3 
2 M 10.83 126 28 3 
3 F 11.42 104 23 3 
4 M 9.08 100 18 4 
5 F 8.83 101 18 4 
6 M 7.25 111 20 6 
7 M 7.08 107 16 4 
8 F 10.75 93 18 6 
9 F 7.33 85 15 6 
10 F 5.11 117 11 4 
11 M 6.42 82 14 4 
Control Group 
1 M 12.75 124 26 2 
2 F 10.42 133 27 2 
3 M 11.58 106 22 3 
4 M 9.17 95 26 3 
5 F 8.83 100 15 3 
6 M 7.17 103 18 3 
7 M 7.25 95 15 3 
8 F 10.67 87 24 3 
9 F 6.83 81 18 3 
10 M 6.17 102 16 3 
11 M 6.42 90 23 3 
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Appendix Thirteen 
Chapter Nine - Executive Dysfunction, Control Group Study 
RAW DATA - PKU Group Indices of Dietary Control (Years 1 to 5) 
and Test-Concurrent Phenylalanine Concentration 
Phenylalanine (Ilmol/I) 
S Yr 1 Yr 2 Yr 3 Yr 4 Yr 5 Cone 
1 360 600 480 420 480 501 
2 480 240 120 120 120 193 
3 360 360 360 480 480 544 
4 660 120 240 120 120 401 
5 480 240 300 420 360 475 
6 480 660 480 600 685 562 
7 120 240 120 180 139 240 
8 360 360 390 240 240 437 
9 240 240 120 120 133 336 
10 420 120 306 124 284 312 
11 360 240 240 180 195 269 
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Appendix Fourteen 
Chapter Nine - Executive Dysfunction, Control Group Study 
RAW DATA - Continuous Performance Test, One-Back Version, 
Hits, False Alarms and Reaction Time per Trial Block 
Hits 
(0-20) 
False Alarms 
(0-20) 
Reaction Time 
(Centisec) 
S B1 B2 B3 84 81 82 B3 84 81 82 B3 84 
PKU Group 
1 19 20 18 18 1 1 1 1 41 43 43 48 
2 19 20 20 20 0 0 1 0 37 39 35 36 
3 20 20 20 20 0 1 0 0 37 38 40 40 
4 20 19 20 17 1 1 1 5 46 49 52 47 
5 17 18 16 17 1 5 2 2 60 66 52 53 
6 14 16 15 10 1 1 2 5 51 60 67 66 
7 17 19 19 18 3 4 9 9 86 53 55 45 
8 20 19 20 20 0 0 0 1 48 46 44 47 
9 18 20 15 17 3 5 2 0 49 51 57 50 
10 18 18 16 19 1 3 1 2 48 52 46 51 
11 18 17 16 17 8 1 3 4 55 53 54 54 
Control Group 
1 20 20 20 20 0 0 0 0 37 37 37 37 
2 20 20 20 20 0 0 0 0 41 41 41 42 
3 17 20 20 20 13 12 10 10 37 39 46 40 
4 20 20 20 20 2 1 2 2 37 34 34 36 
5 18 16 16 18 5 0 1 1 41 40 49 43 
6 14 16 15 20 2 5 0 2 43 47 39 42 
7 19 15 19 17 1 3 7 1 48 55 39 40 
8 20 19 19 17 0 3 3 3 41 45 44 44 
9 15 13 9 12 5 4 1 1 52 59 53 61 
10 13 14 13 14 15 16 16 15 59 69 64 65 
11 18 16 18 17 2 2 2 6 62 54 58 56 
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Appendix Fifteen 
Chapter Nine - Executive Dysfunction, Control Group Study 
RAW DATA - Continuous Performance Test, Two-Back Version, 
Hits, False Alarms and Reaction Time per Trial Block 
Hits 
(0-20) 
False Alarms 
(0-20) 
Reaction Time 
(Centisec) 
S B1 B2 B3 B4 B1 B2 B3 B4 B1 B2 B3 B4 
PKU Group 
1 18 17 17 19 3 0 2 1 38 40 36 39 
2 20 19 18 17 0 1 2 0 41 44 47 43 
3 20 19 16 19 8 1 4 1 37 49 45 53 
4 20 18 16 16 1 0 3 2 51 52 54 63 
5 16 14 13 14 1 1 2 2 54 49 47 56 
6 17 18 14 15 2 3 4 6 51 59 69 63 
7 18 17 14 15 2 7 5 6 51 55 47 49 
8 16 20 15 18 0 0 0 2 51 54 48 49 
9 17 13 15 12 2 10 2 2 40 55 47 42 
10 14 15 12 13 2 1 6 2 68 56 57 67 
1 1 17 14 11 14 2 0 3 2 55 50 58 54 
Control Group 
1 19 20 20 20 1 0 1 2 36 37 34 37 
2 20 19 20 20 0 0 0 1 43 45 38 38 
3 19 19 20 17 3 0 2 1 35 36 34 36 
4 20 19 20 18 1 2 1 2 30 31 35 36 
5 14 15 15 13 8 4 7 7 41 61 49 58 
6 11 10 13 9 8 4 8 11 34 40 52 43 
7 17 16 16 15 2 5 3 5 47 46 42 48 
8 20 19 16 19 0 6 4 4 43 46 59 53 
9 10 9 7 10 0 1 5 5 63 72 65 78 
10 18 19 18 18 1 3 4 5 48 48 45 48 
1 1 10 8 12 8 11 18 13 15 130 63 55 56 
Appendices: Page 299 
